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ABSTRACT 
Obesity and overweight are considered as challenging health problems worldwide. 
Despite several modern methods for treatment of obesity such as medical nutrition 
therapy, low-energy diets, and physical activity. The prevalence of this disease is still 
high, suggesting the need for alternative therapies. One of the trending approaches is the 
consumption of traditional medicinal plants. Caraway (Carum carvi L.), has been 
traditionally used as a spice in Iran. It is also claimed as a potent medicinal plant that is 
used to treat a variety of ailments including obesity. The objectives of this study are to 
analyse the phytochemicals present in caraway water extract (CWE), to measure body 
composition, anthropometric indices, dietary food intake and appetite, and clinical and 
para-clinical parameters before and after twelve-weeks of  intervention. Hence, a 
randomized triple blind placebo controlled clinical trial was carried out on healthy, 
overweight and obese adult women in Yazd, Iran. The phytochemical content of CWE 
was analysed using the gas chromatography-mass spectrometry (GC-MS) technique. Out 
of 110 volunteers registered, 70 eligible candidates were randomized into two groups of 
caraway treatment and placebo (N=35 in each group) and were assigned to participate in 
a twelve-week intervention. Data were collected through questionnaire, face-to-face 
interview, physical examination and biochemical tests. Body composition and 
anthropometric indices were measured using bioelectrical impedance analyser (BIA) and 
measuring tape, while the appetite index was assessed using visual analogue scale method 
(VAS). Participants received either 30mL/day of CWE or placebo without changing their 
diet or physical activity and were examined at baseline and after twelve weeks of 
intervention and the data were analysed using SPSS. Results showed that the predominant 
ingredients detected from the GC-MS analysis were of different volatile and phenolic 
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compounds, including limonene, terpinene, carveol, carvone, carvacrol, and thymol. 
After twelve weeks of study results showed significant reduction of weight (-1.9 kg), 
body mass index (-0.8 kg/m2), body fat percentage (-0.7%), appetite level (-1) and 
carbohydrate intake (-30g) in the CWE group. All anthropometric indices including waist 
circumference, waist to hip ratio, thigh circumference and mid-upper arm circumference 
also reduced significantly (-6.2, -0.1, -5.4, and -2.2 cm respectively). Besides, significant 
increase was observed in the muscle percentage of the CWE group (+0.2%). No changes 
were detected in blood and urine tests, blood pressure and heart rate of respondents. 
Moreover, after twelve weeks of study, the red blood cell (RBC) level showed a clinically 
significant rise (+0.3 106/µL), whereas the platelet distribution width (PDW) showed a 
significant drop in the CWE group (-1.8 fL). The results suggest that adding CWE into 
the daily diet with no restriction in food intake, when combined with exercise, is of value 
for obese and overweight women wishing to reduce their body weight, BMI, body fat 
percentage, body size and appetite and carbohydrate intake. In addition, CWE intake has 
also improved body muscle and RBC level of the subjects with no clinical side effects. In 
conclusion, the results of this study suggest a safe weight loss adjuvant and a potential 
phytotherapeutic approach for CWE in the management of obesity. 
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ABSTRAK 
Obesiti dan berat badan berlebihan merupakan masalah kesihatan yang kian mencabar 
di seluruh dunia. Walaupun terdapat pelbagai kaedah terapi moden di pasaran tetapi ia 
masih pada tahap yang sukar untuk dilakukan. Sebagai cadangan, terapi alternatif iaitu 
dengan pengambilan atau penggunaan tumbuh-tumbuhan tradisional boleh dilakukan. 
Jintan (Carum Carvi L.) telah digunakan secara tradisional sebagai herba di Iran. Ia 
dinyatakan mempunyai potensi sebagai tumbuhan yang mempunyai nilai perubatan untuk 
mengatasi pelbagai masalah kesihatan termasuk menurunkan berat badan yang berkait 
rapat dengan obesiti. Objektif utama kajian ini adalah untuk menganalisa kandungan 
fitokimia yang terdapat dalam ekstrak air jintan (CWE), mengkaji kesan pengambilan 
CWE terhadap komposisi badan dan indeks antropometri, serta mengkaji selera makan 
responden. Analisa terhadapkandungan fitokimia CWE dilakukan dengan menggunakan 
teknik gas kromatografi–spektrometri jisim(GC-MS). Penentuan beberapa parameter 
secara klinikal dan para-klinikal sebelum dan selepas masa intervensi turut dilakukan 
kepada wanita Yazd, Iran terpilih, iaitu yang sihat dan mempunyai berat badan berlebihan 
serta obes. Ia dilakukan melalui ujian secara rawak `triple blind placebo’. Seramai 110 
orang responden telah mendaftar tetapi hanya 70 responden sahaja dipilih untuk 
mengambil bahagian selama tiga bulan.. Mereka dibahagikan secara rawak kepada dua 
kumpulan iaitu yang mengambil CWE ( n=35) dan kumpulan kawalan atau plasebo 
(n=35). Data diperolehi melalui soal selidik, temuduga bersemuka, pemeriksaan fizikal 
dan ujian biokimia. Komposisi badan dan indeks antropometri diukur dengan 
menggunakan Bioelectrical Impedance Analyzer (BIA) dan pita mengukur, manakala 
tahap selera makan pula dinilai dengan kaedah visual analogue scale (VAS). Responden 
akan diberi sama ada 30ml/hari CWE atau 30ml/hari plasebo. Responden kedua-dua 
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kumpulan ini tidak akan mengubah corak pemakanan atau aktiviti fizikal sepanjang 
kajian ini dijalankan. Responden akan dinilai sebelum dan selepas 3 bulan tempoh yang 
ditetapkan. Hasil kajian menunjukkan bahan utama yang dikesan daripada analisis GC -
MS adalah sebatian yang berbeza kadar pemeruapan dan terdapat kumpulan fenolik 
seperti limonene, terpinene, carveol, carvone, carvacrol, dan thymol. Hasil kajian 
terhadap responden selepas 12 minggu, menunjukkan berat badan (-1.9 kg), indeks jisim 
(-0.8 kg/m2), peratusan lemak (-0.7%), selera makan (-1g) dan pengambilan karbohidrat 
(-30g) menurun bagi kumpulan CWE. Malah hasil juga menujukkan semua indeks 
antropometri iaitu lilitan pinggang, nisbah pinggang ke pinggul, tahap purata lilitan paha 
dan lilitan pertengahan atas lengan ke pinggul turut berkurangan bagi kumpulan CWE (-
6.2, -0.1, -5.4, dan -2.2cm). Peningkatan peratusan otot yang signifikan turut berlaku bagi 
kumpulan CWE (+0.2%). Seterusnya, tiada perubahan dikesan dalam darah, air kencing, 
tekanan darah dan kadar denyutan jantung responden bagi kumpulan CWE. Kajian juga 
mendapati tahap bilangan sel darah merah (RBC) meningkat (+0.3 106/μL) manakala 
julat taburan platelet (PDW) menurun bagi kumpulan CWE (-1.8 fL) selepas 12 minggu. 
Didapati dengan menambah CWE kedalam pemakanan harian dan digabungkan dengan 
senaman, kesan yang lebih signifikan diperolehibagi wanita obes dan mempunyai berat 
badan berlebihan untuk menurunkan berat badan, BMI, peratusan lemak badan dan , 
menurunkan selera makan. Pengambilan CWE juga dibuktikan secara klinikal dapat 
meningkatkan otot badan dan sel darah merah tanpa memberi kesan 
sampingan.Kesimpulannya, kajian menunjukkan terdapat pendekatan fitoterapi yang 
berpotensi bagi penggunaan CWE dalam mengatasi dan mengawal obesiti dan ia 
merupakan produk alternatif yang selamat digunakan. 
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CHAPTER 1: INTRODUCTION 
Health issues have become an indispensable aspect of human life, and the importance 
of wellness and fitness in modern and emerging societies around the world is established. 
Global health has become a fundamental element of foreign policy and many governments 
now emphasize community health, and encourage institutions, researchers, and the media 
to develop, support and publicize research projects related to health promotion and 
wellness (Farr & Virchow, 2009). This greater need for health awareness among societies, 
brings focus to those factors which influence, positively or negatively, both individual and 
societal health. 
Controlled clinical trials, which can assess the use of plant materials in the treatment 
and prevention of various diseases and human conditions are also needed, particularly 
when the existing therapeutic modalities are either not accessible or present a clinical risk. 
The World Health Organization (WHO) has recognized this for many years (World Health 
Organization, 2002) and has further encouraged countries to place the issues of both safety 
and efficacy as a priority in countries where traditional medicines and a variety of plant 
products are present in the health care market place (World Health Organization, 2014b). 
Another factor which has now emerged as being crucial to medicinal plant research and 
development is sustainability, and the term “sustainable medicine” has been developed 
(Cordell, 2009, 2011a, 2011b; Cordell & Colvard, 2012) to describe the importance of 
considering the long-term use of traditional medicines (and synthetic drugs) from a 
perspective of reliable and non-destructive sourcing for the future. This is of particular 
importance where population use of traditional medicines is expanding, where the 
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globalization of products is increasing demand, or where climate change may impact areas 
for growing traditional medicines. In the research component of this scenario, preference 
is given to studies on those plant materials which are already established as sustainable 
commercial entities, or which are easily grown agronomically in order to derive an 
accessible (affordable and sustainable) product (Cordell, 2012). Another aspect with 
respect to the sustainability of traditional medicine applies to the knowledge of the use of 
medicinal plants, and how that information is recorded and maintained from generation to 
generation of practitioner. 
One of the major global health problems that has emerged as a result of improved 
economic status, the globalization of certain eating practices, and personal health 
awareness, is overweight and obesity. Since 1997, the WHO has warned that obesity is 
rapidly becoming a global epidemic, although it was not a noticeable health care concern 
during most of the 20th century (Auld & Powell, 2009; Caballero, 2007; World Health 
Organization, 2000b) . The use of the word “Globesity” in reports indicates the severity of 
the issue worldwide (Delpeuch et al., 2013).  
The consequences of obesity to society in terms of morbidity and mortality are 
enormous. Based on recent research, obesity is implicated as one of the leading causes of 
death worldwide, and is a well-established, threatening element for human health (Barness 
et al., 2007; Mokdad et al., 2004). Furthermore, excess body fat can lead to the 
development of numerous, life-threatening, chronic diseases (Calle et al., 2003; Guh et al., 
2009; Shehzad et al., 2011).  
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In order to combat obesity and its health consequences, governments have adopted 
different policies which are essentially based on modifying lifestyle habits and increasing 
the health awareness of individuals. These programs mainly aim to promote healthy eating 
patterns and increase physical activity among people, especially school children. However, 
despite great efforts to fight this disease, “Globesity” remains a very challenging issue, 
and the management of obesity has become one of the crucial components of global and 
national health policies (Nestle & Jacobson, 2000). 
Despite a variety of different treatment modern approaches for obesity, including 
surgery, weight loss pills, and dietary supplements, they do not satisfactorily impact 
weight loss, or are not tolerated by the body (Chaput et al., 2007; Pittler et al., 2005). In 
addition, the high costs and the side-effects of these methods, drive patients and 
researchers to seek alternative approaches (Clegg et al., 2003; Pittler & Ernst, 2005) . 
Many scientists and patients believe that treatment with medicinal plants may provide a 
safer, more reliable, and also cheaper, approach to addressing issues of overweight and 
obesity, than the prevalent contemporary methods (Chang, 2000). 
Based on literature review, different medicinal plants such as green tea, cinnamon, and 
turmeric have shown antiobesity activity which is evidenced scientifically (Hasani-
Ranjbar et al., 2013; Vermaak et al., 2011; Yun, 2010). However, in spite of several studies 
on the application of traditional medicinal plants for managing body weight, many 
challenging issues, including the safety and efficacy of anti-obesity plants remain, and 
there are continuing deficiencies in the deployment of natural approaches for treating 
obesity (Jacobs & Gundling, 2009). Consequently, seeking sustainable, natural product-
based solutions, and examining a variety of natural sources for methods to safely and 
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reliably treat obesity are important, albeit neglected, research targets. Success in 
developing such strategies will subsequently help to reduce the global health implications 
of obesity.  This study describes an approach to establishing the safety and efficacy of a 
plant-based material, caraway water extract (CWE), for treating obesity and overweight, 
which might be considered as a natural alternative to the currently available dietary 
supplements and commercial products.  
Caraway, particularly the fruit, is an ancient spice and flavoring material used in many 
parts of Europe, the Middle East, and Asia (Mariaca et al., 1997). It is derived from the 
umbelliferous plant, Carum carvi L. (Apiaceae) (Hammer et al., 1988), and is used world-
wide as a natural flavoring in various food products, including rye bread, curries, to flavour 
rice, in sauerkraut, in cheeses, and as a liquor. Traditionally, caraway tends to be more 
widely used for weight loss purposes, especially in the countries of the Middle-East region.  
One of the reasons is historical. In Islamic traditional references, such as Khorasani’s 
Makhzan al-adviyah (The Storehouse of Medicaments), and Avicenna's Canon of 
Medicine (980-1037 AD), the consumption of caraway aqueous extract is recommended 
specifically for weight loss (Aqili Khorasani, 2001; Nasser et al., 2009). 
Moreover, a number of the components present in caraway, including the polyphenols 
and specific essential oil components have been attributed to possess anti-inflammatory, 
anti-hyperlipidemic, and anti-obesity effects (Cho et al., 2012). A multi-targeted, anti-
obesity effect of carvacrol - one of the major constituents of caraway - on animals was 
demonstrated through modifying the gene expressions associated with inflammation and 
adipogenesis (Cho et al., 2012). Evidence also shows that there is a relationship between 
the gut flora and obesity (Angelakis et al., 2012; Armougom et al., 2009). Consequently, 
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plant materials such as caraway, which have intestinal relaxant and soothing effects (Al-
Essa et al., 2010) could also possess anti-obesity properties. However, there is no clinical 
scientific evidence which specifically focusses on exploring the possible role of caraway 
on weight loss. The aim was therefore to investigate the therapeutic potential of caraway 
aqueous extract on clinically obese and overweight human subjects.  
Despite a significant number of in vitro and in vivo studies on the constituents of 
caraway and their remedial effects (discussed in the next chapter), there are limited clinical 
studies on the effects of this plant on weight. Hence, there is a need to examine the anti-
obesity effect of caraway clinically. Accordingly, the problem statement of this study will 
be explained in the next section. 
1.1 Problem Statement 
Today, weight control is recognized as a common human concern. According to Weiss 
and colleagues (Weiss et al., 2006), 51% of American adults above 20 years old had tried 
at some point to control their weight. This subject has attracted the attention of 
manufacturers, personal health advisors, physicians, patients, and especially governments, 
to find and develop new approaches and improved solutions for the treatment and 
prevention of obesity. One attractive method of losing weight is the consumption of natural 
and synthetic anti-obesity drugs, the long-term usage of these products is typically not 
under any medical supervision (Blanck et al., 2001). In addition, of the different weight 
loss pills available in the market, including Xenical (Orlistat), Phentermine/Fentermine, 
Meridia (Sibutramine), Adipex, Bontril, Didrex, Phentermine, and Tenuate, only two are 
USFDA-approved: namely Orlistat and Sibutramine (Padwal & Majumdar, 2007; Weigle, 
2003). The long-term consumption of the present anti-obesity products is not 
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recommended as they have exhibited several side effects, including gastrointestinal, 
psychiatric, and kidney problems which might be irremediable. Such negative symptoms 
may be due to changes in metabolic rate, and the metabolism of dietary intake (Blanck et 
al., 2007; Rucker et al., 2007). 
Another important issue in the application of such dietary products is their efficacy, 
short-term and long-term. Some of these supplements might be effective only if taken 
along with a suitably modified weight loss diet and enhanced physical activity. 
Consequently, these remedies may be useful only over a short period of time, as the body 
usually adjusts quickly to most of these dietary supplements. These negative trends may 
misguide patients, wherein the products do not satisfactorily provide a long term impact 
on weight loss, and are not tolerated on a chronic basis (Pittler & Ernst, 2004). In this 
regard, the permitted promotional claims on dietary and slimming products sold to enhance 
weight loss are relevant, since they pertain to patient expectations without a clinical 
evidence base. 
The current methods being used for the treatment of obesity, such as synthetic anti-
obesity drugs, various dietary supplements, or bariatric/gastric bypass surgery are not 
satisfactory for addressing the issue of obesity on a long-term, global basis because of high 
consumer cost, limitations of chronic usage, and unfavourable side-effects (Balsiger et al., 
2000). Therefore, obesity remains a major global health challenge, and accessible solutions 
for sustainable weight loss and prevention of weight gain are urgently needed (Fouad et 
al., 2006). There is a profound lack of scientific information on the rationale for using the 
presently available alternative therapies, such as dietary supplements, anti-obesity drugs, 
and other slimming products. Hence, patients are confused in deciding between synthetic 
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weight loss pills and slimming aids on one hand, and natural sources, such as medicinal 
plant products, on the other hand. Patients are therefore challenged in searching for a safe 
and effective method of long-term weight management. 
However, despite the strong global market influence, and patient desperation for 
alternative anti-obesity products and traditional medicinal plants, the awareness of the 
usefulness of these products is neither sufficient nor clearly perceived. In major part, this 
is because there is still doubt about their quality, standardization, safety, and efficacy for 
long-term human use (Kumari et al., 2011; Smyth & Heron, 2006). So, it is necessary to 
seek for other sustainable solutions and examine other potent natural sources for treating 
obesity. From that point of view, the researcher aims to introduce one of the potent 
traditional medicinal plants to be used as a natural weight loss adjuvant. In so doing, this 
study will examine the effect of CWE on body weight loss. 
1.2 Contribution and Significance of the Study 
The context of this study is that the use of natural remedies for inducing weight loss has 
increased dramatically over the last few decades, and typically involve the inclusion of 
particular medicinal plants in the diet on a regular basis to assist an individual to lose 
weight gradually (Chang, 2000). Most of the anti-obesity medications studied presently 
are based on plants used in traditional medicine, as they have been found to be more 
acceptable than the synthetic medications (Kumari et al., 2011). One example is the weight 
loss reported in animals and humans treated with "WeighLevel", a combination of four 
medicinal plants used in traditional Arabic and Islamic medicine, including the leaves of 
Alchemilla vulgaris, Olea europaea, and Mentha longifolia, the seed extract of Cuminum 
cyminum, and other ingredients (Said et al., 2011).  
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In traditional medicine resources, caraway is recommended as a remedy for a variety 
of health problems, especially digestive disorders (Sadowska & Obidoska, 2003). 
Moreover, based on a patented natural supplement formula, combinations of carminative 
herbs, including caraway, have been used to reduce the adverse effects of weight loss 
drugs, such as orlistat and oral lipase inhibitors (Thompson, 2008). Caraway seed acts as 
a carminative, and adding this herb to the diet helps in preventing or relieving flatulence. 
The carminative volatile oils present in caraway induce a relaxant effect on the movements 
of the intestine muscle (Alhaider et al., 2006; Charles, 2013; Plant & Miller, 1926). Such 
an effect will synergistically aid in digestion, which, in turn, has a direct effect on food 
absorption and calorie intake. In addition, using this spice will provide healthful and 
therapeutic effects for the patient, and will improve the taste and flavor of the final product 
(Mariaca et al., 1997). Hence, adding caraway to the recipe of food products, may lead 
food technologists towards novel formulations in the production of functional food 
preparations. 
1.3 Objectives of the Study 
This study will present information on the properties of caraway as one of the traditional 
medicinal plants, and to determine the effect of the consumption of CWE in the 
management of obesity and overweight in human. To fulfil this aim, the following 
objectives are determined for this study:  
1. To propose the effect of CWE intake on body composition, anthropometric indices 
and appetite in overweight and obese women 
2. To disclose the safety of CWE intake for human  
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3. To identify the types of phytochemicals present in CWE 
1.4 Research Methodology 
In order to achieve these objectives, two different methods were applied. A randomized 
triple-blind placebo-controlled clinical trial was planned to examine the efficacy and safety 
of caraway intake on overweight and obese women in Yazd, Iran. Also, the chemical 
analysis of CWE phytochemicals were done using Gas chromatography-mass 
spectrometry (GC-MS) technique. 
1.5 Limitations and Scope of the Study 
As mentioned before, based on the main concerns and priorities of WHO traditional 
medicine strategies on the both safety and efficacy issues for examining traditional 
medicinal plants, this study has only focused on the safety and efficacy of caraway water 
extract as a potential traditional medicinal plant for weight loss. 
Respondents in this study were selected from healthy overweight and obese women 
aged 20-55. CWE is consumed regularly in Iran especially in Yazd for losing weight. 
Furthermore, as the rate of obesity is mostly higher in females, and women are usually 
more interested to attend weight loss programs than men (Yach et al., 2006), the researcher 
have selected only overweight and obese women as the study population. Among the 
recruited candidates, only healthy women with BMI of more than 25 were included and 
screened for the dietary intervention program. Pregnant and lactating women and 
individuals who suffered from specific health problems were excluded from this 
intervention. In general, individuals presenting with any medical condition or the use of 
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any medication that could have interfered with the conduct of the study or placed the 
prospective subject at risk; or known allergy or sensitivity to any of the ‘active’ or 
‘placebo’ product ingredients were excluded.  
Furthermore, the population is selected from Yazd wherein caraway is the common 
medicinal herb which is used traditionally in their regular diet as a flavoring for culinary 
purposes and also of its remedial benefits especially for decreasing weight in the form of 
water extract. Hence, it could be more acceptable for the population and also it would be 
easier to convince the individual to participate in this dietary intervention program. 
Moreover, caraway water extract is an affordable product which would be easily accessible 
at the Yazd market in the low price for consumption.  
The required data will be collected through questionnaire, face-to-face interview, 
physical examination, and biochemical tests on the candidates. In general, assessments 
were on body composition, anthropometric indices, appetite, and clinical and para-clinical 
variables of participants during twelve weeks intervention period. As there are a number 
of studies on anti-obesity effect of caraway constituents on animals, here, the researcher 
will conduct a clinical trial to evaluate the effect of CWE on human body weight. 
This study will introduce an alternative, natural product-based approach for weight loss 
which is potentially cheaper and healthier to consume, and with minimum human health 
risks. It is hoped that the results of this research will lead to additional studies which 
eventually will help patients shift from a temporary weight loss solution to a dietary 
practice that is long-lasting and sustainable. The findings of this study may be a useful 
indicator for patients who are not satisfied with the currently available slimming products, 
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and are still seeking a suitable, safe, and natural alternative. Incorporating natural products 
with potent anti-obesity properties into a daily human dietary regimen could be a safe, 
effective, consistent, and inexpensive method for both the treatment and prevention of 
obesity. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Traditional and Complementary Medicine 
2.1.1 Background 
Traditional and Complementary Medicine (T&CM) is a form of health-related practice 
with a long history in disease prevention, treatment, and management of different diseases 
especially for chronic ailments. Based on a recent WHO report on “Traditional Medicine 
(TM) Strategy 2014–2023”, “traditional medicine (TM) is an important and often 
underestimated part of health services”. In a number of countries, Traditional Medicine 
(TM) or non-conventional medicine is also characterized as complementary medicine 
(CM) (World Health Organization, 2014b). As stated by WHO (World Health 
Organization, 2001), “Traditional medicine includes a diversity of health practices, 
approaches, knowledge, and beliefs incorporating plant, animal, and/or mineral-based 
medicines; spiritual therapies; manual techniques; and exercises, applied singly or in 
combination to maintain well-being, as well as to treat, diagnose, or prevent illness.”  
According to a report by the National Medical Advisory Committee, Scottish Office 
Department of Health, Complementary Medicine and the National Health Services (1996), 
“Complementary medicine, in practice refers to a wide range of health interventions 
originating from different cultures across thousands of years of history.” In fact, TM is an 
ancient therapeutic practice which evolved and was practiced in human societies before 
the application of modern medical sciences to health care. It has developed based on 
various historical backgrounds and traditional ethnic origins (World Health Organization, 
2009b). Examples of T&CM practices include Iranian traditional medicine, Malay 
traditional medicine, many African traditional medicine systems, Islamic medical practice, 
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traditional Chinese medicine (TCM), traditional Indian medicine systems, such as the 
Unani and Ayurvedic systems, and many local practices of indigenous groups in other 
parts of the world (Shamsuddin, 2011). Complementary and Alternative Medicine (CAM) 
has been extensively and globally applied for decades. Although the use of modern 
medicine is widespread, the practice of TM is still applied in most countries of the world. 
However, application of TM is frequently not involved as a part of the accepted medical 
system by the government, and it is one of the numerous forms of non-standardized health-
care options (Bodeker et al., 2005). 
Traditional and complementary medicine plays a crucial role in the aspect of 
prevention, health promotion and healing. In some countries, it is used to quicken the 
remedial procedure, and also in sustaining health after treatment (World Health 
Organization, 2009b). At present, T&CM is a significant part of the health-care system 
which co-exists with modern medicine to improve health and the quality of life (Azaizeh 
et al., 2010). In a number of Asian and African nations, 80% of the people rely on TM for 
primary health care issues. In various developed countries including Australia, the United 
States, and European countries, 70% to 80% of the people practice some form of T&CM, 
especially using traditional medicinal plants (Barnes et al., 2008; Shamsuddin, 2011). At 
present, more than 100 million (one fifth) Europeans are using T&CM on a regular basis, 
and showing a higher preference for the T&CM system (European Information Centre on 
Complementary and Alternative Medicine - EICCAM, 2013). 
2.1.2 Policies on Traditional Medicine and Regulation of Herbal Medicines 
Traditional medicine has continuously sustained its global popularity. During the recent 
decades, the practices and applications of CAM has been growing in several developed 
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and developing countries. Numerous TM practices are developed in various nations and 
regions with different cultures. Over 70% of the people living in developing countries still 
depend mainly on the CAM practices (Azaizeh et al., 2010). The safety, efficacy, and 
quality control of TM and CAM have become significant concerns for both the health-care 
system and the patients. However, there is no comparable improvement of transnational 
and global standards and applicable approaches or appropriate systems for assessing TM 
safety, efficacy, and quality control (World Health Organization, 2005). 
According to the latest report of WHO on TM (World Health Organization, 2014b), 
different countries have encountered a number of problems concerning regulatory issues 
associated with application of T&CM. These issues include lack of research data and 
knowledge about medicinal plants; lack of appropriate systems to monitor and regulate 
herbal medicines, and T&CM advertising and claims; a deficiency of suitable assessment 
techniques to evaluate the safety of these products, and to control and regulate T&CM 
providers; insufficient financial support for the study of T&CM, a lack of proficiency and 
expertise within national health organizations and control agencies, insufficient education 
and training of providers, and an absence of cooperative channels between national health 
organizations to share data and knowledge about T&CM. These factors are sometimes 
responsible for the delays in the formation or updating of national strategies, laws, and 
protocols for TM, CAM, and herbal medicines. To meet these challenges, the WHO TM 
Strategy was established “to support countries in:  
a) Harnessing the potential contribution of TM to health, wellness and people centred 
health care  
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b) Promoting the safe and effective use of TM by regulating, researching and 
integrating TM products, practitioners and practice into health systems, where 
appropriate 
c) Developing proactive policies and implementing action plans that will strengthen 
the role TM plays in keeping populations healthy.” 
The WHO 2014 report was a follow-up to the earlier WHO Traditional Medicine 
Strategy 2002–2005 (World Health Organization, 2002) which had aimed to establish four 
main objectives:  
a) “Policy — integrate TM within national health care systems, where feasible, by 
developing and implementing national TM policies and programs.  
b) Safety, efficacy and quality — promote the safety, efficacy and quality of TM by 
expanding the knowledge base, and providing guidance on regulatory and quality 
assurance standards.  
c) Access — increase the availability and affordability of TM, with an emphasis on 
access for poor populations. 
d) Rational use — promote therapeutically sound use of appropriate TM by 
practitioners and consumers.” 
This new strategy document necessitates Member countries to define and regulate their 
own countrywide conditions with regard to T&CM, and then to improve and implement 
guidelines, policies, strategies, and protocols that reveal these authenticities. Member 
countries are suggested to respond to these challenges by establishing and organizing their 
accomplishments in the subsequent three strategic directions and strategic actions listed as 
follows: 
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“1. Build the knowledge base that will allow T&CM to be managed actively through 
appropriate national policies that understand and recognize the role and potential of 
T&CM.  
2. Strengthen the quality assurance, safety, proper use and effectiveness of T&CM by 
regulating products, practices and practitioners through T&CM education and training, 
skills development, services and therapies.  
3. Promote universal health coverage by integrating T&CM services into health service 
delivery and self-health care by capitalizing on their potential contribution to improve 
health services and health outcomes, and by ensuring users are able to make informed 
choices about self-health care.”  
Although important improvements were made known in applying these strategies 
around the world, Member states continued to encounter challenges associated with:  
a) “Development and enforcement of policy and regulations;  
b) Integration, in particular identifying and evaluating strategies and criteria for 
integrating TM into national and primary health care (PHC);  
c) Safety and quality, notably assessment of products and services, qualification of 
practitioners, methodology and criteria for evaluating efficacy;  
d) Ability to control and regulate TM and CM (T&CM) advertising and claims;  
e) Research and development;  
f) Education and training of T&CM practitioners;  
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g) Information and communication, such as sharing information about policies, 
regulations, service profiles and research data, or obtaining reliable objective information 
resources for consumers.”  
In general, countries encounter important challenges in the application and 
development of the T&CM and herbal medicines regulation. These challenges are linked 
to the regulatory conditions, safety and efficacy valuation, quality control, safety checking, 
and an absence of awareness about TM/CAM within the nation-wide drug regulatory 
system. 
2.1.3 Challenges Associated with the Regulatory Status of Herbal Medicines 
Before synthetic drugs became common, the application of medicinal plants played a 
significant, in many instances sole, role in treating different ailments (Roberti di Sarsina, 
2007). Different countries have great dissimilarity in the description and classification of 
medicinal plants (Association of the European Self-Medication Industry-AESGP, 2010). 
A medicinal plant might be known as a food, a functional food, a dietary supplement, a 
phytotherapeutical, or a herbal medicine being contingent to the protocols relating to the 
regulations applied to foods and drugs in each country. This issue causes difficulty in 
establishing what information should be available on medicinal plants for national drug 
instruction in training centres, and also patients might become confused of using these 
products (World Health Organization, 2005). 
2.1.4 Challenges Associated with the Medicinal Plants 
There are several issues and complications associated with the use of herbal medicines. 
The most important issues are including the evaluation of quality, safety, and efficacy 
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monitoring of medicinal plants in a national strategy (World Health Organization, 2000a). 
In general, procedures and necessities for investigation and assessment of the quality, 
safety and efficacy of medicinal plants are more challenging than those for orthodox 
medicines and drugs (World Health Organization, 2010). A single medicinal plant is 
comprised of numerous phytochemicals, and a mixed medicinal plant preparation may 
have hundreds of constituents. Moreover, excessive time, means and resources are needed 
to isolate every bioactive constituent from every plant. In reality, such an examination and 
analysis is practically unmanageable and difficult, especially for the mixed medicinal plant 
preparations (World Health Organization, 1998a).  
Moreover, the safety and efficacy of medicinal plants is determined by the quality of 
the ingredients applied in their production. Also, the quality of ingredients is closely linked 
with intrinsic aspects (genetic) and extrinsic aspects (environment, growing crop and 
harvesting conditions, collecting field and post-harvest, transportation and storing) (Fong, 
2002). Consequently, it is very problematic and hard to accomplish quality controls on the 
basic and primary resources of medicinal plants (World Health Organization, 2011b). In 
the quality control of final medicinal plant preparations, especially a mixed herbal formula, 
it is harder to determine the safety and efficacy of the mixed product. Because the 
combination of phytochemicals might result in inter-reactions between the ingredients 
which also probably affects the quality of the mixed product (Heber, 2003; World Health 
Organization, 1998c). Adverse effects caused by use of medicinal plants might be due to 
several reasons. These factors involve the consumption of the mistaken species of herb, 
contamination or adulteration of plant product, over dosage, misusage, or drug 
interactions. Consequently, the investigation of adverse or side effects associated with the 
consumption of medicinal plants is more problematic and complicated than modern 
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medications (World Health Organization, 2004). Additionally, medicinal plants are 
usually used for self-care; hence, there is a substantial need to educate patients and 
community in their appropriate and correct use (World Health Organization, 1998b, 
2009a). 
Overall, the policy could play important role in regulating safety and efficacy of 
traditional medicinal plants which is considered as a challenging issue in recent researches. 
Herbal medicine is generally categorized into four elementary classifications including: 
“Traditional Chinese herbalism, Ayurvedic herbalism, Western herbalism, and Traditional 
Islamic herbal medicine” (Azaizeh et al., 2010). One of the options is traditional herbal 
medicine based on Islamic perspectives which will be discussed in the next section.  
2.1.5 Traditional Medicine and Practices in Iran 
The practice and research on medicine in Iran goes back to the olden times over six 
centuries ago. TM in Iran reached to its uppermost activities during nine and tenth century 
AD. However, it started to weaken at the beginning of 18th century mostly due to the 
development of allopathic medicine. Regardless of the growing expansion of the allopathic 
medical structure, TM retained its popularity with patients. The endurance and 
sustainability of TM among Iranians are mostly due to public belief and more trust in TM, 
the failure of orthodox medicine in curing certain ailments, the research and practice on 
medicinal plants among the patients and scholars, and Islamic perspectives (Bodeker et 
al., 2005; Mosaddegh & Naghibi, 2001). 
Islamic medical practices were likely implemented from the Byzantine and Persian  
philosophies. Ancient Iranian Medicine called “Irani-tebb/Tebb-e-Sonnati” is one of the 
20 
well-known forms of TM which was developed by Ibn Sina, known as Avicenna in the 
West (Peewãz, 1986; wikipedia.unicefuganda.org, 2013). The most influential medical 
texts are from the medieval Persian Islamic Medicine in the 9th and 10th centuries AD. 
Some of these references are mentioned in Table 2.1 (Ghadiri & Gorji, 2004). One of the 
greatest methodical and inclusive manuscripts was Avicenna's Canon of Medicine, which 
was translated into Latin and then distributed all over Europe. This medical literature was 
used in European scientific centres for more than 600 years and only during the period of 
the 15th and 16th centuries, it was published above 35 times (Siraisi, 2001).  
The Islamic Republic of Iran established its national policy on TM/CAM in 1996, along 
with developing guidelines and regulations on herbal medicine. Annual market sales in 
Iran for herbal products was around US$ 3 million, in 1999, US$ 3.1 million in 2000, and 
US$ 3.5 million in 2001 respectively (World Health Organization, 2005). In recent two 
decades, there is great rise in experimental studies on Iranian TM using modern scientific 
methods (Bodeker et al., 2005). These studies raised the possibility of revival of traditional 
treatments on the basis of evidence-based medicine (Gorji & Khaleghi Ghadiri, 2001).  
One of the well-known medicinal plants in Iranian traditional medicine, is caraway with 
several healing properties. It is mostly used for alimentary problems due to its carminative 
and stomach-calming properties. In Iranian-Islamic traditional references such as Makhzan 
Al-Advieh, regular consumption of caraway extract is prescribed for losing weight (Aqili 
Khorasani, 2001), and today, it is sold as an anti-obesity product in Iran’s markets. In this 
study, the researcher will examine the anti-obesity effect of caraway on human through a 
randomized clinical trial (RCT). 
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Table 2.1: Some of the most influential medical texts in Islamic medicine 
Persian 
Name 
Name in 
Farsi 
English/Latin 
Name/Meaning 
Author Theme, description Century 
Firdous al-
Hikmah 
ةمکحلا سودرف Paradise of 
Wisdom 
Al-Tabari 
(teacher of 
Rhazes) 
Ancient medical 
encyclopedia on general 
medicine, psychotherapy, 
… 
9 (A.D) 
Kitab al Nibat باتک تابنلا Book of Plants Ibn Dawoud Al-
Dinawari (the 
father of Arabic 
botany) 
Described more than 
600 plants and their uses in 
his book  
9 (A.D) 
al-Hāwī fī al-
Tibb 
يواحلا یف بطلا TheVirtuous Life, 
Liber Continens 
Rhazes, Rāzi The comprehensive book 
on general medicine 
9 (A.D) 
Al Mansuri Fi 
al-Tibb 
 باتكلا
 يف يروصنملا
بطلا 
Liber Medicinalis 
ad. 
Almansorem,The 
Book on 
Medicine 
Dedicated to al-
Mansur 
Rhazes, Rāzi General medicine, medical 
pathologies of the body 
10 
(A.D) 
al-Judari wa 
al-Hasbah 
یردوجلا و 
هبصحلا 
Treatise on small 
pox and measles 
Rhazes, Rāzi Infectious diseases, 
differential diagnosis 
10 
(A.D) 
Al-Qanun 
fi’al-Tibb 
نوناقلا  بطلا يف The Canon, the 
rules of medicine 
Avicenna General medicine 10 
(A.D) 
Resaleh dar 
Nabz 
هلاسر رد ضبن Pulse Avicenna Cardiovascular diseases 10 
(A.D) 
Zhakhireh 
Kharazmshahi 
هریخذ 
یهاشمزراوخ 
The treasure of 
Khvarazm’Shah 
Esmail Jorjani General medicine 10 
(A.D) 
Somom مومس Poisons Qhortabi Toxicology  10 
(A.D) 
Source: Modified from Ghadiri and Gorji (2004) 
In conclusion, based on previous studies, one of the recent initiatives of the Western 
Pacific Regional Office of WHO has been the development of a revised Regional Strategy 
for Traditional Medicine in the Western Pacific for the period 2011-2020 (World Health 
Organization, 2012). The strategic directions describe possible approaches to improve the 
quality, safety, and efficacy of traditional medicinal plants in health care in the region, and 
recognize that the 27 regional countries embrace broad stages of economic development 
and research capacity. Cooperation within and between countries to address issues of 
quality, safety, and efficacy of botanical materials of known or standardized content is 
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therefore strongly encouraged to enhance regional health care (World Health 
Organization, 2014b). 
Since obesity is recognized as one of the global health concern, and also recently, there 
has been a renewed interest in natural obesity medications and application of herbal 
medicine for weight loss, in the next section, the researcher will discuss on obesity as a 
challenging health issue, describing the prevalence, risk factors, and consequences of 
obesity, coming together with the challenges in treating obesity. Further, the weight loss 
claims on dietary supplements and natural medications will be discussed, focusing on the 
safety and efficacy of medicinal plants. Finally, the researcher will give details on the 
application of caraway, as a potent traditional medicinal plant for weight loss. According 
to the ancient Persian-Islamic references in the 9th and 10th century AD such as Rhazes' 
book al-Hāwī fī al-Tibb, Ibn Dawoud Dinawari’s book Kitab al Nibat (Book of Plants) and 
Avicenna's Al-Qanun fi’al-Tibb (The Rules of Medicine), caraway is acclaimed to have 
healing properties especially for treating obesity. Hence, the researcher has tried to conduct 
a clinical trial to evaluate the efficacy and safety of caraway water extract on overweight 
and obese women. 
2.2 Obesity and Overweight 
Obesity is an important global health concern, and is associated with high morbidity 
and mortality rates. Today, it is recognized as a global health problem which occurs as a 
result of the accumulation of excess fat in the body. Based on the classification by WHO 
(World Health Organization, 2000b) a body mass index (BMI) greater than 25 kg/m2 is 
defined as overweight (pre-obese) and BMI value of greater than 30 kg/m2 is termed as 
obesity. This classification is shown in Table 2.2. Despite a variety of studies on the 
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treatment and management of this disease, “Globesity” remains a challenging issue 
(Cheng, 2006). Most interventions conducted on obese children afforded outcomes which 
were negligible, demonstrating the requirement for more specific, focused research (Boon 
& Clydesdale, 2005). The majority of the current approaches to treat obesity typically use 
synthetic chemical-based medicines. However, the high costs and the side-effects of these 
drugs necessitate that patients and researchers in most of the world seek alternative 
therapeutic approaches (Rucker et al., 2007). One of the main factors related to prevalence, 
as well as the management of obesity, is the dramatic changes that have occurred on a 
global basis in dietary patterns during recent decades (World Health Organization, 2003).  
Table 2.2: Classification of obesity according to WHO 
BMI Classification 
< 18.5 underweight 
18.5–24.9 normal weight 
25.0–29.9 overweight 
30.0–34.9 class I obesity 
35.0–39.9 class II (severe obesity) 
≥ 40.0 class III (morbid obesity) 
Source: World Health Organization (2000b) 
2.2.1 Prevalence of Obesity 
Since 1997, the World Health Organization (WHO) has warned of obesity as a global 
epidemic although it was not noticeable during most of the 20th century. Statistics show 
that the prevalence of obesity had reached 400 million adults by 2005, which is equal to 
9.8% of the global population, and had risen to 500 million (11%) in 2008. Also, 1.4 billion 
equal to 35% of adults over 20 years old were overweight in 2008. Recently, WHO has 
informed that global prevalence of obesity and overweight is almost doubled since 1980 
(Caballero, 2007; World Health Organization, 2011a).  
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As the population grows, simultaneously, obesity penetrates all layers of the population. 
Across OECD (Organization for Economic Co-operation and Development) countries, one 
in two adults is currently overweight, and one in six is obese (Maury & Brichard, 2010). 
The rate of overweight people (BMI>25 kg/m2) is projected to increase by a further 1% 
per year for the next 10 years in some countries (Sassi, 2009). Figure 2.1 shows this trend 
graphically. This prevalence is greater in older people, especially in the age range of 50-
60 years old, and higher rates of obesity are seen among women than men (James, 2008; 
Seidell, 2005). Besides, severe obesity grows faster than the overall rate of obesity in the 
developed and high income countries such as United States, Australia, and Canada 
(Howard et al., 2008).  
 
Figure 2.1: Past and projected overweight trends in different countries 
Adopted from: Sassi (2009) 
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According to the ‘International Association for the Study of Obesity/International 
Obesity Taskforce’ (IASO/IOTF) analysis (2010), around 1.0 billion adults are presently 
overweight, and an additional 600 million are considered obese globally. Also, up to 150 
million school aged children are overweight, and 40-50 million are categorized as obese. 
In the European Union (EU) 27 member states, almost 260 million (60% of adults) and 
over 12 million equal to 20% of children are either overweight or obese. In addition, severe 
obesity (BMI between 35-39.9) has grown faster than the overall rate of obesity in the 
developed countries, such as the United States, Australia, and Canada (Howard et al., 
2008). However, during recent decades, obesity has penetrated the developing countries, 
even in the rural areas, at a faster rate (Kopelman, 2000; World Health Organization, 
2014a). Sub-Saharan Africa is the only area where obesity is not seen to any great extent 
(Haslam et al., 2006). In Western Africa, obesity rates in 2008 were around 10% which 
was higher in urban residents and women (Abubakari et al., 2008). In China, overweight 
and obesity in adult raised from 12.9% in 1991 to 27.3% in 2004 (Popkin, 2007). The 
overweight and obesity rate in Iran in 2008 was 40.6% and 26.3% respectively, wherein, 
the rate of central obesity was higher among women (72.2%) than men (26.6%) (Rashidy‐
Pour et al., 2009). In 2013, the prevalence of overweight and obesity in the adult Iranian 
population over 20 years old has been raised up to 50 to 70% (Delshad, 2013). In brief, 
obesity has become a widespread disease existing in different social, economical, cultural, 
regional, and age groups. Consequently, this hidden hazard is affecting human life multi-
dimensionally (Kottke et al., 2003; Yach et al., 2006). The next section will discuss on the 
obesity causes and risk factors. 
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2.2.2 Etiology and Risk Factors of Obesity 
Urbanization and modernization are reported as two major factors related with obesity. 
Following globalization, people in the developing countries are also accepting the 
unhealthy Western dietary habits and lifestyles which contribute to weight gain and 
obesity. During recent decades, intake of sweetened beverages, vegetable oils and animal-
origin foods (meat, poultry, fish, eggs and dairy products) is increased dramatically 
especially in low income population and developing countries (Radzi et al., 2013). 
Although governments are bearing in mind various interventions and aid programs, still 
limited countries have been able to effectively reduce their overweight populations 
(Popkin, 2004; Popkin, 2007). Nutritionists believe that sedentary lifestyles, stress, and 
dietary habits resembling those of Western countries are the main underlying factors of 
overweight and obesity in the global population (Maddock, 2004; World Health 
Organization, 2011a). 
2.2.3 Obesity Consequences and Health Problems 
Overweight, as a major obstacle in the maintenance of human health, may lead to a 
large number of chronic diseases (Wyatt et al., 2006). Moreover, the consequences of 
obesity in terms of morbidity and mortality are very important, as it is now one of the 
leading causes of death worldwide. According to the classification of obesity by WHO, a 
body mass index (BMI= weight/height2) value of greater than 40 Kg/m2 is termed “morbid 
obesity” (World Health Organization, 2000b). Studies show that obesity is related to 
cardiovascular diseases, hypertension, diabetes mellitus, gallbladder disease, different 
types of cancer, endocrine and metabolic disturbances, osteoarthritis, gout, pulmonary 
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diseases, as well as psychological issues, including social bias, prejudice, discrimination, 
and overeating (Mokdad et al., 2004; World Health Organization, 2011a).  
Excess body fat is also associated with the development of several life-threatening 
chronic conditions (Guh et al., 2009). According to a WHO report, obesity is related to a 
wide range of health problems, including cardiovascular diseases, hypertension, diabetes 
mellitus, gall bladder disease, cancer, endocrine and metabolic disturbances, osteoarthritis, 
gout, pulmonary diseases, and eating disorders, as well as psychological problems 
resulting from social bias, prejudice, and discrimination (World Health Organization, 
2011a). Accordingly, overweight is regarded both as a cosmetic issue, and as a major risk 
factor for human health (Kopelman, 2000) which may decrease life expectancy (Olshansky 
et al., 2005). Consequently, the potential health benefits of a reduction in excess weight 
are of considerable public health and economic importance (Sofi et al., 2010). However, 
despite vast attempts to address this issue, “globesity” remains an enormous challenge.  
From an economic perspective, obesity, and its related health consequences, involves 
enormous costs for both the current and future health care systems, including physician 
visits, hospitalization, and numerous other related expenses (Picot et al., 2009; Wolf & 
Colditz, 1998). According to recent statistics, the health care costs related to obesity and 
its complications in 2005 were estimated around $70 to $100 billion, and this amount is 
projected to increase quickly with rapid escalations in the prevalence of obesity and its 
health complications such as diabetes, heart diseases, and cancer, which is unavoidable. 
These data include Medicare, Medicaid and private insurers, and reflect the ascending 
trend in the obese adult population in the US from 12% to 35.7% between the years 1989-
2010, and which is projected to rise further to 47.5% by 2020. In short, obesity can cause 
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a decline in life expectancy (Olshansky et al., 2005). However, despite vast attempts to 
address this issue, “globesity” remains an enormous challenge (Delpeuch et al., 2013; 
Wang et al., 2011). Based on the previous literature review, there are still challenges in 
the current methods for treatment and management of obesity which will be discussed in 
the next section.  
2.2.4 Challenges in Treating Obesity 
Today, weight control is recognized as a common global concern (Kruger et al., 2004). 
Millions of people have attempted to control their weight at some time to have a healthier 
and happier life. One of the most favoured ways for losing weight is self-medication with 
over-the-counter anti-obesity pills and weight-loss dietary supplements. According to a 
survey of around 15,000 US adults, in 1996-1998, 7% of them had consumed non-
prescription weight loss products. It is presumed that this percentage would be greater if a 
survey were conducted today. Also, the demand for these slimming aids is high, and it is 
likely to increase simultaneously with obesity rates (Blanck et al., 2001). During 2000-
2001, Americans spent $50 billion each year on anti-obesity programs and products. 
However, $6 billion of this was spent on dietary supplements and weight loss pills. This 
investment in personal concerns with respect to weight rose to $55.4 billion in 2006 
(Blanck et al., 2007; Sharpe et al., 2007). However, most of the long-term usage of these 
weight-aid products is not under any medical or nutritional supervision (Kruger et al., 
2004). 
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2.2.5 Weight Loss Claims on Dietary Supplements 
Recently, there has been a proliferation of different anti-obesity products appearing on 
the market (Viner et al., 2009). They are typically high-cost products and their long-term 
consumption is not recommended, as several have exhibited significant side effects, 
including gastrointestinal symptoms, kidney and liver dysfunctions, and even 
psychological problems (Rucker et al., 2007). For example, among the varieties of anti-
obesity drugs, only Orlistat and Sibutramine can be used long-term (Padwal & Majumdar, 
2007). In addition, a number of the synthetic products and dietary supplements do not 
satisfactorily impact weight loss, or are not well-tolerated (Dwyer et al., 2005). 
Meanwhile, the use of natural remedies for weight loss has increased. Scientists believe 
that botanical sources maybe safer, more reliable, and also cheaper than current 
conventional methods, such as synthetic drugs or surgical procedures, which may have 
adverse effects, or be of limited duration in effectiveness (Chang, 2000; Clegg et al., 2003; 
Sui et al., 2012).  
Can medicinal plants serve as a sustainable resource for standardized agents which can 
meet patient expectations for weight loss and provide long-term, consistent health 
benefits? This issue will be discussed in the following section.  
2.2.6 Natural Anti-Obesity Medications: Medicinal Plants 
Currently, nutritionists and healthcare specialists believe that a reasonable level of 
physical activity, in combination with proper eating habits, are the two basic principles of 
a healthy lifestyle (Lau et al., 2007). Habituating these major components will help 
individuals to maintain their body weight and health in the ideal situation. Meanwhile, 
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approaching a balanced body weight could be easier and faster by integrating other useful 
methods which enhance weight loss. One of these methods is the consumption of 
medicinal plants which people use traditionally to lose weight. Recently, the use of natural 
remedies for weight loss has increased, based on reliability, safety, and cost compared with 
synthetic drugs or surgical procedures, which may have limitations. Incorporating these 
natural ingredients within a daily diet will assist an individual to lose weight in a cheaper, 
easier, faster, and healthier way (Picot et al., 2009; Roy & Nallanayagam, 2011). Here the 
researcher will provide a review of the accessible botanical sources for the treatment of 
obesity, explaining how these medicinal plants act in humans to cause weight loss, and 
which method of usage is safer and more efficient. 
Studies show that a number of natural food ingredients and medicinal plant preparations 
are able to enhance satiety, boost metabolism, and speed up weight loss (Yun, 2010) . The 
weight lowering effects of these potent plants might be due to the presence of fibre which 
suppresses appetite, or specific phytochemicals such as caffeine, phenolic compounds, etc. 
which are able to down-regulate obesity by enhancing thermogenesis, lipolysis, etc. (Hsu 
& Yen, 2008; McCrory et al., 2010). Including these foods in the diet on a regular basis 
will therefore assist an individual to lose weight slowly and safely. However, there are still 
some doubts about the application of these products for humans. Because usually, there is 
a misunderstanding in the consumption of plant products without any limitation in dosage, 
preparation and composition (mixed with other herbs) while in some cases, consumption 
of a number of plant-based food supplements have shown adverse effects on the human 
body, such as liver toxicity which might be due to over dosage intake or possible 
synergistic effects of mixed plant  components (Arbo et al., 2009; Dara et al., 2008; 
Hansen et al., 2013). On the other hand, despite the global market for satiety, fat burning, 
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dietary supplements, and other weight management remedies, the awareness of the 
usefulness of these products is neither sufficient, nor clearly perceived by patients, 
physicians or nutritionists (Esmaillzadeh & Azadbakht, 2008).  
2.2.6.1 Mechanism of Action of Antiobesity Medicinal Plants 
Natural anti-obesity preparations can induce weight loss through several mechanisms. 
Their functions can be classified into five major categories, as shown in Table 2.3. 
Table 2.3: Different functions of anti-obesity medicinal plants in humans 
Anti-obesity 
function 
Mechanism of 
action 
Anti-obesity preparations from different natural sources 
Reducing food 
intake  
Inhibiting appetite 
and reducing food 
intake 
pine nut (Pasman et al., 2008), pomegranate leaf (Lei et al., 2007), 
ginseng (Kim et al., 2005), Hoodia gordonii (Van Heerden, 2008) 
Enhancing 
thermogenesis  
Stimulating 
sympathetic 
nervous system and 
increasing 
metabolic rate 
sea weed (Maeda et al., 2005; Maeda et al., 2007; Maeda et al., 2008), 
bitter orange (Haaz et al., 2006), red orange (Dallas et al., 2013), sour 
orange (Preuss et al., 2002), soybean (Ishihara et al., 2003)  
Decreasing the 
absorption of 
lipids  
Inhibiting 
pancreatic lipase 
activity 
chitosan (Bondiolotti et al., 2007; Jun et al., 2010), levan (Kang et al., 
2006), mate tea (Martins et al., 2009), oolong tea (Hsu et al., 2006; 
Nakai et al., 2005), green tea (Koo & Noh, 2007) 
Preventing 
adipogenesis  
Inhibiting adipocyte 
differentiation 
turmeric (Ahn et al., 2010), capsicum (Hsu & Yen, 2007a), palm oil 
(Uto-Kondo et al., 2009), banana leaf (Bai et al., 2008; Klein et al., 
2007), brown algae (Maeda et al., 2006), garlic (Ambati et al., 2009), 
flaxseed (Tominaga et al., 2009), black soybean (Kim et al., 2007) 
Increasing 
lipolysis and fat 
oxidation 
Stimulating 
sympathetic 
nervous system, 
enhancing lipid 
metabolism 
herb teas (Okuda et al., 2001), cinnamon (Sheng et al., 2008), orange 
and grapefruit (Dallas et al., 2008), Nelumbo nucifera leaves (Ohkoshi 
et al., 2007) 
Source: Taken from several sources  
Based on the inhibition of pancreatic lipase activity, the intake of some medicinal plants 
will prevent the absorption of lipids in the intestine. Consequently, non-absorbed fat will 
be excreted through oily faeces. Furthermore, certain bioactive components can promote 
energy expenditure by increasing basic the metabolic rate, which enhances thermogenesis. 
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This function will help the body to burn additional calories and excess body fat. Through 
prevention of adipocyte differentiation, medicinal plant consumption will inhibit 
adipogenesis and the formation of fat cells in adipose tissues. Moreover, based on 
enhancing lipid metabolism (lipolysis) some medicinal plant products can increase 
lipolysis through inducing β-oxidation or noradrenaline secretion in fat cells. Other anti-
obesity ingredients are able to suppress appetite and induce satiety, which will help 
individuals to control their appetite. Finally, these different functions of antiobesity 
medicinal plants will cause a reduction of food and energy intake (Yun, 2010). 
2.2.6.2 Efficacy and Safety of Antiobesity Medicinal Plants 
Medicinal plant samples can be collected from the whole plant, or from parts of the 
plant, such as the stem, bark, leaf, flowers, and roots. These materials are then processed 
into different forms, such as powder or capsules. However, most of the medicinal plants 
which have shown antiobesity properties were prepared in the form of aqueous or alcoholic 
extracts. This may be because the decoction, distillation, and infusion procedures can 
concentrate the constituents responsible for the therapeutic efficacy of the examined herb.  
Some components which might inhibit the anti-obesity function of the bioactive 
compounds might be removed by the extraction procedure. Extraction and partial 
purification, or the isolation of the active principle(s) could increase the bioavailability of 
the bioactive constituents in medicinal plant extracts which consequently will enhance the 
efficacy of medicinal agent in losing weight (Calixto, 2000).  
In other studies, scientists have examined the anti-obesity properties of mixtures of 
medicinal plants. However, in several cases shown in Table 2.4, the consumption of 
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different antiobesity preparations in combination with other plant-based ingredients could 
produce unexpected side-effects. Based on previous studies, the application of single 
medicinal plants has not caused any adverse events. On the other hand, the undesired 
effects on the human body could be due to interactions between the different 
phytochemical constituents present in the different plants (Heber, 2003). 
In summary, consumption of such potent plants regularly, and in optimum dosage, can 
induce weight loss gradually and naturally while the chemical anti-obesity products 
usually act faster with severe and considerable changes on the normal body function, and 
which most probably could result in unfavorable effects on the human body. Hence, the 
medicinal plants can be considered as a safe alternative for chemical anti-obesity 
medications (Preuss et al., 2002). 
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Table 2.4: Safety and efficacy of antiobesity medicinal plant preparations 
Medicinal 
Plant  
*Result Adverse 
effects 
Combination formula Result Adverse 
effects 
Kidney bean 
(Phaseolus 
vulgaris) (Udani 
et al., 2004) 
+ (p=0.07) Not 
reported 
In  combination with green tea 
extract (Birketvedt, 2009) 
inter group 
differences (+) 
Flatulence, soft 
stool, 
constipation 
Green tea 
(Camellia 
sinensis) 
(Nagao et al., 
2007) 
+ 
(p<0.05) 
Not 
reported 
In combination with 
asparagus, black tea, 
guarana, kidney bean, 
Garcinia cambogia and 
chromium yeast (Opala et 
al., 2006) 
no inter-group 
difference in 
weight (-) 
Gastrointestina
l complaints 
Rhubarb 
(rheum) (Jin & 
Jiao, 1994) 
+ Not 
reported 
In combination with ginger, 
astragulus, red sage, and 
turmeric, combined with gallic 
acid (Greenway, Liu, et al., 
2006; Roberts et al., 2007) 
greater weight 
gain in 
intervention 
group/ (-) 
Gastrointestina
l, oral, 
dermatologic, 
irritation, 
headache. 
Glucomannan 
fiber (Walsh et 
al., 1984) 
+ 
(p<0.005) 
Not 
reported 
In  combination with chitosan, 
fenugreek, Gymemna 
sylvestre, vitamin C 
(Woodgate & Conquer, 2003) 
inter group 
differences (+) 
(p<0.01) 
Constipation, 
headache, 
indigestion 
Garcinia 
cambogia 
(Mattes & 
Bormann, 2000) 
+ 
(p=0.03) 
Not 
reported 
In  combination with natural 
caffeine (Rothacker & 
Waitman, 1997) 
No inter 
group 
differences 
(p=0.3) 
Not reported 
Bitter orange 
Citrus 
aurantium) 
(Stohs et al., 
2011) 
+ Not 
reported 
In combination with 
pantothenic acid, green tea leaf 
extract, guarana, white willow 
bark and ginger root 
(Greenway, de Jonge-Levitan, 
et al., 2006) 
greater weight 
gain in 
intervention 
group 
(p<0.04) 
Hypertension, 
musculoskeletal, 
neurological, 
migraine, 
anxiety 
* Results indicate the efficacy and intergroup difference      
Source:  Taken from several sources 
 
On the other hand, single and mixed, anti-obesity medicinal plant preparations can have 
different effects. In fact, the dietary intake of these medicinal plants in the natural form, 
when taken singly, can apparently provide a higher degree of safety and efficacy than when 
mixed medicinal plant preparations are applied. These findings support the 
recommendation of many health organizations regarding the consumption of natural 
ingredients on a regular basis. However, there are other factors which can also affect the 
results of such studies, including the treatment dosage applied, the quality of the botanical 
preparations, the route of administration, the presence and concentration of various 
bioactive components, and their respective functions, the experimental methods used, the 
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study design, the duration of treatment, and the safety and efficacy of the ingested plant. 
Introducing such potential plants will help patients to use them as an alternative approach 
along with other alternative treatments, such as acupuncture and hypnotherapy, in the 
management of obesity (Sui et al., 2012). 
Efforts to improve knowledge for patients regarding the consumption of anti-obesity 
medicinal preparations other than chemical medicines which have become popular, and 
provide encouragement to overweight and obese patients to consume them at an optimum 
dosage, along with an enhanced exercise regimen and a healthy diet should be continued. 
In addition, more chemical, biological, and controlled clinical studies are needed on the 
effectiveness of standardized, selected medicinal plants, particularly those used as spices 
and condiments, in ameliorating and treating obesity in humans.  
In the next section, the researcher will discuss on caraway as one of the potent medicinal 
plants for treating obesity, focusing on various aspects of the background of caraway. 
Among the topics covered here include the use, the definition and classification of 
caraway, the botanical description and morphology, the etymology, and the geographical 
distribution, cultivation, and regions of production. Attention is then turned to the 
ethnopharmacological and therapeutic applications of caraway, the chemical compounds 
and the biological activities, and the safety and toxicological evaluations of caraway-based 
products.
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2.3 Caraway (Carum carvi) 
2.3.1 Background Literature on Caraway 
Carum carvi, which belongs to the Apiaceae family, is one of the earliest cultivated 
herbs in Asia, Africa and Europe. Caraway seeds have remained popular as culinary 
spices and are also overwhelmingly used in traditional therapy since antiquity in diverse 
geographical areas.  
The Apiaceae family is a collection of typically aromatic plants having hollow stems 
comprised of more than 434 genera and 3,780 species. Among the well-known members 
of the family are anise, asafoetida, caraway, carrot, celery, coriander, cumin, dill, fennel, 
parsley, parsnip, and sea holly (Bennett, 2010; Brechbill, 2012; Papini et al., 2007). 
Caraway is sometimes referred to as meridian fennel, even though another plant, 
Foeniculum vulgare Mil. (Apiaceae) has also been ascribed the name fennel.  In Arabic, 
C. carvi is known as “Karawiya”. Previous studies have established an association 
between the moderate consumption of caraway oil/aqueous extract and other caraway-
derived preparations with a lower incidence of diabetes, dyslipidemia, hypertension, liver 
dysfunction, reproductive hormone imbalance, osteoporosis, cancer, and gastrointestinal 
and inflammatory diseases (Johri, 2011). 
2.3.2 Definition and Classification, Botany and Morphology of Caraway 
Caraway is defined as the dried ripe fruit of the biennial, usually white-flowered, 
aromatic Old World herb (Carum carvi L., Apiaceae), also known as Persian cumin or 
meridian fennel, and is one of the ancient cultivated plants of Asia, Africa, and Europe 
(Khan & Abourashed, 2011).  The fruits (also known, erroneously, as “seeds”) are used 
extensively as a mild spice and flavoring for culinary purposes in many cuisines. Caraway 
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seeds are also widely used in various systems of traditional medicine, and the aromatic 
constituents have been studied for their health beneficial effects (Perry & Metzger, 1980; 
Prance & Nesbitt, 2005). The plant resembles a carrot plant with feathery leaves and is 
slender, branched, and hollow-stemmed, 30-80 cm in height. The dried, brown fruits are 
hard, crescent-shaped achenes, around 2 mm long, with five pale ridges (Vaughan & 
Geissler, 2009). Caraway flowers, and caraway ripened and dried fruits are shown in 
Figure 2.2 (© Copyright Mel Harte 2010), Figure 2.3 (© Les Mehrhoff, 2008-2010), and 
Figure 2.4 (Discover Life organization), and in sketched form in Figure 2.5 
(http://www.discoverlife.org/ap/copyright.html). The fruits have a pleasant odor, and an 
aromatic flavor and sharp taste; they are similar to cumin, with which they are sometimes 
confused (Prance & Nesbitt, 2005). In Middle East countries they are distinguished by 
their color; caraway is known as black zeereh and cumin seeds known as green zeereh 
(Ghazanfar, 2011). 
 
Figure 2.2: Caraway plant in flower 
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Figure 2.3: Caraway plants with ripening fruits 
 
 
Figure 2.4: Dried caraway fruits (often termed caraway seeds) 
Adopted from: http://www.discoverlife.org/ap/copyright.html 
 
 
Figure 2.5: Carum carvi L. 
Adopted from: Britton and Brown (1913) 
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Several other plants are often mistaken for caraway (Carum carvi) due to their 
similarity in odour or appearance, including anise, fennel, cumin, black cumin, and black 
caraway (Natural Resources Conservation Service; United States Department of 
Agriculture: USDA-NRCS, 2013) Please refer to the Appendix A which shows the 
appearance and common name of some of these aromatic plants. Also, the etymology and 
synonyms of caraway in different languages will be explained in Appendix B. 
2.3.3 Origin, Geographical Distribution, and Cultivation 
The origin of caraway, as one of the oldest recognized spice plants, is unknown. 
However, the names Persian caraway and Roman cumin suggest that it was introduced 
into global commerce and usage from Persia or Europe. It has been cultivated since olden 
times, and is found growing wild all over central Asia, especially in Iran, the Himalayas, 
northern and central Europe, the Balkans, and North Africa. By 1806 it was being 
cultivated in North America, where it was used as a flavoring to season bread and cheese, 
and as a pickling spice, to prepare the liquor Kummel, and to give flavor to sausages. 
Presently, it is mainly cultivated in North Africa, especially Egypt, and in Finland, the 
Netherlands, Eastern and Northern Europe, and Germany, the Mediterranean regions, 
Russia, Iran, Indonesia, and North America (Levetin & McMahon, 1999; Rosengarten, 
1969; Sadowska & Obidoska, 2003). 
Even though the plant is indigenous to Asia, Europe, and Northern Africa, the plants 
are cultivated in several different regions throughout the world, this plant is better adapted 
to cooler climates than other Apiaceae species. Caraway plants are grown widely as a 
winter plant and as a summer crop in different regions, such as in Northern France, and 
the north Himalayan region in India (Khare, 2008; Prance & Nesbitt, 2005). In warmer 
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regions, it is cultivated in the winter months as an annual, and in temperate climates it is 
cultivated as a summer annual or biennial plant. There is still some domestic production 
of caraway in Europe, including Germany and Scandinavia, even though it is mostly 
imported from Egypt, and the cultivation of caraway as a spice crop has been expanding 
in the United States and Canada (Rosengarten, 1969; Sher et al., 2010). Figure 2.6 shows 
the point growth map of Carum carvi in different regions worldwide.  
 
Figure 2.6: Point growth map of Carum carvi (Discover Life organization) 
Adopted from: http://www.discoverlife.org/ap/copyright.html 
2.3.4 Historical Background and Traditional Usage of Caraway 
For thousands of years, caraway has been used, particularly in China, Egypt, Roman 
Britain, the Sumer area, and India, as a culinary seasoning (Jones, 1996), and may have 
been in use in Europe longer than any other spice.  It was used by the Early Greeks in 
their recipes, and also recommended and prescribed by Dioscorides for healing purposes 
(Prance & Nesbitt, 2005). It is one of the most important species used as a wild food plant 
in the Eurasia regions and Estonia (Kalle & Soukand, 2012), and is utilized in the cuisines 
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of the Middle East, India, Central Europe, and North Africa, especially Tunisia and 
Yemen (Lim, 2013) for its pungent licorice flavor (Halberstein, 2005), which is derived 
from the essential oils, especially carvone and limonene. This culinary flavoring is found 
in sauerkraut, casseroles, curries, and other foods such as specific cheeses, different 
liqueurs, breads, cakes, desserts, and salads (McKenna, 1999) as well as a spicy marinade 
for meats, dumplings, and goose (Vaughan & Geissler, 2009). In the Middle East, 
caraway pudding is a popular dessert during Ramadan, and the seeds are added as a spice 
in Persian cuisine to foods such as bread, yogurt, pickles, sauces, and salads (Zargari, 
1995). Caraway seed oil is also used as a fragrance component in soaps, lotions, and 
perfumes.  
2.3.5 Ethno-Pharmacological and Therapeutic Applications of Caraway in 
Traditional Medicine 
From a therapeutic perspective, caraway is known as a traditional medicinal plant with 
a long history of healing (Johri, 2011; Jones, 1996; Kenner & Requena, 2001). It is 
believed to have many of the medicinal properties similar to dill, fennel, and anise, and 
is reported to have potent anti-spasmodic, antiseptic, aromatic, carminative, digestive, 
and stimulant properties. It has been used by chewing the raw dried fruits, and also in the 
form of drink or tea through brewing, decoction, distillation, fermentation, or as a tisane 
(Bown, 2001; Chevallier, 2000; Chopra et al., 1986; Grieve, 1971; Sastri, 1956). 
Therapeutic use of caraway products has been widely known in different ethnomedical 
systems from Northern Europe to the Mediterranean regions, Russia, Iran, Indonesia, and 
North America, where the use continues  as a primary component of  traditional 
treatments (Sadowska & Obidoska, 2003). Traditionally, it was believed to warm and 
stimulate a cold, languid stomach.  In folklore, it is used for the treatment of stomach 
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complications, dysentery, uterine problems, internal wounds, and ulcers (Fahad & Bano, 
2012).  The fruits have also been applied in the form of a condiment, and the oil for the 
treatment of colds, coughs, sore throat, fever, bronchitis, gingivitis, and gastrointestinal 
complaints (Dachler, 2005). 
Greek physicians prescribed caraway oil or seeds for 'pale-faced girls'. Also, Romans 
consumed caraway to relieve indigestion (Kenner & Requena, 2001). Caraway is well-
known for its carminative and stomach-calming properties, being mostly used for 
alimentary problems (Nasser et al., 2009; Saad & Said, 2011a, 2011b). In the herbal 
remedies of India and Ayurveda, the fruits of caraway are mostly prescribed as a 
carminative, eupeptic, anti-spasmodic, and astringent, and applied for the treatment of 
mild gastrointestinal ailments, such as stomach-ache, bloating, indigestion, cramp, and 
flatulence due to its stomach-strengthening properties (Balch, 2002; Khare, 2008). 
Caraway aqueous brewed extract is commonly used for pediatric conditions, especially 
digestive complaints. Also, in Ayurveda, it is claimed to improve the absorption of other 
plants, and to promote the function of vital organs, such as the liver. Extracts have also 
been used in broncho-pulmonary conditions, as a cough therapy, and also as an analgesic. 
Vapors from caraway seeds are known to provide relief in patients suffering from back 
pain and rheumatism (Joshi, 2000; Mhaskar et al., 2000; Perry & Metzger, 1980; 
Sivarajan & Balachandran, 1994). In Tibetan traditional medicine, caraway is considered 
to have a pungent taste and a warming influence due to its hot nature (Lim, 2013).  
In the Moroccan system of folk medicine, the fruits of caraway are well-known as a 
stimulant, being consumed as a galactagogue to stimulate milk production in lactating 
mothers, and to stimulate menstruation (emmenagogue) in women, as a digestive and 
appetite stimulant, also to increase sexual desire (aphrodisiac), and urine flow (diuretic) 
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(Lahlou et al., 2007). It has been prescribed for healing hyperglycemia, hypertension, also 
heart and renal diseases (Eddouks et al., 2009; Eddouks et al., 2002; El Amrani et al., 
2010; Jouad et al., 2001; Tahraoui et al., 2007). In addition, it has been used to treat 
flatulent colic in infants, and for relieving stomach complaints, being frequently applied 
to flavor children's medicines (Bnouham, 2010; Halberstein, 2005; Reynolds, 1996). In 
Jordanian traditional medicine therapies, caraway is used as a home remedy to treat 
different gastrointestinal and respiratory problems (Barakat Abu-Rmailah & Afifi, 2000). 
In the traditional medicine of Poland, caraway is known as a therapy for alimentary 
disorders, flatulence, appetite imbalances, and as a galactagogue plant, while in Russia, 
it is recommended as a cure for pneumonia. In Great Britain and the USA, it is considered 
as a stomachic and carminative. In the Malay Peninsula, caraway is one of the important 
medicinal plants used during confinement, and in Indonesia, it is regarded as the therapy 
for inflamed eczema. Also, in India, it has been commonly used traditionally as a female 
fertility regulating agent (Kumar et al., 2012; Perry & Metzger, 1980; Sadowska & 
Obidoska, 2003).  
In Iranian traditional medicine, caraway has been recommended as an antiseptic, 
antispasmodic, anti-parasitic, lactigenic, hypolipidemic, anti-flatulence, carminative, and 
for digestive complains (Mikaili et al., 2011). Also in Iran, caraway is considered 
energizing, carminative and astringent and its healing properties have been applied to 
gastrointestinal, gynecological, and respiratory conditions, and recommended for the 
treatment of toothache, diarrhea, and epilepsy (Ghazanfar, 2011; Zargari, 1995). Today, 
in the Middle-East region, it is considered a medicinal plant commonly used for losing 
weight due to its ability to soothe the stomach, improve digestion, and regulate appetite 
(Dasgupta & Hammett-Stabler, 2011; Saad et al., 2008; Saad & Said, 2011a). 
44 
2.3.6 Chemical Compounds of Caraway 
A large number of experimental studies investigating the chemical and biological 
properties of various caraway preparations have been reported attempting to correlate the 
chemistry and the biological activities of this plant. From a chemical perspective, the 
aqueous and oil extracts of the roots of caraway have afforded a variety of phenolic and 
aromatic compounds including different flavonoids, iso-flavonoids, flavonoid glycosides, 
mono-terpenoids, such as carvone and its derivatives, glucosides, lignins and alkaloids, 
as well as poly-acetylenic compounds (Kunzemann & Herrmann, 1977; Matsumura et 
al., 2001; Matsumura et al., 2002a, 2002b; Najda et al., 2008; Nakano et al., 1998). A 
number of phyto-nutrients have been found in caraway seeds, including different 
vitamins, amino acids, proteins, and minerals, also starch, sugars and other carbohydrates, 
tannins, phytic acid and dietary fibres (Al-Bataina et al., 2003). The other constituents 
present in this plant are fatty acids (saturated and unsaturated), triacylglycerol, 
polysaccharides, and lignin (Reiter et al., 1998; Seidler-Lozykowska et al., 2010). 
Carvone and limonene are usually reported as the main phytochemicals present in 
caraway seeds. The other important compounds extracted usually from hydro/steam 
distillation include: carvacrol, α-pinene, γ-terpinene, linalool, carvenone, and p-cymene 
(Raal et al., 2012; Razzaghi-Abyaneh et al., 2009; Simic et al., 2008). Analysis of the 
caraway seed essential oils showed they varied in different regions and climates (Laribi 
et al., 2013). Detected phytochemicals are mostly phenolic and aromatic compounds 
including monoterpenes (hydrocarbons/oxygenated), oxygenated sesquiterpenes, 
aldehydes, ketones, and esters (Johri, 2011). 
45 
2.3.7 Biological Activities, and Therapeutic Uses of Caraway 
As discussed earlier, since ancient times, caraway and its derivatives have been widely 
and commonly applied as traditional medicinal plants for treating different health 
problems in different cultures. A variety of the therapeutic properties of caraway 
mentioned in traditional medicine have been investigated and confirmed experimentally.  
Recently, significant developments in the pharmacological assessments of caraway have 
been reported resulting in several recommended therapeutic activities for this plant. The 
main reported pharmacological actions include anti-oxidant, anti-microbial, anti-
carcinogenic/anti-mutagenic, anti-diabetic/hypoglycemic, hypolipidemic/anti-
hyperlipidemic, diuretic, estrogenic/anti-osteoporotic, and immuno-modulatory. 
Caraway is also reported to have other functional properties, including: larvicidal, anti-
bacterial, and anti-fungal activities, and health promoting effects on the central nervous 
system with adaptogenic property (anti-stress), as well as carminative and laxative for 
gastrointestinal conditions, anti-dyspeptic, anti-ulcerogenic, anti-asthmatic, antitussive, 
and anti-spasmodic activity. Furthermore, it is used industrially, in cosmetics, and also as 
fumigant, molluscicide, insecticidal, or pesticide (Lim, 2013). 
The diversity of bioactivities expressed by caraway preparations is attributed to the 
multiplicity of bioactive constituents, hence its description as having a “hot” nature in 
some medical systems, attributed to the high content of essential oils, flavonoids, and 
phenolic compounds present (Charles, 2013; Khare, 2008; Sadowska & Obidoska, 2003). 
However, linking a certain biological activity to a particular compound, which is the 
classical Western reductionist approach, has remained a challenging issue. It is more 
probable that multiple targeting (network pharmacology) of individual compounds and 
the synergy between and within specific types of phytochemicals is responsible for the 
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diverse notable pharmacological properties. Nonetheless, the biological actions reported 
for caraway compounds support the traditional medicinal properties (Johri, 2011; Khan 
& Abourashed, 2011). 
2.3.7.1 Anti-Obesity Activity of Caraway 
There are a number of evidences concerning the antiobesity potential of caraway. In 
an animal study, administration of carvacrol inhibited obesity in diet-induced obese mice. 
In this experiment, the weight gain decreased remarkably in obese mice fed with high-fat 
diet. Also, significant reduction was observed in their visceral fat-pad weights and plasma 
lipid levels. These biological changes are assumed to be linked with inhibitory effect of 
carvacrol on visceral adipogenesis, inhibiting formation of pro-inflammatory cytokines 
in visceral adipose tissues (Cho et al., 2012). These findings suggest that carvacrol 
supplementation can induce weight loss through regulating gene expressions and 
modulating adipose tissue proteins involved in adipogenesis, thermogenesis and 
inflammation, reversing obesity.  
With respect to the anti-inflammatory effect of caraway, several studies have stated 
inflammation as one of the major risk factors linked with obesity, also anti-inflammatory 
compounds have shown positive effect on weight loss (Barness et al., 2007; Bastard et 
al., 2006; Clement et al., 2004; Dandona et al., 2004; Dandona et al., 2005; Xu et al., 
2003; Yang et al., 2001). Besides, different studies have reported anti-inflammatory 
potential of caraway derivatives. A recent research has reported lipopolysaccharide-
induced inflammation in macrophage cells. In this study, administration of limonene 
showed suppressing effect on formation of pro-inflammatory cytokines and inflammatory 
mediators (Yoon et al., 2010). Other studies have reported anti-inflammatory effect of 
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caraway ingredients (Can Baser, 2008; Johri, 2011) such as carvone and limonene on skin 
through treating inflamed eczema (Sadowska & Obidoska, 2003), also in gut due to 
inhibiting several M.O that could cause inflammation related to digestive system such as 
gastritis (Simic et al., 2008). Moreover, hypoglycemic and hypolipidemic property of 
caraway reported in several studies is another prove for anti-obesity potential of caraway 
as these biological activities are inter-correlated with obesity and weigh loss (Lebovitz, 
2003). In addition, a recent patent has mentioned caraway as one of the potent plants for 
prevention or treatment of obesity due to containing camphene as a bioactive ingredient 
(Park, 2013). In another patented formula, caraway seeds are recommended as one of the 
ingredients in the rye bread with non-absorbable lipid binding activity (Furda, 1980).  
2.3.8 Safety and Toxicity of Caraway 
The safety of a traditional medicine is frequently assumed based on historical use, and 
rarely scientifically established through a well-constructed clinical trial. This is especially 
an issue when different preparations are made which do not follow traditional methods, 
an aqueous extract, rather than an expressed, or steam-distilled, essential oil for example.  
Possible therapy constraints (dose, route of administration, etc.) must therefore be 
deliberated as limiting aspects based on clinical evidence. Presenting products of this 
plant as a safe and harmless substitute therefore involves examination of the probable 
side-effects of consuming caraway. Research shows that a combination of caraway seed 
oil and peppermint oil (50 and 90 mg, respectively) has shown skin allergy, burning 
sensation with eructation, and nausea in sensitive patients with functional dyspepsia (May 
et al., 2000). In addition, due to the blood glucose-lowering activity of caraway, diabetics 
and patients taking drugs, plant medicines, or supplements with hypoglycemic property 
should consume this plant with caution. Such negative reports are rare, and there is no 
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sufficient evidence regarding the negative reactions of caraway essential oil in humans 
(Nicotra, 2012).  
On the other hand, several studies have described the safety of caraway. In an animal 
study, the effects of different doses of caraway seed powder (30, 60, and 90 mg/kg body 
weight) on the formation of aberrant crypt foci in DMH-induced colon cancer in rats were 
examined, with the result that no clinical signs of toxicity were detected in the treated rats 
(Kamaleeswari et al., 2006). The potential hepatoprotective ability of caraway oil extract 
was assessed through the carbon-tetrachloride-induced hepatotoxicity test in mice. The 
findings showed that this plant extract probably exhibits a hepatoprotective effect through 
maintaining the activity of xenobiotic detoxifying enzymes, including glutathione S-
transferase (GST), and glutathione peroxidase (GSH-Px), lowering GSH, and inhibiting 
lipid peroxidation (Naderi-Kalali et al., 2005; Samojlik et al., 2010).  
Another animal study reported the reno-protective potential of caraway showing 
protective activity of this plant against kidney toxicity. In this experiment, administration 
of CWE in high dosage (60 mg/kg) in rats, exhibited nephron-protection against STZ-
induced diabetic nephropathy (Sadiq et al., 2010). Also, findings showed reduction in the 
raised glucose, serum urea, creatinine, total urinary volume, protein micro-albuminuric, 
and lipid peroxidation after CWE intake. In addition, usages of CEO in septic rats induced 
reduction in raised kidney lipid peroxidation and plasma urea/creatinine ratio levels 
(Dadkhah & Fatemi, 2011). These records indicate that caraway extracts could possibly 
provide a protective effect in kidney and liver tissues. While these findings support the 
safety and tolerability of caraway extract, additional safety studies are necessary to define 
the suitable dosage, guidelines, cautions, and other recommendations for the usage of 
various caraway preparations. 
49 
In summary, concerns regarding efficacy and safety of traditional medicinal plants 
have become progressively significant. Hence, administration and regulation of the 
modern techniques and procedures is necessary for commercial and traditional 
applications. Accordingly, more research studies are required to understand this form of 
medication and guarantee its quality, safety and efficacy in clinical practice. Since there 
are limited studies on the antiobesity property of caraway, this study will examine the 
efficacy and safety of caraway water extract on overweight and obese women through a 
randomized triple blind placebo controlled clinical trial. The materials and methods 
applied for evaluating the effect of CWE, also the procedures for extraction and 
preparation of herbal extract and placebo, will be explained in details in the next chapter. 
The overall framework of this study is shown in Figure 2.7. 
 
Figure 2.7: Framework of this study 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 An Overview 
This chapter provides detailed explanation about the methods that had been applied by 
researcher to conduct this study. In accordance with the objectives of this study mentioned 
previously, two major experimental studies were conducted in this research. Firstly, a 
randomized clinical trial (RCT) was conducted to gain an in depth insight into the safety 
and efficacy of CWE. In addition, chemical analysis was conducted to assess the CWE 
compounds using GC-MS technique. Figure 3.1 shows the flow chart of the study. 
 
Figure 3.1: Flow chart of the measurements 
3.2 Study Design 
A randomized triple-blind placebo-controlled, clinical trial was designed to examine 
the efficacy and safety of caraway water extract (CWE) on overweight and obese women. 
The study was carried out at the fitness centre in Yazd, Iran, on subjects who were 
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recruited for aerobic trainings. Following advertisement and recruitment, the candidates 
were screened through health examinations by the physician and the researcher. To 
evaluate the effects of caraway intake, participants were randomized into test and control 
groups, and they were asked to consume either the prepared caraway product or the 
placebo preparation daily for twelve weeks. The baseline data were assessed in both 
groups before starting the intervention program which were finally compared with the 
collected data at the end of intervention, after twelve weeks. Figure 3.2 shows the study 
design of the clinical trial.  
 
Figure 3.2: Diagram showing study design of the clinical trial 
This interventional study was approved by the medical ethics committee of UMMC 
(University of Malaya Medical Center) under the reference number 925/15 (Appendix 
H). The clinical trial was conformed to the Declaration of Helsinki/Malaysian Good 
Clinical Practice (GCP) Guidelines. The Patient Information Sheets were provided to the 
participants and the written informed consent forms were signed and taken from all the 
volunteers. The protocol is registered at clinical trial.gov protocol registration system 
with the Protocol ID: NCT01833377.  
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3.2.1 Rationale for Study Design 
To asses a causal relation, the control group with characteristics similar to test group 
was assigned to compare the effects of active herbal compound with the effects of placebo 
under similar controlled conditions. Moreover, the adequate period of time (12 weeks) 
which is the average duration of similar previous clinical trials (Hasani-Ranjbar et al., 
2013; Opala et al., 2006; Vermaak et al., 2011; Yun, 2010) and also extra subjects were 
assumed to assess the more valuable results.  This is the strength of this study comparing 
to similar previous clinical trials.  
The triple blinding (investigator, subject, and statistician) in this study could be as an 
outstanding parameter which decreases information and expectation bias. The 
investigators, subjects, and the data collectors were masked to the treatment regimens. 
The placebo and CWE samples were similar in appearance and the bottled samples were 
coded by the co-investigator who was not involved in the study. A statistician, who was 
not directly involved in the establishment of the groupings and the design of the trial, was 
provided with the codes and the data for analysis (triple-blind). This method is in line 
with several previous studies which have conducted triple-blind controlled trial (Hopkins 
et al., 2004; Schulz & Grimes, 2002; Weatherley-Jones et al., 2004; Wheatley, 2004). 
3.3 Study Population and Subject Sampling 
Overall, 110 overweight and obese women aged 20-55 years were enrolled for this 
study. Among the recruited candidates, only healthy women with body mass index (BMI) 
between 25.0 and 39.9 kg/m2 were included and screened for the dietary intervention 
program. All subjects were doing moderate aerobics training for 180 minutes/week, with 
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an estimated energy expenditure of 1000–1200 kcal/week at different fitness centres in 
the city of Yazd, located in the centre of Iran.  
Pregnant and lactating women, and individuals who suffered from specific health 
problems, were specifically excluded from this intervention. Also excluded were 
individuals with hypo/hyperthyroidism, a significant history or current presence of type I 
or II diabetes mellitus, or who were hypertensive (systolic blood pressure 140 and/or 
diastolic blood pressure 90), had clinically significant endocrine, hepatic, renal, or 
cardiovascular disease, such as impaired liver function, chronic renal disease, primary 
dyslipidemia, myopathy, or patients presently using drugs affecting metabolism or 
appetite. Individuals who have maintained a weight loss of 41 kg in the preceding three 
months, have the habit of not eating meals at regular intervals, have participated in 
another investigational study within the past 30 days, have a history of alcohol or drug 
abuse within the past year, have a history of sleep disorders, clinical depression, or other 
psychiatric or psychological conditions, and who are abnormally obese were also 
excluded. In general, individuals presenting with any medical condition or the use of any 
medication that could interfere with the conduct of the study, or which placed the 
prospective subject at risk, or who had a known allergy or sensitivity to any of the ‘active’ 
or ‘placebo’ product ingredients, were excluded. In order to reduce the possibility of 
allergic reactions due to the consumption of caraway, only eligible females who were 
familiar with caraway were selected for the intervention treatment. 
3.3.1 Rationale for the Study Population 
This study was carried out in Iran, as an example of an emerging country with a high 
outbreak of obesity and overweight (Esteghamati et al., 2010; Mirzazadeh et al., 2009; 
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Rashidi et al., 2005). Importantly, the people in Iran are familiar with the use of caraway 
seeds or its derivatives, as a flavoring agent for culinary purposes, and also of its remedial 
benefits, especially for decreasing weight in the form of water extract. Furthermore, 
caraway products are affordable and easily available in Iran, especially at the Yazd 
market. In addition, caraway water extract is consumed regularly in Iran, especially in 
Yazd, for losing weight. Overweight and obese women were selected as the study 
population as the rate of obesity is mostly higher in females especially among adults. 
Also, women are usually more interested to attend weight loss programs than men (Sassi, 
2009; Yach et al., 2006).  
3.4 Screening and Data Collection 
For gathering the required data, three methods were used: questionnaire, face-to-face 
interview, and a physical examination of the prospective study subjects. All the data were 
collected at baseline (before starting the intervention) and after week twelve of the 
intervention. The possible changes in body composition, anthropometric indices, appetite, 
blood and urine profile, and vital parameters were investigated before and after 
intervention. Moreover, food intake status and physical activity level were measured 
during this period to ensure the harmony between the test and control groups.  
For collection of data, participants were asked to fill the validated questionnaires 
including Food Frequency Questionnaire (168-item FFQ), International Physical Activity 
Questionnaire (IPAQ), and general information questionnaire (Appendix F). Food and 
nutrient intakes were calculated using Food Frequency Questionnaire 168-items. 
Adjustments of subjects to the study protocol was followed up by direct interview, 
observation, phone call, continuous visits to the fitness centre and returning back the 
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empty bottles. Primary data including medical history, nutritional and health status of the 
volunteers were obtained through general information questionnaire, interview and 
physical examination prior to starting the program. At randomization and each subsequent 
visit, brief physical assessments and interview were repeated for all participants.  
Before starting the randomization, candidates were invited to participate in a 
nutritional counselling section and they were given guidelines regarding the procedures 
of this intervention and the benefits of participation in this study. Besides, subjects were 
guided how to fill the questionnaires. However, no additional advice was provided 
regarding the modification of dietary or exercise behaviours during the study. Volunteers 
were instructed to maintain their regular diet and physical activity throughout the 
intervention. 
3.5 Study Groups and Randomization 
The selected subjects were randomized, and allotted equally into CWE and placebo 
groups. The randomization was done through the online randomization program 
(www.randomization.com) which is based on the randomly permuted blocks method 
(Fleiss, 1986; McLeod, 1985; Wichmann & Hill, 1982). By using the first and original 
generator which randomizes each subject to a single treatment, all the 70 allotted subjects 
were randomized into blocks of 35-35 named Test and Control (Appendix C): 
- Group 1 (the control group; n = 35) were given placebo samples 30 ml per day 
- Group 2 (the test group; n = 35): were given caraway water extract 30 ml per day 
Both the placebo and caraway extract samples were coded and were provided to the 
participants weekly. Also, participants were provided with measured bottles (Figure 3.3) 
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and were asked to dissolve 30 mL of the placebo or caraway extract with 30 mL of water. 
Subjects were instructed to consume caraway extract or placebo samples 20 minutes 
before meal (lunch) for 12 weeks intervention. They were also recommended to refrain 
from consuming caraway from sources other than the study products.  
 
Figure 3.3: Measured bottles provided to participants 
 
3.6 Sample Size Calculation 
Based on similar previous studies, the required sample size was calculated using the 
Greenberg sample size formula (Greenberg et al., 2001) with 99% level of confidence, 
1% precision (alpha < 0.01) with a power level of (1-β) 0.9. The primary variable was 
weight and the sample size was based on a two-tailed t test. The standard deviation of 
weight in the study population was anticipated to be 14 kg which is in line with the 
previous studies (Hauptman et al., 2000; Hollander, 2003; Muls et al., 2001; Wadden et 
al., 2012). 
Greenberg (2001) formula:  
(1-β)= power (90%) 
= significance level = 0.01 
Z=1.282 (Values of Z for 90% power) 
Z=2.58 
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Accordingly, a total sample (2N) of 60 subjects (30 subjects in each group) was 
required to detect a significant difference in weight loss of participants from baseline 
compared to control group. To ensure that this sample size would be available for 
analysis, and assuming dropouts and loss to follow up during 12 weeks intervention, 10 
extra patients were randomized and included. Hence, a total of 70 overweight and obese 
women with BMI>25 were recruited for this study. All the results are expressed as mean 
± SD (Figure 3.4). 
 
Figure 3.4: Flow chart of study groups and randomization 
3.7 Demographic and Baseline Assessments 
The demographic characteristics of the selected volunteers were assessed at baseline 
before starting the intervention. The features measured were included age (year), body 
weight (Kg), body mass index (BMI: Kg/m2), physical activity level (PAL), bone mass 
(Kg), sleep (hours/day), basic metabolic rate (BMR), active metabolic rate (AMR), 
resting energy expenditure (REE), and total daily energy expenditure (TDEE). 
3.7.1 Determination of Physical Activity Level 
Physical activity level was estimated using the International Physical Activity 
Questionnaire (IPAQ) (Appendix F). The reliability and validity of this questionnaire is 
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reported in previous studies (Craig et al., 2003; Fogelholm et al., 2006; Hagströmer et 
al., 2006). Volunteers were asked to calculate the average time (hours and minutes) spent 
daily on any types of physical activity including sedentary, low, moderate or high 
intensity. The data were presented as metabolic equivalent (MET) hours per day 
(kcal/kg/day) using the formula as follows (Giovannucci et al., 1995): 
MET value is defined as calorie need per kg body weight per hour activity divided by 
the calorie need per kg body weight per hour activity at rest and was calculated based on 
the following formula: 
MET = sum of the average hours per day for each activity × MET value of each 
activity. 
3.7.2 Determination of Basic and Active Metabolic Rate 
The basic metabolic rate (BMR) (calorie per meteres2 per hour) was calculated based 
on the following formula: 
BMR = 447+ (9.25×weight) + (3.1×height) - (4.3×age)] 
Active metabolic rate (AMR) was assessed using the BIA. The BIA has divided 
physical activity level of the subjects into 5 categories. As all subjects had similar physical 
activity level (all of them practiced aerobic exercises 3days/week) during the study, the 
researcher had appointed all the volunteers in the moderate level. 
Resting energy expenditure (REE) was calculated using the formula as follows: 
REE= [655+ (9.6×weight) + (1.8×height) - (4.7×age)] 
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The total daily energy expenditure (TDEE) was calculated by the following formula: 
TDEE = (BMR×1.55) 
3.8 Clinical Trial Assessments 
Clinical trial assessments in this study are comprised of efficacy and safety evaluation 
of CWE. The efficacy studies include anthropometric measurements which consists of 
body size and body composition assessments. The details of materials and methods 
applied for assessing these parameters are described in the next section.  
3.8.1 Efficacy Evaluation of CWE 
3.8.1.1 Assessment of Anthropometric Indices 
The anthropometric indices including height, waist circumference, hip circumference, 
mid-upper arm circumference (MUAC) and thigh circumference (THC) were measured 
in centimetres (cm) and were assessed using circular ergonomic circumference measuring 
tape with automatic roll-up (Seca 201). Measurements were performed early in the 
morning with empty stomach while the subjects were not in the menstrual cycle.  
(a) Body Height 
Height was measured to the nearest 0.1 cm (within 0.1 cm), using Seca measuring tape. 
Subjects were instructed to stand barefoot with straightened legs, their heels almost 
together touching measurement board and looking straight ahead with Frankfurt plane 
horizontal and the shoulders parallel to the floor (Gibson, 2005) (Figure 3.5).  
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Figure 3.5: Positioning of subjects for measuring height 
Adopted from: Gibson (2005) 
(b) Waist, Hip and Mid-Upper Arm Circumference 
To assess waist, hip and mid-upper arm circumference, subjects were asked to stand 
with their heels together and both arms up to the sides. The waist circumference was 
measured by placing the measuring tape at the umbilicus point (the site between the 
lowest rib and the iliac crest) (National Institutes of Health, 2000; Rudolf et al., 2007). 
Figure 3.6 shows the measuring-tape position for waist circumference.  
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Figure 3.6: Assessing waist circumference 
Adopted from: Almoosawi et al. (2010) 
 
Hip circumference (HC) was measured at the maximum circumference over the 
buttocks (WHO, 2008). Waist to hip ratio (WHR) was then calculated using the waist and 
hip circumference data according the following equation: 
WHR= waist circumference (cm) / Hip circumference (cm) 
Mid-upper arm circumference (MUAC) was measured at the mid-point of the left arm. 
Subjects were asked to keep their hands up in the straight position parallel to the floor 
and avoid bending their arms. Also, thigh circumference was measured at the midway 
between the hip and the knee. Subjects were asked to open their legs to shoulder width 
apart. 
62 
(c) Assessment of Body Weight and Body Composition 
Body weight was measured within 0.1kg intervals. Participants were weighed in light 
clothing and without shoes using a bioelectrical impedance analysis (BIA) (Beurer digital 
diagnostic scale with remote control, Model BG63, Beurer Products, Ulm, Germany). 
Beurer BIA has been examined for the body composition analysis in the previous studies 
(Das & Roy, 2010; Knechtle et al., 2011; Mittal et al., 2011; Nayebi, 2011; Nikooyeh et 
al., 2011; Salekzamani et al., 2011). The precision of the scale was checked regularly to 
ensure the scale calibration. Other body composition parameters including body fat 
percentage, water percentage, muscle percentage, bone density as well as AMR (active 
metabolic rate) were measured simultaneously. Body fat, body water and muscle mass 
were displayed with 0.1% graduation; bone mass and body weight with 100 gram 
graduation and the active metabolic rate (AMR) was measured in calorie with five activity 
levels. Weight measurements were performed early in the morning with empty stomach. 
According to the instruction of the digital scale, subjects were asked to moisten their feet 
by putting their feet on a damp cloth before stepping on the scale.  
(d) Body Mass Index Measurement 
From the height and weight measurements, BMIs were calculated according to the 
following formula:  
BMI = weight (kg)/ height2 (m2) 
To reduce intra-individual errors, weight and height were measured twice by the co-
investigators and the mean value was used as the final data for the analysis. 
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3.8.1.2 Food Intake and Appetite Assessments 
(a) Assessing Food and Dietary Intake 
Dietary calorie and nutrient intakes were assessed using the Food Frequency 
Questionnaire (168-item FFQ) (Appendix F). “The 168-item FFQ was a Willett format 
questionnaire modified based on Iranian food items. It included a list of foods (with 
standard serving sizes) commonly consumed by Iranians.” The reliability and validity of 
this questionnaire has been reported in previous studies (Asghari et al., 2012; Mirmiran 
et al., 2010). 
(b) Appetite and ad Libitum Pizza Tests 
To examine the motivation to eat and appetite rate in the participants the satiety 
experiment was done one week before starting the study and one week after intervention 
program. To study the suppressing effect of caraway water extract on appetite, volunteers 
were asked to record their subjective feeling of hunger, satiety, and desire to eat on a 10 
cm visual analogue scales (VAS) (Jiménez-Cruz et al., 2006) (Table 3.1). The scales 
were rated 1 to 10 and the end points were signed as “extremely hungry” and “extremely 
full”. All participants were asked to rate their appetite every waking hour for three days 
before starting the intervention and three days after completing the intervention. 
To confirm the satiating effect of caraway water extract participants from both groups 
were asked to go through an ad libitum pizza test at the end of the intervention at week 
12. Subjects were instructed to have a standard breakfast at 8 am and consume 30 ml 
preloads of either caraway water extract or placebo 20 minutes before lunch. Volunteers 
were asked to have an ad libitum pizza meal at 1 pm as lunch and they were instructed to 
eat pizza slices until complete fullness and then record the number of slices they had 
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eaten. The amount of food intake (number of pizza slices consumed) was compared 
between test and control group which were further analysed by SPSS to identify the 
significant difference between groups. 
Table 3.1: Visual analogue scale (VAS) for rating fullness and hunger 
 Appetite scale code* 
 1 2 3 4 5 6 7 8 9 10 
 Extremely hungry         Extremely full 
 
Feeling  of fullness/hunger *Appetite code 
Extremely hungry, famished, starving 1 
Feel hungry, low energy, weak 2 
Want to eat now, stomach growls and feels empty 3 
Hungry but could wait to eat, starting to feel empty but not there yet 4 
Not hungry, not full 5 
Feeling satisfied, stomach feels full and comfortable 6 
Feeling full, definitely don’t need more food 7 
Uncomfortably full 8 
Stuffed, very uncomfortable 9 
Extremely full, bursting, painfully full 10 
 
3.8.2 Safety Evaluation of CWE 
The safety evaluation of CWE includes the clinical (blood and urine tests) and para-
clinical assessments (blood pressure and heart rate). At the baseline randomization visit 
and after 12th week consumption of caraway water extract or placebo, candidates were 
asked to refer to the allotted laboratory in hospital for blood and urine test sampling for 
biochemical analyses. Blood sampling and analysis were taken between 07:30 and 09:30 
am by an experienced technician at the Yazd Central/Reference Medical Laboratory, 
Yazd, Iran. 
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All the blood tests were conducted at the reference laboratory of Shahid Sadoughi 
hospital in Yazd, Iran in the fasting condition. Blood sampling were done by a trained 
nurse and in each sampling, 10 ml blood were taken from the forearm vein of the 
volunteers. The biochemical parameters were analysed using the ELITECH diagnostics 
Kits (SEPPIM S.A.A.-Zone Industrielle– 61500 SEES FRANCE) with the detection 
precision of 0.5 mg/dL within run. The procedure employed was as described in “Clinical 
guide to laboratory tests” by Tietz (1995). The performance data including analytical 
range, detection limit, sensitivity, precision and correlation were obtained at 37 °C on 
Selectra. The detection limit was determined according to SFBC protocol (Vassault et al., 
1986). For separation of serum from plasma, Sigma centrifuge (SIGMA Laborzentrifugen 
GmbH, Germany) were used at 3500-4000 RPM for 12 minutes at 4ᵒC.   
To assess the probable toxicity or side-effects effects of caraway water extract, the 
blood tests including alanine transaminase (ALT), aspartate transaminase (AST), alkaline 
phosphatase (ALP), and total (Bilirubin, T), and bilirubin direct (Bilirubin, D) were done. 
These blood parameters were known as the biomarkers of liver cell injury. The 
biomarkers of lipid metabolism were also determined which include: total cholesterol (T-
C), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol 
(HDL-C), and triglyceride (TG). The hematological parameters (Peripheral 
blood/Complete blood cell count- CBC test) include: white blood cell (WBC), red blood 
cell (RBC), Hemoglobin (HGB), Hematocrit (HCT), mean corpuscular volume (MCV), 
Red cell distribution width (RDW-CV), Platelets count (PLT), Mean corpuscular 
hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC), mean 
platelet volume (MPV), and platelet distribution width (PDW). The other biochemical 
tests including fasting blood sugar (FBS), urea, creatinine, and uric acid (UA) as well as 
urine-specific gravity (USG) were analysed. 
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In the following section, the clinical significance, and methods used for assessing each 
biochemical parameter is mentioned. The other information including principle of the 
method, reagents composition, reference values, procedure, and calculation of each 
parameter is described in details at the Appendix D. 
3.8.2.1 Serum Glucose Assessment 
Glucose is the main source of energy for the human body. Glucose is converted either 
into glycogen to be stocked in the liver or into triglycerides to be stocked in fatty tissues. 
Glucose concentration in blood is regulated by several hormones, including two 
antagonists: insulin and glucagon. Quantification of glucose in blood is used to diagnose 
metabolic carbohydrates disorders such as diabetes, neonatal glycaemia, idiopathic 
hypoglycemia and pancreatic disease. The man physiological troubles were linked to 
hyperglycemia (type I and type II diabetes mellitus). Type I diabetes mellitus is insulin 
dependent and appears mainly before 30 years old. Type II diabetes mellitus is non-
insulin-dependent and usually appears after 40 years old, but can occur earlier for obese 
people. Other diabetes have secondary origin and appear after endocrinal or hepatic 
diseases (Sacks et al., 2002). Fasting blood sugar was determined using kits GPSL– 
0490/0500/0700/0507/0707 by enzymatic-colorimetric (Trinder – Kinetic) technique.  
3.8.2.2 Lipid Profile 
Lipid profile including determination of total serum cholesterol, serum cholesterol 
LDL, serum cholesterol HDL-C and triglycerides were assessed before and after twelve 
weeks intervention. The procedures are explained in details as the following. 
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(a) Determination of Total Serum Cholesterol 
Cholesterol is both coming from food and synthesized by the human body, mainly in 
hepatic and intestinal cells. Cholesterol is a component of cells and organoids membrane. 
It is a metabolic precursor of bile acids, vitamin D and steroid hormones. Cholesterol, 
insoluble molecule, circulates associated with lipoproteins (HLD, LDL and VLDL). 
Quantification of total cholesterol allows the detection of hypercholesterolemia, isolated 
or associated with hypertriglyceridemia. High cholesterol concentrations were associated 
with a high risk for vascular accident and apparition of atherosclerosis. The LDL/HDL 
ratio should be taken in consideration for evaluating the risk of developing cardiovascular 
diseases (Naito, 2003; Rifai et al., 1999). Cholesterol was determined using kits CHSL – 
0490/0500/0700 by enzymatic-colorimetric (Trinder-End point) method. The samples 
were serum and heparin or EDTA plasma from fasting patients. 
(b) Determination of Serum Cholesterol LDL 
Low density lipoprotein (LDL) come from very low density lipoprotein (VLDL) 
hydrolysis by different lipolytic enzymes. LDL, which transports approximately 60% of 
total plasmatic cholesterol, is mainly taken up through specific receptors by extra-hepatic 
and hepatic tissues. A positive association exists between the incidence of coronary heart 
disease and LDL cholesterol. LDL is an atherogen lipoprotein: LDL cholesterol increase 
is a major cause of apparition and evolution of atherosclerosis, in particular, coronary 
atherosclerosis. Therefore, the treatment of elevated LDL cholesterol is the primary target 
of cholesterol-lowering therapy. An increase in LDL cholesterol may be seen in different 
pathological states including hyperlippoproteinemia types IIa and IIb, premature coronary 
heart diseases, hyperlippoproteinemia due to hepatic or renal disorder, to hypothyroidism 
and diabetes (Naito, 2003; Rifai et al., 1999). Cholesterol LDL was determined using kits 
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LDLL – 0380 using enzymatic- selected detergent End point method. The samples were 
serum and heparin or EDTA plasma from fasting patients. 
(c) Determination of Serum Cholesterol HDL-C 
The high density lipoprotein cholesterol (HDL-C) test is an in vitro assay for the 
quantitative determination of HDL-C in serum. Lipoprotein is classified into LDL, VLDL 
and chylomicrons (CM) according to specific gravity. In recent years, in addition to total 
cholesterol, HDL-C has become an important tool used to assess an individual risk of 
developing coronary heart disease (CHD) since a strong negative relationship between 
HDL-C concentration and CHD was reported (Graham et al., 2007; Rifai et al., 1999). 
HDL-C has been assayed by ultracentrifugation, gel filtration, electrophoresis, high 
performance liquid chromatography (HPLC), precipitation, and direct process (Gordon 
et al., 1977). Recently, direct process has been widely used.  
Here, stable liquid Reagent-Immunoinhibition method has been used to determine 
Cholesterol HDL using kits HDLL – 0507 D8. HDL-C is a liquid type reagent that assays 
HDL cholesterol in serum directly by employing antibody.  
(d) Determination of Triglycerides 
Triglycerides constitute 95% of tissue storage fat and their main role is to provide 
energy for the cell. They were synthesized both in the intestine from dietary fats and in 
liver from dietary carbohydrates, and were then transported in blood by chylomicrons and 
VLDL. High serum triglyceride levels were associated with important risks of 
atherosclerosis. They can be due to several diseases like different lipid metabolism 
disorders (hyperlippoproteinemia, lipase activity deficiency), also to diabetes, renal or 
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endocrine disorders (Naito, 2003). Triglyceride was determined using kits TGML – 
0425/0515/0700 by enzymatic-colorimetric (End point) method.  
3.8.2.3 Hematological Analysis (CBC)  
The samples were used for complete blood cell count (CBC) by automated hematology 
analyzer (Sysmex blood cell counter auto-analyzer model KX21; Japan). The analysis 
parameters include WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT (platelet), RDW-
CV, PDW, and MPV (Appendix D).  
Concerning the side effects of CWE intake, changes in a number of blood parameters 
including liver functions (ALT, AST, ALP, and bilirubin) as well as creatinine and urine-
specific gravity along with changes in SBP, DBP, and HR were examined. Furthermore, 
participants showing any probable allergy or clinical side-effects related to consumption 
of CWE or placebo would be excluded from continuing the intervention. The details of 
these examinations will be discussed in the next section. 
3.8.2.4 Liver Function Tests 
(a) Determination of serum alanine aminotransferase (ALT/GPT) 
Alanine aminotransferase (ALT) also known as glutamate pyruvate transaminase 
(GPT) is a transaminase. ALT catalyses the transfer of the amino group of L- alanine to 
α-ketoglutarate to give L-glutamate. The highest levels were found in liver and the 
kidneys, and in smaller amounts in heart and skeletal muscle. ALT concentration is 
increased when hepatic cells were damaged (liver cell necrosis or injury of any cause). 
Indeed, viral and toxic hepatitis induced a marked elevation of ALT activity in serum. 
Intake of alcohol, delirium tremens, and administration of various drug induce slight or 
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moderate elevation of ALT. ALT concentration in serum is also slightly increased in 
various conditions such as muscular dystrophy, haemolytic disease and myocardial 
infarction. ALT is more liver specific than aspartate aminotransferase (AST). 
Measurement of both AST and ALT has same value in distinguishing hepatitis from other 
parenchymal lesions. ALT serum level can decrease in case of vitamin B6 deficiency 
(Tietz, 1995). Alanine aminotransferase was determined using kits ALSL – 
0410/0430/0510 by IFCC method (Kinetic-UV) without pyridoxal phosphate (P-5’-P).  
(b) Determination of Serum Aspartate Aminotransferase (AST/GOT) 
Aspartate aminotransferase (AST) also known as glutamate oxaloacetate transaminase 
(GOT) is a transaminase. AST catalyses the transfer of the amino group of L- aspartate 
to α-ketoglutarate to give L-glutamate. AST is widely distributed in the body, but the 
highest levels were found in heart, liver, skeletal muscles and the kidneys. Damages to 
cells of these tissues induce AST increase in serum. In case of fulminant forms of 
hepatitis, especially viral hepatitis the enzyme level is markedly elevated. In case of 
myocardial infarction, AST activity increases and reaches a peak after 18-24 hours. The 
activity falls back to normal after four to five days, provided no new infarct has occurred. 
The following pathological states were examples of disorders also resulting in an increase 
of enzyme activity: liver cell necrosis or injury of any cause (for example, intake of 
alcohol, delirium tremens, and administration of various drug induce moderate AST 
elevation), alcoholic hepatitis, muscular dystrophy and gangrene, infectious 
mononucleosis, acute pancreatitis, heart affection as myocarditis or pericarditis and 
pulmonary emboli. On the contrary, AST serum level can decrease in case of vitamin B6 
deficiency (Tietz, 1995). Aspartate aminotransferase was determined using kits ASSL – 
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0410/0430/0510 by IFCC method (Kinetic-UV) without pyridoxal phosphate (P-5’-P). 
The samples were serum free from haemolysis or heparinized plasma. 
(c) Determination of Alkaline Phosphatase (ALP) 
Alkaline phosphatase (ALP) corresponds to a group of phosphatases that display 
maximum activity at alkaline pH. ALP is widely distributed in liver, osteoblasts, intestinal 
epithelium, kidneys, and placenta. The rate of ALP rises physiologically for children and 
teenagers during periods of active growth, as well as for women during the third trimester 
of pregnancy. Marked increases of ALP rate were observed in cases of extra-hepatic 
obstruction (gallstones, tumors, etc.) and bone diseases such as Paget’s disease and 
osteogenic bone cancer. ALP activity can also increase moderately in the event of intra-
hepatic obstruction, hepatitis, cirrhosis, or along with rickets, osteomalacia, 
hyperparathyroidism, healing of bone fractures (Moss & Henderson, 2001). Alkaline 
phosphatase was determined using kits PASL – 0400/0420/0500 based on DGKC and 
SCE (Enzymatic-Kinetic) technique (Hørder et al., 1979). The Samples were serum free 
from haemolysis or heparinized plasma.  
(d) Determination of Bilirubin 
Approximately 80-85% of the bilirubin produced is derived from the heme moiety of 
the hemoglobin released from aging erythrocytes in the reticuloendothelial cells. 
Bilirubin bound to albumin, is transported into the liver where it is rapidly conjugated 
with glucuronide to increase its solubility. Then it is excreted into biliary canaliculi, and 
hydrolysed in the gastrointestinal tract. Unconjugated bilirubin serum concentration 
increase in case of over production of bilirubin (acute or chronic haemolytic anemia) and 
in case of disorders of bilirubin metabolism and transport defects (impaired uptake by 
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liver cells: Gilbert’s syndrome; defects in the conjugation reaction). Reduced excretion 
(hepatocellular damage such as hepatitis and cirrhosis) and obstruction to the flow of bile 
(most often produced by gallstone or by tumors) induce an important elevation of 
conjugated bilirubin and in a minor extent an increase of unconjugated bilirubin 
(conjugated hyper-bilirubinemia) (Sherwin, 2003). Bilirubin was determined using kits 
BITD–0600 (total & direct 4+1), BIDI-600 (DIRACT 4+1) and BITO-600 (total 4+1) by 
Malloy-Evelyn modified (Endpoint) method.  
3.8.2.5 Kidney Function Tests 
(a) Determination of serum urea 
Urea is the major metabolite product of protein catabolism. The biosynthesis of urea 
from ammonia is exclusively carried out by hepatic enzymes. More than 90% of urea is 
excreted through the kidneys, with the remainder excreted through the gastrointestinal 
tract or skin. Blood urea concentrations can be increased by numerous factors linked to 
pre-renal causes (increased protein catabolism, as in haemorrhage into gastrointestinal 
tract, shock, some chronic liver disease) or renal/postrenal causes (acute or chronic renal 
diseases, postrenal obstruction to urine flow). Uraemia is also increased by high protein 
diet, state of dehydration, muscle wasting (as in starvation). The determination of urea 
rate is used together with the determination of creatinine rate to discriminate-between-
prerenal (normal Creatinine) and renal/postrenal (increased Creatinine) disorders 
(Newman & Price, 2001). Urea was determined using kits CHSL– 
0400/0420/0500/0407/0427/0507 by enzymatic-UV (Kinetic) method.  
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(b) Determination of Serum Creatinine 
Creatinine is the waste spontaneous product of creatine metabolism. It is an excellent 
marker of the renal function. The serum Creatinine rate tends to remain constant. A high 
serum creatinine rate (associated to a high urea rate) corresponds to a decrease in 
glomerular filtration rate (GFR). The serum Creatinine test is more reliable than the urea 
test. Indeed, the urea serum rate is affected by factors such as diet, dehydration degree 
and protein metabolism (the serum Creatinine rate is not influenced by these factors). The 
test of Creatinine clearance can also be used to measure the GFR. In the case of renal 
transplantation, any increase in serum Creatinine, as little as it may be, can reflect the 
rejection of the transplant. An increase of Creatinine serum and urine can be the sign of 
muscular necrosis (Newman & Price, 2001). Creatinine was determined using kits CRCO 
– 0600/0700 by colorimetric, Jaffe (Kinetic) method.  
(c) Determination of Uric Acid 
Uric acid is the major product of the catabolism of endogenous and exogenous 
(dietary) purine nucleosides (adenosine and guanosine). This transformation mainly 
occurs in the liver. Approximately, 75% of uric acid is eliminated by kidneys; the 
remainder is secreted into the gastrointestinal tract, where it is degraded by bacterial 
enzymes. Uric acid is not very soluble in water; urate crystals can occur in urines when 
the concentration is abnormally high. It can also happen in plasma, crystals then deposit 
essentially in joints, which induce intense inflammatory responses (gout). Some causes 
for increasing uric acid rate in serum were: increasing of purines synthesis, metabolic 
disorders, nutritional troubles, increasing of nucleic acid turn-over in case of proliferation 
of tumor cells, leukaemia, psoriasis, cytotoxic drugs, renal failures, etc. The increased 
uric acid is a physiological biomarker of obesity, diabetes mellitus, hypertension and 
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cardiovascular diseases (Masuo et al., 2003). Uric acid was determined using kits AUML 
– 0420/0500/0700 by enzymatic –colorimetric (Trinder. Endpoint) method.  
3.8.2.6 Urine-Specific Gravity (USG) Assessment 
The urine tests are part of screening tests for detection of diabetes, metabolic 
abnormalities, liver diseases, biliary and hepatic obstructions, haemolytic diseases and 
diseases of kidney and urinary tracts. The well sterilized and clean vessels were provided 
to patients to collect the urine samples. Test strips (Medi-Test Combi 11) were used for 
rapid determination of density in urine through reflectophotometrical evaluation with 
URYXXON 200. The qualified personnel use fresh and un-centrifuged urine. The 
instructions are as the following: 
1) Shake urine sample well before use 
2) Dip the test strip for approximately 1 second into the urine 
3) Draw it across the rim of the container to remove excess urine 
4) Place the test strips on to the instruments according to the instructions for use 
in the manual. 
The tests pads were reflectophotometrically evaluated and the results were printed out. 
The results obtained with the URYXXON 200 correspond to the concentration ranges 
indicated on the colour chart after 30-60 seconds. Colour changes that take place after 
more than two minutes are of no significance. The urine should not be more than 2 hours 
old when tested. Due to the fact that the human eye evaluates colour changes somewhat 
differently than a URYXXON 200 reflectometer, there can also be differences between 
these two evaluations. 
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3.8.2.7 Para-Clinical Assessments (Blood pressure and Heart Rate) 
Vital parameters including blood pressure and heart rate were measured by a trained 
physician using a calibrated mercury sphygmomanometer, stethoscope and an appropriate 
cuff sizes on the sitting subject’s right arm after a 10-min rest. Systolic as well as diastolic 
blood pressure was defined according to phase I and phase V Korotkoff sounds, 
respectively.  
3.8.3 Statistical Analysis 
Values for each subject were standardized for each dependent variable to remove 
outliers using Z-scores, and the normal distribution was tested using the Kolmogorov-
Smirnov test. Student’s t-test, with a 99% confidence interval, was applied to identify the 
significant differences in values between groups, and the paired t-test was used to 
examine mean differences within each group during the 12-week treatment period. All 
statistical analyses were performed using SPSS software version 18.0.0 (SPSS Inc., 
Chicago, IL, USA), and all data are expressed as mean ± standard deviation (SD); p values 
less than 0.01 were considered to be significant and equal variances were assumed. 
3.9 Preparation of Herbal Extract and Placebo 
The caraway extract samples (0.1 w/v) obtained from the Baharan Company, Yazd, 
Iran (Industrial Ministry License no. 28/1232 and Health Ministry License no. 35/10500) 
were extracted from the seeds of caraway through steam distillation. The placebo was 
prepared by dissolving edible caraway essence (Givaudan Flavours Co., Kempthal, 
Switzerland) in drinking water (1% g/L) which was identical with caraway extract in 
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appearance and flavour. Subjects were provided with measured bottles and were asked to 
dissolve 30 mL of the placebo or caraway extract with 30 mL of water. 
3.10 Extraction Procedure of CWE 
Previously, herbal distillates were considered as a by-product of distillation while 
today, they are highly used as an outstanding co-product of aromatic herbs as they contain 
bioactive compounds (Teo et al., 2010). Moreover, the steam distillation of aromatic 
plants is known as one of the most economical, simplest and fastest method of extraction 
commonly used (Douglas et al., 2006). 
In this study, steam distillation was carried out for producing the aqueous solution or 
water extract of caraway which is also called as “herbal distillate, herbal water or essential 
water”.  The distillation procedure was taken around 5-6 hours in 100-120 ᵒC at the 76 
cm Hg pressure (equal to the atmosphere pressure).  All the tanks were stainless steel with 
the 1000-2000 litres capacity which were made by the Taghtiran Company (Kashan) and 
Shayansazan (Yazd), Iran. The caraway seeds were collected from the plains between 
Khorasan and Kerman provinces including Kerman, Yazd and Shiraz cities in the south 
of Iran. The seeds were harvested during September and October and stored in storage 
rooms until processing in the Baharan manufacturing plant (Appendix E).  
3.11 Gas Chromatography-Mass Spectrometry (GC-MS) Analysis 
The phytochemical constituents present in CWE were identified using GC-MS 
analysis with a flame ionization detector (FID), and extracted by HS-SPME with 
subsequent hexane extraction. The capillary gas chromatographic profiles of the CWE 
constituents were reported as their retention time compared with the MS of standard 
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compounds. The GC-MS analysis was performed on the Younglin gas chromatograph 
series YL 6100 with a capillary column DB-5MS (J&W Scientific) fused silica (60 m × 
0.25 mm i.d. × 0.25 μm film thickness). The purified helium was applied as the carrier 
gas and the SPME Fibre, CAR/PDMS fiber (75μm), was used for volatile extraction. 
Figure 3.7 shows the schematic of GC-MS instrument.  
The operating conditions were included hydrogen flow 30 ml/min, air flow 300 
ml/min, helium flow 0.8ml/min; and the injector and detector temperatures were 260, and 
280°C, respectively. The GC oven was held at 40°C for 1 min, it was then ramped at 
15°C/min to 90°C and held for 4 min, and finally ramped at 10°C/min to 170 °C/min and 
held for 4 min. The data related to the isolated compounds were shown on the screen of 
a compact PC computer connected to the GC-MS instrument and then identified from MS 
Libraries NIST 0.5 L (Adams, 2007). 
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Figure 3.7: GC-MS schematic 
Adopted from: (http://chemwiki.ucdavis.edu)  
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CHAPTER 4: RESULTS 
4.1 An Overview 
Of the 110 overweight and obese women who originally registered for screening, only 
seventy were deemed eligible to have met the study requirements and constraints. The 
selected subjects were randomized and assigned equally to the CWE and placebo groups. 
Of the selected participants, ten of the subjects- six in the placebo group and four in the 
CWE group- failed to complete the study. Of these ten subjects who dropped-out during 
the intervention (Figure 4.1), one was excluded due to pregnancy, three due to personal 
reasons, two in the placebo group because of lack of weight loss, and four subjects could 
not be followed-up during the study. At the termination of the study, therefore, sixty of 
the seventy patients completed the full twelve weeks of treatment. 
 
Figure 4.1: Follow-up of subjects involved in the clinical trial 
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4.2 Demographic and Baseline Characteristics of The Study Population 
The demographic and baseline features of the participants in the study are illustrated 
in Table 4.1. Approximately 54% of the participants were overweight, and 46% were 
obese.  All of the participants had abdominal obesity (waist circumference >88 cm). The 
average values (mean ± SD) of age, body weight, and body mass index (BMI) of the 
subjects were 37.1 ± 8.6 years, 75.4 ± 11.7 kg, and 29.8 ± 4.1 kg/m2, respectively. The 
subjects had an average (mean ± SD) 44 ± 2.6 (kcal/kg/day) of physical activity level 
(PAL) and 7.9 ± 1.4 hours sleep during a 24-hour period.  
There were no significant differences in any of the demographic variables measured 
including age, height, weight, BMI, and bone mass between the study and control groups. 
Similarly, no significant differences were observed in sleep hours, PAL, basic metabolic 
rate (BMR), active metabolic rate (AMR), resting energy expenditure (REE), and total 
daily energy expenditure (TDEE) measurements between the CWE group and the placebo 
group at baseline. Also, there were no significant differences in the average levels of body 
composition, anthropometric indices, food intake and appetite, and clinical and para-
clinical assessments between the two groups at baseline. Hence, there were homogeneity 
and balance between the two groups at baseline.  
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Table 4.1: Demographics and baseline characteristics of the study population 
randomized to the placebo or CWE groups (n=35) 
Variables 
Placebo Group CWE Group 
p-value 
Mean ± SD Mean ± SD 
Age (years) 37.0 ± 7.9 37.2 ± 9.3 0.91 
Height (cm) 158.2 ± 4.9 159.7 ± 6.2 0.25 
Weight (kg) 74.9 ± 11.7 76.0 ± 11.8 0.70 
BMI (kg/m2) 30.4 ± 4.7 29.2 ± 3.4 0.24 
Bone Mass (kg) 7.8 ± 1.1 8.1 ± 1.1 0.35 
Sleep (hours/day)  7.9 ± 1.6 7.9 ± 1.3 0.97 
PAL (kcal/kg/day) 43.7 ± 2.5 44.4 ± 2.8 0.26 
BMR (kcal/m2/hour) 1474.4 ± 123.5 1488 ± 154.4 0.69 
AMR (kcal/m2/hour) 2241.4 ± 216.3 2176.6 ± 260.5 0.30 
REE (kcal) 1453.2 ± 133.3 1503.1 ± 127.4 0.15 
TDEE (kcal) 2236.1 ± 206.9 2308.3 ± 193.2 0.17 
Abbreviations: BMI: body mass index; PAL: physical activity level; BMR: basic metabolic rate; AMR: active 
metabolic rate; REE: resting energy expenditure; TDEE: total daily energy expenditure 
4.3 Comparison Within and Between CWE and Placebo Groups During the 
Trial 
The changes in variables over the twelve-week intervention period within and between 
the CWE and the placebo groups are also calculated. The alterations in variables including 
body composition and anthropometric indices, as well as clinical and para-clinical 
assessments are discussed in details in the following section. 
4.3.1 Effect of CWE on Weight and Body Composition 
The changes in body composition variables over the twelve weeks of the trial for the 
CWE and placebo groups are summarized in Table 4.2. Following the twelve weeks of 
treatment, the mean body weight, BMI, and body fat (BF) percentage, had significantly 
decreased compared with placebo, whereas in the placebo group, these values increased 
slightly, although changes were not significant. Therefore, CWE possibly had a positive 
effect on inducing weight and fat loss.  
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Findings show that in the CWE group there was an average weight loss of 1.9 kg, while 
in the placebo group, an average weight gain of 0.81 kg was observed. Also, the BMI 
showed a significant reduction of 0.8 in the CWE group, while in the placebo group, the 
BMI showed an increase of 0.2 which was not significant. The BF percentage showed a 
significant reduction of -0.7% in the CWE group, while in the placebo group BF showed 
an increase of 0.2%. In contrast, body muscle (BM) percentage increased significantly in 
the CWE group after treatment (0.2%), while in the placebo group, no significant changes 
were observed. Furthermore, the difference in growing body muscle after the twelve-
week intervention was considerably higher in the subjects consuming CWE, compared to 
the placebo group. The percentage of body water (BW) reduced in both groups (-0.01% 
in the CWE and -0.2%, in placebo group), and was not significant, either within, or 
between, groups. 
4.3.2 Effect of CWE on Anthropometric Indices 
The measured anthropometric indices are also presented in Table 4.2. After the twelve-
week intervention, the waist circumference (WC) and the waist to hip ratio (WHR), were 
reduced significantly only in the CWE group, while the average levels of thigh 
circumference (THC) and mid-upper arm circumference (MUAC) showed significant 
reduction in both treatment groups. In addition, the level of reduction in all body size 
measurements and anthropometric indices were significant between the CWE group and 
the placebo group.  
After the intervention period, the WC in the CWE group showed a considerable drop 
of -6.2 cm, while in the placebo group the reduction was not significant (-0.1 cm). Also, 
the WHR was reduced (-0.03 cm) in the CWE group, while no significant changes were 
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observed in the placebo group. The reduction in THC was significant in both groups (-
5.4 cm in the CWE and -1.9 cm, in placebo group) after treatment, and the difference in 
reduction between the two groups was significant. Mid-upper arm circumference 
(MUAC) showed a significant reduction of 2.2 cm in the CWE group, while the reduction 
in MUAC in the placebo group was only 0.8 cm, and the decrease in MUAC during the 
intervention was significantly higher in CWE group compared to the placebo group. 
Accordingly, the CWE showed greater efficacy compared to placebo for each of the 
primary outcome variables with respect to the anthropometric indices and body 
composition measurements, except for body water. 
Table 4.2: Changes (Mean ± SD) in body composition and anthropometric indices 
between and within groups after twelve weeks intervention 
Variables 
Week 0 (baseline) 
 
Week 12 
Placebo (n=29) CWE group (n=31) Placebo (n=29) CWE group (n=31) 
Body 
composition 
            
 Weight (kg) 72.0 ± 10.7 76.9 ± 12.2  72.8 ± 10.8 75.0 ± 12.2* 
 BMI (Kg/m2) 28.3 ± 2.6 30.7 ± 4.7  28.5 ± 2.8 29.9 ± 4.7* 
BF (%) 33.8 ± 2.4 35.4 ± 3.6  34.0 ± 2.5 34.7 ± 3.7* 
BM (%) 31.8 ± 1.3 31.4 ± 1.6  31.8 ± 1.3 31.6 ± 1.6* 
BW (%) 48.3 ± 1.9 47.2 ± 2.6  48.1 ± 1.8 47.2 ± 2.7 
Anthropometr
ic indices 
           
  
WC (cm) 91.3 ± 7.3 96.0 ± 10.2  91.2 ± 7.9 89.8 ± 8.6* 
WHR 0.9 ± 0.0 0.9 ± 0.1  0.9 ± 0.1 0.8 ± 0.1* 
THC (cm) 59.7 ± 4.5 61.7 ± 5.8  57.9 ± 4.6 Ɨ 56.3 ± 5.6 Ɨ * 
MUAC (cm) 31.0 ± 3.4 32.4 ± 3.3  30.2 ± 3.2 Ɨ 30.2 ± 2.7 Ɨ * 
Abbreviations: BMI: body mass index; BF% body fat percentage; BM%: body muscle percentage; BW%: body 
water%; WC: waist circumference; WHR: waist to hip ratio; THC: thigh circumference; MUAC: mid-upper arm 
circumference  
*, Significantly different from baseline compared to placebo (p <0.01), independent samples t-test 
Ɨ, Significantly different from baseline within group (p <0.01), paired samples t-test 
4.3.3 Effect of CWE on Food and Energy Intake 
The mean (mean ± SD) weight (g) and energy (kcal) of food consumed daily, and the 
average daily intake of protein (g), carbohydrate (g), and total fat (g) were calculated 
according to the Food Frequency Questionnaire (FFQ-148 items), and the results are 
shown in Table 4.3. At baseline, there were no significant differences in any of the food 
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and energy intake variables measured, including weight, energy, protein, carbohydrate, 
and total fat between the CWE and groups, which indicates a good matching between two 
groups. After the twelve-week intervention, the average values of all food intake variables 
showed a reduction in both groups, however, the CWE group showed a greater drop in 
all variables compared to the placebo group. At the end of the intervention period, all of 
the variables, except for energy intake, showed significant reduction in the CWE group 
from baseline, while the drop in the placebo group was not significant. However, there 
was no significant difference in the reduction between the CWE group and the placebo 
group in any of the measured variables at week twelve, except for carbohydrate intake, 
which was remarkably decreased in the CWE group compared to the placebo group. 
Table 4.3: Changes (Mean ± SD) in daily total energy and macro-nutrient intake 
between and within groups after twelve weeks intervention 
Variables 
 Week 0 (baseline) Week 12  
Placebo CWE group  Placebo CWE group 
              
#Weight (g) 1964 ± 499 2525 ± 1303   1938 ± 461 2109 ± 663 
Energy (kcal) 2408 ± 440 2496 ± 589   2346 ± 400 2270 ± 596 Ɨ 
Protein (g) 79 ± 15 88 ± 25   79 ± 17 80 ± 25 Ɨ 
Carbohydrate 
(g) 
319 ± 70 345 ± 80   313 ± 69 315 ± 82 Ɨ * 
Total fat (g) 99 ± 29 94 ± 29   95 ± 25 85 ± 28 Ɨ 
#Weight (g): The weight (g) of daily food items consumed by participants 
*, Significantly different from baseline compared to the placebo (p <0.01), independent samples t-test 
Ɨ, Significantly different from baseline within group (p <0.01), paired samples t-test 
The weight (g) of daily food items consumed by participants was reduced in both 
groups (-416.1±917.2 g in the CWE group and -26.1±129.5 g, in the placebo), and was 
not significant either within or between groups. The food energy intake showed a 
significant reduction of 225.4±276.3 g in the CWE group, but only a decrease of 
62.8±181.1 g in the placebo group which was not significant. The reduction from baseline 
in protein intake was also significant in the CWE group (-7.8±9.0 g), but was not 
significant in the placebo group (-0.5±13.2 g). Similarly, the total fat in the CWE group 
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showed a significant reduction from baseline (-4.5±12.8 g), while there was no significant 
reduction in the placebo group (-9.2±11.6 g). The carbohydrate intake in the CWE group 
was reduced significantly from baseline (-30.1±37.0 g), while the reduction in the placebo 
group (-5.9± 18.9 g) was not significant. However, a significant difference was observed 
between the CWE group and the placebo group in carbohydrate intake at week 12. Hence, 
it is plausible that CWE has a positive effect on reducing food and energy intake, 
especially the intake of carbohydrates, which might help in losing weight in subjects 
naturally.   
4.3.4 Effect of CWE on Appetite 
The average (mean ± SD) appetite of the participants in both groups measured at 
baseline and after twelve weeks of treatment, and the average number of pizza slices 
consumed by the subjects (ad libitum pizza test) at the end of the intervention period were 
calculated, and the results are shown in Table 4.4.  
Table 4.4: Changes (Mean ± SD) in appetite measurements between and within groups   
after twelve weeks intervention 
Variables 
             Week 0 (baseline)                                       Week 12 
Placebo Group    CWE group             Placebo Group      CWE group 
Pizza test 
Pizza slices no. 
 
VAS test 
Appetite 
      
                    -  
 
          4.7  ±  1.0          3.9  ±  1.1* 
4.0 ±  1.1             4.3  ±   0.9                    4.0  ±  1.1          3.3  ±   1.0  Ɨ * 
*, Significantly different from baseline compared to the placebo (p <0.01), independent samples t-test 
Ɨ, Significantly different from baseline within group (p <0.01), paired samples t-test 
The average appetite was decreased significantly only in CWE group during the twelve 
weeks of  study. In the CWE group, significant appetite loss of 1.0 was observed, while 
the reduction in the placebo group was not significant (-0.01). Correspondingly, the 
appetite loss in the CWE group was significantly greater compared to the placebo group. 
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Also, the average number of pizza slices consumed after the twelve-week treatment 
period was significantly lower in the CWE group (4.7±1.0) compared to the placebo 
group (3.9±1.1), although the average appetite was not significantly different between the 
two treatment groups at baseline. Consequently, the CWE possibly has a positive effect 
on suppressing appetite and moderately reducing food intake, especially for 
carbohydrates.  
4.3.5 Effect of CWE on Clinical and Biochemical Variables 
The mean values (mean ± SD) of blood markers, including blood glucose, liver 
function and kidney function tests, lipid profile, and CBC tests in both groups were 
measured at baseline and after twelve weeks treatment, and the results are shown in 
Table 4.5. After twelve weeks of treatment, statistically significant differences were 
observed either within or between groups in any of the blood markers, except for the CBC 
test. After the intervention period, the RBC level showed a clinically significant rise, 
whereas the PDW showed a significant drop in the CWE group compared to the placebo 
group. 
4.3.5.1 Effect of CWE on Blood Serum Glucose 
During twelve weeks of treatment, the fasting blood sugar (FBS) level increased in 
both groups (3.95±20.2 mg/dL in the CWE group and 2.14±7.2 mg/dL in the placebo 
group). However, the differences were not significant either within or between the CWE 
group or the placebo group. 
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4.3.5.2 Effect of CWE on Liver Function 
Liver function parameters, including alanine transaminase (ALT), aspartate 
transaminase (AST), alkaline phosphatase (ALP), and direct and total bilirubin were 
assessed at baseline and after the twelve-week intervention, and are summarized in 
Table 4.5. The average AST level showed a rise of 0.8±9.4 IU/L in the CWE group,  and 
a reduction of 0.3±4.6 IU/L in the placebo group. Conversely, ALT level showed a 
reduction of 0.03±2.7 IU/L in the CWE group, and an increase of 0.2±5.4 IU/L in the 
placebo group. Also, the ALP level showed a reduction of 18.5±64.4 IU/L and 25.14±49.7 
IU/L in both the CWE and the placebo group respectively. In addition, direct bilirubin 
showed a reduction of 0.03±0.1 mg/dL and 0.02±0.1 mg/dL in both the CWE group and 
the placebo group respectively. Similarly, a reduction of 0.09±0.3 mg/dL and 0.1±0.5 
mg/dL was observed in the average total bilirubin in both the CWE group and the placebo 
group respectively. However, based on the paired and student t-tests, the changes in 
average values of any of the variables mentioned, were not significant either within or 
between any of the treatment groups.  
4.3.5.3 Effect of CWE on Kidney Function 
Kidney function parameters, including uric acid, urea, and creatinine, were measured 
at baseline and after the twelve-week intervention, and are presented in Table 4.5. In the 
CWE group, the uric acid level showed no visible changes during intervention, whereas 
in the placebo group a rise of 0.1±1.2 mg/dL was observed, which was not significant. 
The average urea level was decreased in both groups (-0.8±10.8 mg/dL in the CWE group 
and -0.5±6.7 mg/dL in the placebo group). Although the urea reduction in the CWE group 
was higher than in the placebo group, the differences in the reductions were not significant 
either within, or between, the two groups. Similarly, the mean creatinine levels showed a 
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reduction in both groups (-.0.1±0.2 mg/dL in the CWE and -0.1±0.2 mg/dL in the placebo 
groups), but the differences were not significant between the treatment groups. 
4.3.5.4 Effect of CWE on Lipid Profile 
Lipid profile variables, including serum total cholesterol (T-C), triglyceride (TG), 
HDL-cholesterol, LDL-cholesterol, LDL to HDL ratio (LDL/HDL), and cholesterol to 
HDL ratio (Chol/HDL) were measured at baseline and after twelve weeks of treatment, 
and are shown in Table 4.5. During the intervention period, the mean cholesterol values 
in the CWE group showed a reduction of -10.3±36.4 mg/dL, whereas the average 
cholesterol level in the placebo showed an increase of 7.1±39.1 mg/dL. However, the 
changes in average total cholesterol were not significant either within, or between, the 
CWE group and the placebo group.  
Also, the triglyceride levels increased in both groups (11.6±48.8 mg/dL in the CWE 
group and 23.1±56.7 mg/dL in the placebo group) during the twelve-week study. The 
average triglyceride level in the placebo group was nearly doubled compared to the CWE 
group. However, the differences were not significant between two groups. In the CWE 
group, an increase of 0.8±12.0 mg/dL was observed in HDL level, whereas in the placebo 
group, a reduction of -1.2±7.9 mg/dL was detected. However, the differences between 
two groups during the treatment period were not significant. The LDL level increased in 
in both groups (1.8±41.8 mg/dL in the CWE group and 4.0±39.9 mg/dL in the placebo 
group), but the changes were not significant either within, or between, the CWE group 
and the placebo group. Also, the LDL to HDL ratio in the placebo group showed a rise of 
0.1±0.9, whereas in the CWE group, no significant changes were observed. However, the 
differences were not significant either between or within any of the treatment groups. 
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Also, the cholesterol to HDL ratio showed reduction of 0.2±1.2 in the CWE group, but 
an increase of 0.2±1 in the placebo group. However, the differences which occurred 
during the twelve-week study were not significant between the CWE group and the 
placebo group. 
4.3.5.5 Effect of CWE on Hematological Parameters (CBC) 
The hematological parameters (complete blood cell count - CBC test) which were 
determined included WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, RDW-CV, 
PDW, and MPV. The mean values of these variables, assessed at baseline and after twelve 
weeks of treatment, are summarized in Table 4.5. After twelve weeks of treatment, the 
WBC levels increased in both groups (0.45±1.8 103/µL in the CWE group and 0.2±1.8 
103/µL, in the placebo group). However, the changes in WBC level were not significant, 
either within or between the two groups. The RBC levels in the CWE group increased 
significantly during the intervention (0.3±0.3 106/µL), whereas in the placebo group, a 
reduction of 0.2±0.5 106/µL was observed, which was not significant. However, the 
differences in the mean RBC changes were significantly higher in the CWE group 
compared to the placebo group. Similarly, the average hemoglobin values were 
significantly increased in the CWE group (0.5±0.7 mg/dL), whereas the rise in the 
placebo group was not significant (0.4±1.0 mg/dL), and the differences were not 
significant between the two treatment groups after intervention period.  
The mean HCT percentage increased in both groups (1.8% in the CWE group and 
0.02%, in the placebo group). Again, no significant differences were observed in either 
of the treatment groups during the study. On the other hand, the MCV and MCH values 
were reduced in both groups (-0.6±4.3 fL in the CWE group and -0.2±10.2 fL, in the 
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placebo group for MCV; -0.3±1.7 pg in the CWE group and -0.5±2.2 pg, in the placebo 
group, for MCH). However, the changes were not significant either in the CWE group or 
in the placebo. Also, no significant differences were observed between the two groups 
after 12 weeks of treatment. However, the average MCHC values increase in both groups 
(0.3±1.1 g/dL in the CWE group and 0.18±1.01 g/dL in the placebo group); neither of the 
MCHC levels in the two groups was increased significantly. Also, the differences in 
increase were not significant between the CWE group and the placebo group. 
 After treatment, the PLT values showed an increase of 3.9±53.9 103/µL in the CWE 
group, and a decrease of 19.8±69.8 103/µL in the placebo group. However, the changes 
in PLT values were not significant, both within, and between, the two treatment groups. 
Similarly, the percentage of RDW showed an increase of 0.4% in the CWE group, but a 
reduction of -0.2% in the placebo group, and showing insignificant changes between and 
within the CWE group and the placebo group. In the CWE group a decrease of 1.8±3.1 
fL was observed in the mean PDW, whereas in the placebo group, it showed an increase 
of 2.0±3.4 fL. However, the differences in PDW were significant between the two groups 
after the treatment period. Finally, the MPV values were increased in both groups 
(1.0±1.7 fL in the CWE group and 0.1±1.6 fL, in the placebo group) during the twelve-
week treatment period, and were not significant in either of the treatment groups. 
Although the rise in the CWE group was much higher than in the placebo group, the 
differences were not significant between the two treatment groups.   
4.3.5.6 Effect of CWE on Urine Biomarker (USG) 
Urine-specific gravity (USG), as one of the urine markers, was measured at baseline 
and after the twelve-week treatment, and the mean values are shown in Table 4.5. During 
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the twelve-week intervention, the mean USG showed a reduction of 0.9±6.9 g/mL in the 
CWE group, whereas in the placebo group, an increase of 1.4±7.3 g/mL was observed. 
However, the differences were not significant either within or between CWE group and 
placebo.  
4.3.6 Effect of CWE on Para-Clinical Variables 
Para-clinical variables, including DBP, SBP, and HR, as markers of heart function, 
were measured at baseline and after twelve weeks of treatment, and the mean values are 
summarized in Table 4.5. In the CWE group, the SBP showed an  increase of 0.7±5.4 
mmHg after the treatment period, whereas no significant changes were observed in the 
placebo group. Also, the DBP showed an increase of 0.4±4.7 mmHg in the CWE group, 
and in the placebo group a decrease of  0.8±4.7 mmHg was observed. However, the 
differences were not significant either within or between treatment groups during the 
twelve-week intervention. The average HR showed a minor decrease in both groups (-
0.6±4 bpm in the CWE and -0.8±3.8 bpm in the placebo group) after the twelve-week 
treatment. No statistically significant changes were observed in either of the treatment 
groups. Hence, consumption of CWE did not show any clinically significant effects on 
BP and HR as markers of the heart function. 
4.3.7 Safety Issues and Adverse Events 
According to the findings of this study, no clinically significant changes were observed 
for the clinical and para-clinical parameters between and within the two study groups 
during the twelve-week intervention. Also, no statistically significant effects were 
observed in the heart, liver and kidney functions between the groups (Table 4.5). Of the 
total of sixty subjects who completed the study, only the placebo participants experienced 
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skin allergy to the placebo product. Study also shows that there was no adverse events 
were reported during the physical examinations. Also, no adverse events were reported 
by any of the participants during the 12 weeks of CWE intervention.  
Table 4.5: Changes (Mean ± SD) in clinical and para-clinical parameters between and 
within groups after twelve weeks intervention 
Variables  Week 0 (baseline) Week 12  
 
Reference 
range 
   Placebo Group     
(n=29) 
CWE group 
(n=31) 
Placebo Group 
(n=29) 
CWE group     
(n=31) 
Blood serum 
assessments 
  
FBS 70-110 mg/dL 
91.6 ± 7.4 91.2 ± 12.0 93.7 ± 3.4 95.2 ± 11.8 
Liver function 
test 
              
AST, SGOT 5-40 IU/L 16.9 ± 4.5 16.8 ± 4.4 16.6 ± 1.6 17.6 ± 7.8 
ALT, SGPT 5-40 IU/L 16.1 ± 4.8 16.6 ± 4.7 16.3 ± 5.9 16.3 ± 4.9 
ALP 64-306 IU/L 173.1 ± 28.0 181.5 ± 36.6 148.0 ± 30.9 163.0 ± 46.3 
Bilirubin, D <0.25 mg/dL 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
Bilirubin, T 0.2-1.1 mg/dL 1.1 ± 0.5 1.2 ± 0.6 1.0 ± 0.5 1.1 ± 0.6 
Kidney 
function test 
              
Creatinine 0.4-1.5 mg/dL 0.9 ± 0.2 0.9 ± 0.2 0.8 ± 0.1 0.8 ± 0.1 
UA 3-6 mg/dL 4.1 ± 1.1 4.2 ± 1.0 4.2 ± 0.7 4.2 ± 0.5 
Urea 10-50 mg/dL 28.9 ± 7.0 29.6 ± 7.7 28.4 ± 3.3 28.9 ± 8.3 
Lipid profile   
          
 
 
T-C <200 mg/dL 183.3 ± 22.6 209.3 ± 29.9 190.4 ± 51.9 199.0 ± 25.1 
TG <150 mg/dL 121.9 ± 41.5 112.8 ± 35.1 145.0 ± 50.4 124.4 ± 42.6 
HDL-C >46 mg/dL 53.0 ± 9.9 55.9 ± 9.6 51.7 ± 7.7 56.7 ± 10.1 
LDL-C <130 mg/dL 106.7 ± 17.7 123.9 ± 28.7 110.8 ± 41.9 125.8 ± 25.9 
LDL/HDL <2.8  2.1 ± 0.5 2.3 ± 0.8 2.2 ± 0.9 2.3 ± 0.6 
Chol/HDL <4.3  3.5 ± 0.6 3.9 ± 1.1 3.8 ± 1.2 3.7 ± 1.0 
CBC test               
WBC 4-10 103/µL 6.8 ± 1.6 6.4 ± 1.4 6.9 ± 1.4 6.9 ± 1.8 
RBC 3.6-6.1 106/ µL 4.8 ± 0.5 4.5 ± 0.3 4.6 ± 0.3 4.7 ± 0.3* 
HGB 11.5-18.8 (g/dL) 12.4 ± 0.9 12.8 ± 0.7 12.7 ± 0.6 13.3 ± 0.6 Ɨ 
HCT 34-54 (%) 38.7 ± 3.0 39.0 ± 2.9 38.7 ± 2.4 40.8 ± 1.5 
MCV 80-100 fL 84.7 ± 11.4 87.7 ± 4.2 84.6 ± 6.3 87.1 ± 5.9 
MCH 27-36 (pg) 28.3 ± 2.1 28.8 ± 1.5 27.8 ± 1.8 28.5 ± 1.6 
MCHC 32-36 (g/dL) 32.8 ± 1.1 32.6 ± 1.1 32.9 ± 0.3 32.8 ± 1.1 
PLT 150-450 103/µL 272.5 ± 60.5 228.9 ± 40.3 252.7 ± 63.4 232.8 ± 52.7 
RDW 11.6-14.6 (%) 13.3 ± 0.8 13.1 ± 1.2 13.1 ± 0.5 13.5 ± 1.0 
PDW 7-20 fL 14.0 ± 3.3 13.8 ± 2.9 15.9 ± 0.9 12.0 ± 2.7* 
MPV 6-13 fL 9.5 ± 1.1 8.7 ± 1.2 9.5 ± 1.2 9.7 ± 1.41 
Urine test               
 USG 1.015-
1.025 
g/mL 
1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 
± 0.006 
Vital signs               
DBP 60-90 mmHg 74.3 ± 6.0 75.5 ± 7.9 71.0 ± 7.6 75.9 ± 6.80 
SBP 90-140 mmHg 111.3 ± 10.3 112.7 ± 10.4 111.3 ± 9.5 113.4 ± 11.21 
HR 60-100 bpm 75.2 ± 8.7 78.1 ± 9.1 74.5 ± 8.6 77.5 ± 8.11 
               
*, Significant difference from baseline compared to placebo (p <0.01), independent samples t-test  
Ɨ, Significant difference from baseline within group (p <0.01), paired samples t-test  
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4.4 Detection of Phytochemicals Using GC-MS 
The analytical results of the phytochemicals extracted into the caraway aqueous 
extract (CWE) are shown in the gas chromatogram (Figure 4.2). The predominant 
ingredients detected from the GC-MS analysis were a range of volatile and phenolic 
compounds, especially simple monoterpenes, including limonene, γ-terpinene, trans-
carveol, carvone, carvacrol, and thymol. 
 
Figure 4.2: Chromatogram of CWE infusion extracted by HS-SPME 
*CWE volatiles obtained by steam distillation with subsequent hexane extraction include: 
 1: limonene, 2: γ-terpinene, 3: trans-carveol, 4: carvone, 5: thymol, 6:carvacrol.  
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CHAPTER 5: DISCUSSION 
5.1 An Overview 
Based on the findings mentioned in the previous chapter, the results will be discussed 
in this section based on the objectives of this study. The discussion will be on examining 
the effect of CWE intake on body composition, anthropometric indices and appetite in 
overweight and obese women, investigating the safety of caraway intake for human, and 
analysis of the phytochemicals present in CWE which will be explained in details 
respectively. 
5.2 Efficacy Evaluation of CWE 
5.2.1 Effect of CWE on Body Composition, and Anthropometric Indices 
The initial objective of this study was to study the effect of CWE intake on body 
composition, anthropometric indices and appetite in overweight and obese women. 
Hence, the weight-lowering activity of caraway as an established traditional medicinal 
plant in Iran was studied in a triple-blind, placebo-controlled, clinical trial in Iranian 
overweight and obese females. As nutrition and exercise are the two major components 
of life-style in the control of body weight, participants were enrolled who were habitually 
performing aerobics during the whole period of the intervention, without changing their 
dietary habits and lifestyle patterns.  
This study showed that consumption of 30 ml/day CWE may result in reasonable anti-
obesity effects. Similar findings were observed in a recent animal study reporting that 
0.1% carvacrol, as one the major constituents of caraway, can prevent obesity and induce 
weight and fat loss in mice fed with high fat diet (Cho et al., 2012). Also, several animal 
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studies in normal and diabetic rats have proved the beneficial effects of caraway aqueous 
extract (20 mg/kg) on treating a number of health problems such as hyperglycemia 
(Eddouks et al., 2004), and hyperlipidemia (Lemhadri et al., 2006) which are recognized 
as common health consequences of obesity. Together, this clinical trial suggests a 
possible phytotherapeutic approach and natural medication for the application of CWE in 
the management of obesity. 
In this study, changes in body composition, and anthropometric indices in healthy, 
overweight, and obese females after the twelve-week consumption of CWE or placebo 
were evaluated. Clinically significant improvement in all the stated parameters after the 
treatment period was observed. Among the body composition variables, total body weight 
and fat percentage showed significant reduction in participants consuming CWE. These 
findings support the study hypothesis that consumption of caraway seed extract could be 
helpful in reducing weight and fat percentage in humans.  
Based on the findings of GC-MS analysis of CWE in this study, the main detected 
ingredients were of different volatile and phenolic compounds, including limonene, 
terpinene, carveol, carvone, carvacrol, and thymol. This is in line with a previous study, 
reporting that body weight and fat loss might be linked to anti-oxidant, anti-inflammatory, 
and anti-bacterial properties of caraway phytochemicals, especially phenolic compounds, 
such as carvacrol, and the unsaturated fatty acids (UFA) (Laribi et al., 2013). The intake 
of such bioactive ingredients with high antimicrobial activity, prevents the proliferation 
of pathogenic microorganisms, and thus enhances the growth and multiplying of 
beneficial gut bacteria (Hawrelak et al., 2009; Iacobellis et al., 2005). These interactions 
will possibly improve the balance of gut microbial ecology and alter gastrointestinal (GI) 
microbiome towards higher beneficial gut bacteria which could further improve digestion 
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and absorption of the ingested food providing homeostasis in GI tract (Can Baser, 2008; 
Michiels et al., 2007; Upreti et al., 2008). On the other hand, gut microflora (GM) could 
affect the host metabolism through regulating the expression of human genes. Hence, the 
interplay between GM, gene expression, and the host metabolic activity may have an 
effect on obesity and weight changes. This assumption is in line with the recent findings 
demonstrating that GM composition could have mutual interplay with the host, 
programming and affecting metabolism in human body altering body composition 
(Backhed, 2011; Musso et al., 2011). The suggested mechanism of action is explained in 
Figure 5.1. 
In this procedure, the gut microflora, which were altered following the antimicrobial 
actions of the present bioactive compounds, such as phenolic compounds, may induce the 
expression of specific genes involved in fat metabolism, which consequently leads to 
constraining inflammation in adipose tissue, and preventing adipogenesis (Cho et al., 
2012; Lombardo & Chicco, 2006). Previous studies indicated that the balanced gut 
microbiota prevents macrophage infiltration into adipose tissue causing interruption in 
the transformation of pre-adipocytes to mature adipocytes. This procedure will 
subsequently lead to constraint in adipogenesis and differentiation of adipocytes (Cani & 
Delzenne, 2011). These illustrations reinforce the possible role of the anti-inflammatory 
properties of the compounds present in CWE in weight and fat loss. Also, this hypothesis 
is in line with the findings of recent studies reporting that inflammation is related to body 
fat (Wesseltoft-Rao et al., 2012). Hence reducing the fat mass, which occurred in this 
study, might also be linked with anti-inflammatory reactions occurring in the human 
body.  
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Furthermore, UFAs could induce fatty acid oxidation resulting in lipolysis and fat loss 
(Iyer et al., 2010; Kalupahana et al., 2011). In addition, caraway essential oils and 
phenolic compounds could inhibit lipid peroxidation and enhance apoptosis in pre-
adipocytes due to their antioxidant properties (Samojlik et al., 2010). These compounds 
can diminish adipose tissue and body fat mass through inhibiting adipogenesis, inducing 
apoptosis in pre-adipocytes, and stimulating lipolysis in adipocytes (Hsu & Yen, 2007b; 
Hsu & Yen, 2008; Rayalam et al., 2008). In addition, previous studies have proposed that 
an aqueous extract of caraway could display lipolytic activity due to reducing intestinal 
lipid absorption, by binding with bile acids. A similar mechanism might be appropriate 
to describe the observed fat lowering activity of CWE. Also, caraway may facilitate 
weight and fat loss through inhibiting lipid biosynthesis by altering lipid metabolism 
which may contribute to the regulation of body fat (Lemhadri et al., 2006). Accordingly, 
the weight-lowering property of caraway may be mediated by the improvement of 
digestion, absorption, and lipid metabolism. In conclusion, this trial has revealed that 
daily consumption of CWE (30 ml/day) for twelve weeks evokes an advantageous effect 
on overweight and obesity. This outcome supports its consumption by the Iranian 
population for the treatment and management of obesity. 
With regard to the body composition changes, body weight and fat were decreased 
significantly, and are consistent with a recent animal study demonstrating the potent anti-
obesity activity of carvacrol in obese mice (Cho et al., 2012). In contrast, no significant 
alterations were observed in the body water percentage in participants during the study. 
These findings show that the intake of CWE should not have any adverse effects on body 
health. Usually, the percentage of water will be changed during various disease states, 
and assessing body water is essential in determining the occurrence and progression of 
diseases (Glenda Winson, 2001).  
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Figure 5.1: Possible CWE metabolic actions on the human body during weight loss 
Results on body muscle percentage showed an improvement in the CWE group, 
whereas there were no significant changes in muscle percentage in the placebo group 
during the course of the study. Thus physical activity and aerobic exercises did not have 
an interfering effect on decreasing body weight and fat percentage of the participants. 
Accordingly, these outcomes suggest that the positive alterations in body composition 
were probably related to the phytochemicals present in CWE, and not essentially with the 
exercise, even though it was expected that physical activity would probably have a 
synergistic effect on lowering body weight and body fat in those study participants 
consuming CWE. Furthermore, the bio-products that have been formed during lipolysis 
were probably transformed into muscle induced by exercise, synergistically, and the loss 
in body fat and rise in muscle mass is most likely due to physiological adaptations to 
physical activity (Nissen & Sharp, 2003; Panton et al., 2000; Pittler & Ernst, 2004). 
With regard to the alterations in body size, as expected, all anthropometric indices 
showed a significant decrease in those study participants consuming CWE compared to 
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the placebo group. The findings show that the waist circumference, the waist to hip ratio, 
the thigh circumference, and the MUAC decreased significantly after the twelve-week 
consumption of CWE. According to the demographic values of this study, all of the 
participants had WC greater than borderline, showing abdominal obesity at baseline. The 
WHR and WC are the major determinants and markers of central adiposity, and are 
recognized as the major risk factors for the health related issues, such as cardiovascular 
problems, ischemic stroke, cancer mortality, myocardial infarction, diabetes, impaired 
fibrinolytic activity, etc. (Dagenais et al., 2005; Landin et al., 1990; Lee et al., 2008; Suk 
et al., 2003; Wang et al., 2005; Zhang et al., 2008). Consequently, reducing WHR and 
WC through consumption of CWE may be of value in the prevention and treatment of 
abdominal obesity and its complications. Moreover, waist circumference, reflects the 
content within the abdominal cavity as well as visceral fat and subcutaneous fat (Pouliot 
et al., 1994). Flatus and faecal content of the gut can affect waist circumference. The WC 
reduction in the CWE was 6.2 cm yet the total weight reduction was only 1.9 kg. There 
is very roughly a relationship between WC and body weight of approximately 1 cm WC 
reduction per 1 kg weight reduction. CWE is a carminative, relaxing the gut. It is 
plausible, that the larger than expected reduction of WC reflects an effect of CWE on 
flushing the large colon. This is in line with the reports of the CWE subjects regarding 
improvements in their bowel function and their bloating and flatulence problems. 
On the other hand, the body size values did not show any significant reduction in the 
placebo group during the course of the study, except for the thigh circumference and the 
MUAC, which indicates that exercise did not have any interfering or synergistic effect on 
the reduction of abdominal obesity and visceral fat. 
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Anthropometric indices are known as beneficial indicators for evaluating the adiposity 
of an individual, and worthy markers of the health and nutritional status of an individual 
(Mandal et al., 2011). In this study, the results of the anthropometric assessments are in 
line with the outcomes of body composition measures, indicating that there is a link 
between a reduction in body size, body fat, and weight, as lowering the WHR and WC 
reflects a reduction in visceral fat. Also, these results show a possible contribution of 
CWE in lowering abdominal fat. These findings indicate that the balancing, improvement, 
and normalization in body size and body composition have occurred simultaneously. 
Together, these results provide complementary and supplementary data which support the 
study hypothesis regarding the potential anti-obesity activity of caraway aqueous extract 
ingredients for human.  
5.2.2 Effect of CWE on Food Intake, and Appetite 
With regard to the food intake assessments during the study intervention, the intake of 
calories and all macronutrients, including carbohydrates, proteins, and total fat, showed a 
significant decrease in those subjects consuming CWE, but not in the placebo group. 
However, a significant difference in reduction between the CWE group and the placebo 
group was observed only in CHO intake. These findings are in line with the results of the 
appetite test which showed that the appetite level was reduced significantly in those 
subjects consuming CWE compared to the placebo group. In addition, the results of the 
ad libitum pizza test after completion of the study support these findings, indicating that 
the subjects in the CWE group consumed significantly fewer pizza slices compared to the 
placebo group showing that participants who consumed CWE during the twelve-week 
study period, had a lower appetite compared to those who consumed placebo although 
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there was no significant difference in the average level of appetite between two groups at 
baseline. 
The appetite-suppressant effect of CWE is in agreement with the previous studies 
acknowledging caraway oil/aqueous extract to have appetite-regulating activity which 
might be linked to its carminative properties, and soothing effects on gastric contractions 
(Blumenthal, 1999; Reynolds, 1996; Sadowska & Obidoska, 2003). On the other hand, 
the findings of reducing food and CHO intake are in agreement with the changes in body 
composition which occurred during this study. During this intervention, the reduction in 
food intake following consumption of CWE did not have a negative effect on the body 
composition or nutritional status of the subjects, rather an improvement in body 
composition was observed. From these findings, it is possible that a moderate reduction 
in food intake and of CHO in particular, followed by consumption of CWE would induce 
weight loss, thereby lowering body size, excess body fat, and abdominal obesity, with no 
adverse effect on protein stores and waste in muscle mass.  
As mentioned above, in this study, muscle mass gain was observed in the CWE group. 
On the other hand, clinical validations obtained from this study presented no adverse 
effects in the health status of subjects. These findings are in agreement with previous 
studies reporting that moderate restriction in calorie and CHO intake would have a potent 
beneficial effect on obesity, inflammation, hypertension, cardiovascular problems, 
diabetes mellitus, slow aging, cancer, delay disease onset, and extend lifespan, whereas 
most of the uncontrolled dietary restriction regimens might induce malnutrition and 
health problems, especially taken for a long-term period (Cava & Fontana, 2013; Colman 
et al., 2009; Meckling et al., 2004; Omodei et al., 2013; Ritz & Gardner, 2006; 
Trepanowski et al., 2011). 
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Accordingly, the reduction in food intake which was observed in this study did not 
show any adverse effect on the nutritional status and body composition of the participants. 
These results are consistent with the demonstrations of previous studies indicating that 
body composition and anthropometric indices are beneficial indicators reflecting the 
health and nutritional status of an individual (Glenda Winson, 2001; Mandal et al., 2011). 
Such outcomes suggest that CWE is able to suppress appetite, and lower food intake with 
no depletion in protein stores and waste in muscle mass.  
5.3 Safety Evaluation of CWE 
5.3.1 Effect of CWE on Clinical and Para-Clinical Variables and Safety Issues 
The second objective of this study was to examine the safety of caraway water extract 
(CWE) intake for humans. There appears to be no triple-blind clinical study on the safety 
and tolerability of any caraway preparations taken alone. A few studies have examined 
the safety of caraway oil and as a combination with other phytochemicals, but not as a 
single aqueous extract preparation (Madisch et al., 2004; Westphal et al., 1996). This 
study illustrates that daily consumption of CWE (30 ml/day) has a potential to reduce 
weight with no clinically significant adverse events or serious side effects. During the 
clinical trial, the intake of CWE did not show any side effects on major vital organ 
functions, including the heart, liver, and kidney. Also, no clinically significant changes 
were observed on urine-specific gravity, serum blood glucose level, and lipid profile. As 
a conclusion, no significant adverse events were observed in the clinical and para-clinical 
valuations with either treatment during the twelve-week intervention period, and the 
CWE was well-tolerated by all of the participants. These findings may support other 
opinions which have recommended caraway as a safe natural product with several 
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therapeutic effects for humans (May et al., 2000; Sadowska & Obidoska, 2003; Samojlik 
et al., 2010; Westphal et al., 1996). 
Caraway and its by-products have a long history of folk usage, and are widely-used 
plant-based products (Guarrera & Savo, 2013; Halberstein, 2005). There are a number of 
in vitro and in vivo studies which report different therapeutic potentials and biological 
activities for caraway oil/aqueous extract and its derivatives, for example anti-microbial, 
anti-inflammatory, antioxidant, anti-cancer, and anti-spasmodic effects (Alhaider et al., 
2006; Can Baser, 2008; Johri, 2011). However, studies on the safety and tolerability of 
caraway seed and its extracts in humans are few. In this research, the safety and 
tolerability of CWE were studied in healthy, overweight and obese women in a 
randomized, triple-blind, placebo-controlled clinical trial during twelve weeks. After the 
treatment period, no severe adverse events were observed in any of the participants with 
respect to the cardiovascular, hepatic, renal, or hemopoietic systems. Also, the results 
revealed no significant changes in the clinical and para-clinical variables. As a result, this 
CWE may be regarded as being well-tolerated, and safe to consume with no problematic 
effects for humans. The findings concerning the adverse effects of CWE intake were as 
expected, and in agreement with those of the earlier studies, indicating that there are no 
known and recognized cautions, adverse events, or drug interactions associated with the 
consumption of caraway (Blumenthal, 1999; Capasso et al., 2003). 
During the twelve-week of treatment, there were no significant changes in the average 
values of any of the biomarkers, except in the hematological variables showing an 
increase in RBC and a decrease in PDW. Previous studies have recommended caraway 
oil or aqueous extract  and its derivatives as a potent plant, with anti-hyperglycemic and 
anti-hyperlipidemic activities lowering blood glucose, cholesterol, LDL, and TG levels 
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which could be useful in treating diabetes and hyperlipidemia (Eddouks et al., 2004; Ene 
et al., 2007; Haidari et al., 2011; Lemhadri et al., 2006). The measurements of lipid 
profile in this study showed a slight drop in the total cholesterol level in the CWE group, 
and a slight rise in the placebo group without significantly affecting TG, and LDL and 
HDL cholesterol. The lack of significance may be associated with a number of factors. 
One reason might be due to the small sample size. In this case, allotting a sufficiently 
large sample size might be more effective and helpful to detect substantial change. 
Furthermore, the study population allotted were mainly comprised of subjects with 
normal levels of serum blood glucose and lipid profile at baseline, whereas the reported 
hypolipidemic and hypoglycemic activity of caraway oil or aqueous extract and its 
derivatives were shown in diabetic rats or in animals suffering from hyperlipidemia 
(Eddouks et al., 2004; Ene et al., 2007; Haidari et al., 2011; Lemhadri et al., 2006). An 
alternative explanation for the lack of significant effect of CWE on lipid profile and 
glucose level in this study might be associated with the dosage and composition of 
caraway product applied. Hence, further studies are recommended to assess the 
hypoglycemic and hypolipidemic activity of different caraway products at different 
dosages, and also through the administration of caraway oil containing more bioactive 
and volatile compounds which might result in more biologically diverse findings. 
With respect to the heart function test, no clinically significant changes were observed 
in the blood pressure or heart rate in any of the treatment groups. Such outcomes differ 
from previous findings wherein caraway seeds have been used traditionally as folk 
remedy to treat hypertension and decrease blood pressure (Tahraoui et al., 2007). An 
explanation of this might be due to the fact that the antihypertensive activity of caraway 
has only been reported ethnomedically, and has not been examined scientifically. The 
105 
blood-pressure-lowering effect of CWE should be examined in an animal hypertensive 
model initially to assess perceptible results. 
The kidney function test showed that usage of CWE would not have any untoward 
effects on kidney function. These outcomes are in line with the findings of previous 
studies demonstrating the reno-protective property of caraway aqueous extract (60 
mg/kg) in rodents (Sadiq et al., 2010). Also, after the twelve-week treatment period with 
CWE, no adverse events were shown in liver function biomarkers. These results are 
consistent with the reports supporting hepatoprotective potential of caraway oil extract 
(minimum 0.13 μM) administration in mice (Naderi-Kalali et al., 2005; Samojlik et al., 
2010). 
The findings of the blood CBC test indicated that the average level of RBC improved 
significantly while the mean values of PDW showed a significant reduction in subjects 
consuming CWE as compared with the placebo group after the twelve-week intervention. 
On the other hand, HGB levels showed a significant increase only in the CWE group, 
which supports the findings related to the significant rise observed in the RBC levels. 
These alterations display the potential valuable influence of CWE as a phytotherapeutic 
agent for the treatment of anemia. It is possible that treatment with CWE may well 
compensate for the low RBC level in patients suffering from anemia. These judgments 
are in line with an earlier animal study which suggested that caraway water extract (2.5 
g/100 ml) may have protective properties against anemia through stimulating the 
absorption of iron in the gastrointestinal tract (El-Shobaki et al., 1990). Also, the 
reduction in the PDW levels in patients consuming CWE is in line with a previous study 
which reported the anti-platelet properties of carvacrol (Can Baser, 2008). Prior studies 
revealed that hyperthyroidism is linked to a rise in MPV (mean platelet volume) levels 
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and a decline in PDW levels (Ford & Carter, 1990). In addition, administration of a hydro-
alcoholic extract of caraway (1600 mg/kg) displayed a hyperthyroidism influence through 
escalation in T3 and T4 levels, and a reduction in TSH levels (Dehghani et al., 2010). 
Also, the weight of rats in the caraway extract group was remarkably lower than the 
control group, which shows the weight lowering effect of caraway extract.  
Thyroid hormones are recognized as determining factors of the basal metabolic rate 
and energy expenditure. Therefore, modifying thyroid hormone levels affects 
thermogenesis in the body leading to major changes in body composition, reducing body 
fat, body weight, and appetite (Johnstone et al., 2005; Kim, 2008; Moreno et al., 2008). 
In line with these findings, the present outcomes propose a moderate anti-hypothyroidism 
influence of CWE in humans. This plant preparation may influence hypothyroidism 
homeostasis, which could possibly give rise to an enhanced metabolic rate and, in 
consequence, a reduction of body weight and fat percentage. This is in agreement with 
the body composition and appetite changes observed in this study. The probable 
mechanism of action and effect of consumption of CWE on biochemical variables are 
shown in Figure 5.2. As a conclusion, this study suggests that CWE, as a potential anti-
obesity plant, can be consumed in moderation and regularly as part of a healthy, balanced 
diet for normalizing body composition and appetite without any severe adverse effects. 
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Figure 5.2: Possible therapeutic effects of CWE on the human body 
5.4 Analysis of CWE Phytochemicals 
The third objective of this study was to identify the major phytochemical constituents 
present in the steam-distilled caraway extract using GC-MS analysis. The results show 
that most of the constituents detected from the GC-MS analysis were a range of different 
volatile and phenolic compounds, especially simple monoterpenes, including limonene, 
γ-terpinene, trans-carveol, carvone, carvacrol, and thymol, and the phenylpropene 
derivative, anethole. The results of the GC-MS analysis in this study show that these 
findings are consistent with the major compounds characterized from the caraway extract 
as reported in previous studies (Iacobellis et al., 2005; Laribi et al., 2013; Park et al., 
2008; Razzaghi-Abyaneh et al., 2009; Richter & Schellenberg, 2007; Rivera et al., 2010; 
Samojlik et al., 2010; Seo et al., 2009; Simic et al., 2008). As stated in the previous 
sections, a number of evidences show the relation of these phytochemicals with obesity 
and weight loss which are in line with the findings of this study.  
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CHAPTER 6: CONCLUSION AND RECOMMENDATION 
6.1 An Overview 
In Islamic traditional medicine, there are numerous potential plants recommended for 
treatment of different health problems such as obesity. This research was carried out to 
examine the efficacy and safety of a caraway extract, as an example of a traditional, anti-
obesity medicinal plant, on healthy obese and overweight women in a randomized, triple 
blind, placebo controlled, clinical trial during a twelve-week period.  The results showed 
that consumption of CWE could be of practical value in the management of obesity.  
According to the previous studies, anti-obesity plants are able to induce weight loss 
through four different mechanisms, including suppressing appetite, inducing lipolysis, 
inhibiting lipogenesis, and enhancing metabolism. In addition, some of the potent anti-
obesity plants can induce weight loss through two or more mechanisms (Yun, 2010). 
From the findings of this study, CWE can induce weight loss through all the four 
mechanisms stated earlier.  
Also, it can be concluded that the anti-obesity properties of CWE are due to the 
presence of the bioactive ingredients. As mentioned previously, the phytochemicals 
extracted from the CWE, as detected by GC-MS, were well-known volatile compounds, 
including limonene, γ-terpinene, trans-carveol, carvone, thymol, and carvacrol. These 
bioactive compounds present in CWE may be effective in the management of obesity, 
reducing body size, body weight, body fat and appetite most likely through a combination 
of four major bioactivities including anti-microbial, anti-oxidant, and anti-inflammatory 
properties, together with appetite-suppressing activity. 
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This study is the first triple-blind clinical trial examining the effects of consumption 
of CWE on body composition and anthropometric indices, along with a physical activity 
program, and investigating the anti-obesity effect of CWE in overweight and obese 
females during twelve weeks of treatment. Moreover, this study has four additional 
strengths listed as follows: 
 Firstly, participants consuming 30 ml/day CWE for 12 weeks showed significant 
reductions in body weight, body fat, and also body size, as compared with the placebo 
group, although they did not change their dietary habits. Secondly, oral administration of 
CWE results in lowering CHO intake and appetite, which would induce weight loss, along 
with improving body composition and blood biomarkers with no problematic effects on 
body health. Thirdly, this interventional study was a randomized triple-blinded placebo-
controlled clinical trial which improves the precision and accuracy of the outcomes and 
decreases probable bias in the results. Fourthly, this is the first evidenced-based study 
demonstrating the safety and tolerability of a caraway extract in humans. Treatment with 
CWE was on the whole, well-tolerated with no informed adverse effects. In addition, the 
significant rise in RBC and reduction in PDW afforded by the twelve-week administration 
of the caraway extract suggests a potential use of this plant-derived extract in the 
management of anemia and hypothyroidism, respectively, which requires further 
investigation. 
6.2 Implications and Recommendations 
In this section, the researcher summarizes the findings of all chapters and suggests the 
future direction for research. The recommendations which are acknowledged are listed as 
follows: 
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Firstly, parameters assessed in this study were only limited to blood, para-clinical and 
clinical variable. However, for studying the underlying mechanism of action, 
supplementary assessments such as hormones or other biomarkers which might play role 
in treating obesity are required to be done. Also, for verifying and evidencing the 
metabolisms proposed in this study, examining probable alterations in fecal microflora, 
also possible changes at molecular level and determining the genes involved in these 
changes are suggested.  
Secondly, findings obtained in this trial are restricted to an aqueous extract of caraway, 
and so additional estimates are recommended to examine the anti-obesity influence of 
different type of caraway seed extracts such as caraway oil extract achieved from other 
procedures or preparation methods. Also, studying the effects of caraway by-products or 
bioactive compounds are suggested to identify the major phytochemicals displaying 
different bioactivities. Moreover, only a single dose of CWE was examined in this clinical 
trial. Hence, additional studies are recommended to examine the safety and efficacy of 
CWE in different doses through conducting multiple dosage to achieve more precise 
dosing limitations. 
Thirdly, only healthy Iranian adult female who were overweight and obese were 
eligible to participate in this trial and volunteers with medical complications have been 
excluded from the study. As previous studies have identified several therapeutic 
properties of caraway and its derivatives, it would be much valued and recommended to 
examine the weigh lowering activity of caraway in subjects suffering from other health 
problems such as hormonal dysfunction, hypertension, hyperlipidemia and cardiovascular 
problems, hyperglycemia and diabetes, metabolic syndrome and other health problems 
which are mostly linked to obesity. Also, the study was conducted only in Iranian women 
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living in province of Yazd. Hence, it is proposed to conduct this study in other countries 
with different races, cultures and nationalities wherein the outcomes would be of higher 
value if compared with each other. On the other hand, the study population were in a 
limited age range. So, further studies are required to examine the efficacy and tolerability 
of CWE in other stage of life especially in children and elder population which might 
have lower immune system. 
The other issue is concerned to the size of the study population. Although the sample 
size in this trial was statistically enough to achieve the feasible results, it is suggested to 
perform this study in a larger population to attain more accurate data.  Besides, since this 
trial was examined only in adult females, it is recommended to study the weight lowering 
activity of CWE in males as well in order to achieve more reliable data by having 
homogenous population containing both genders. Finally, as exercise might induce an 
interfering or synergistic influence on weight and fat loss (Ross et al., 2000), repeating 
this trial on individuals without physical activity is suggested. 
This study also implies that intake of caraway could be useful in decreasing the 
complications of obesity, such as diabetes mellitus and cardiovascular diseases. However, 
additional studies, with different doses and preparations of CWE in other national and 
ethnic groups, with multiple genders, with larger population, in wider age groups, with a 
variety of health problems, and over a longer extended period of time, are recommended 
to determine more accurate data about the safety, tolerability, efficacy, and applicability 
of CWE, and to further improve the importance and worth of these primary clinical 
findings.  
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From the evidence presented in this study and in previous researches, it is hypothesized 
that the anti-obesity activity might be from the prebiotic effect of CWE in the 
gastrointestinal tract through modulating gut microflora. The mechanism of action of 
these phytochemical constituents needs to be defined at the molecular level. Altogether, 
the health benefits of CWE lay in the potential contribution of this plant-based product to 
the overall intake of potent phytochemicals, especially phenolic and volatile compounds. 
However, supplementary studies are required to examine the effects of these constituents 
in treating obesity and overweight at the molecular level. Also, the actual sites of this 
activity, the detailed mechanisms of action, and the specific bioactive components of 
caraway involved should be determined. The significant differences in RBC and PDW 
have no sinister meaning as they are well within the normal range. However, the rise of 
haemoglobin and RBC are indeed interesting and merit further investigation. 
 At the same time, efforts to make available this evidence and pursue the expanded 
human use of this traditional medicinal plant, and develop the consumption of caraway 
and its derivatives as a sustainable dietary practice, together with exercise, as a part of a 
healthy lifestyle, should be continued. It  is  hoped  that  the  findings  of  this  study  will  
be  useful  for the  management and fight against obesity and overweight using natural 
sources with potent anti-obesity activity to improve the quality of life of the world’s 
population.  
Overall, the research findings are important to enrich the knowledge and practices of 
Muslim heritage in traditional and complementary medicine with scientific values and 
empirical facts. It is recommended to study other potential herbal compounds and 
medicinal plants acclaimed in Islamic traditional references and disclose their probable 
health benefits, and their safety and efficacy, using modern scientific approaches.    
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APPENDIX 
APPENDIX A: Other aromatic plants mistaken for carum carvi due to their 
resemblance in name or appearance 
Appearance  Scientific Name Common Name Other names 
 
Carum carvi L. Caraway seeds/ Persian 
Cumin 
Jiraa, zeera siyaah, kamoon, 
kamoon-roomi 
 
Cumin cuminum L. 
 
Cumin Safed jeeraa, Kamun 
 
Foeniculum vulgare Mill. Fennel Seeds/ Sweet Cumin Perum Jeerakam 
 
Pimpinella anisum 
L. 
Aniseed, anise Saumph, Aneesun 
 
Nigella sativa L. 
 
Black Cumin, Black 
Caraway, small fennel 
Kalonji, black seeds 
 
Bunium persicum (Boiss.) 
B.Fedtsch. 
Black Caraway Jirak, jiraa siyah, Kamoon-
armani, Shahi Jeera, Kaala 
Jeera 
Sources: Modified from several sources (Khare, 2008; Zaid et al., 2010) 
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APPENDIX B: Etymology of caraway (Carum carvi) 
There is little, incomplete, and yet complex information known about the etymology 
of Carum carvi. The carvi term is initiated from the Arabic al-karwiya seeds, whereas the 
word carum most likely originated from the Latin word Caria, an ancient city in Asia 
Minor, where caraway may have been used in early times. The usage of “Carum carvi” 
probably dates back to very ancient times based on the finding of caraway seeds by 
archaeologists in the artefacts of primitive civilizations in Europe (Gledhill, 2008; 
Şekerci, 2007). In Germany, caraway is one of the most common seeds, and is known as 
Kümmel. This word is derived from Latin word cuminum for cumin, and was used for 
caraway by mistake.  Latin cuminum, through Greek kyminon, dates back to Semitic 
forms, such as Old Hebrew kammon. Some terms for caraway in the languages of Europe, 
especially Northern Europe (where caraway is predominantly popular), similarly link to 
Latin cuminum, including Danish kommen, Latvian ķimenes, Estonian köömen, Polish 
kminek, and Bulgarian kim.  
The English use of the word caraway was initiated over 1400 years ago. The original 
term is cuminum (cumin) in Latin, and karon in the Greek, which is transformed to carum 
(which now means caraway). “Karavi”, the Sanskrit designation of caraway, and the 
Arabic term al-karawya is derived from the Latin carum. These terms are also similar to 
some European designations of caraway such as carvi in French, caro in Italian, karvi in 
Greek, and karve in Norwegian. The English name caraway is most likely mediated by 
Arabic (modern form al-karawya) from the Latin carum. The Iberic terms are in 
Portuguese, alcaravia, and in Spanish, alcaravea. The English Malayalam terms of 
caraway are Sheema Jeerakam (Shia Jeera) in Hindi– Caraway seeds/ Persian Cumin/ 
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Meridian Fennel.  Some synonyms for caraway in different parts of the world are 
indicated in APPENDIX B1. 
APPENDIX B1: Synonyms of caraway in different languages 
 
Language Alternative expression 
English Caraway seeds, Persian cumin, Carum, Meridian fennel, Wild cumin 
Persian (Farsi) Black zeereh, Kermani zireh, Roman cumin 
Arabic Taghde, Roman kommon, Al-Karvia, Kammun Armani, Karawiya 
Azeri Adi Cirə 
Albanian Qimnoni 
Armenian Chaman 
Finnish Kumina, Saksan Kumina, Tavallinen, Kumina 
Dutch Karwij, Karwijzaad, Wilde komijn 
Chinese Fang Feng, Ge Lü Zi, Yuan Sui (Mandarin), Goht Leuih Ji (Cantonese) 
Bulgarian Kim 
Croatian Kim 
Eastonian Harilik Köömen 
Russian Тмин, Tmin 
Burmese Ziya 
Belarusian Kmen 
Catalan Comi De Prat 
Basque Xarpoil 
Yiddish Kiml, kimmel 
Norwegian Karve 
Czech Kmín, Kmín Kořenný, Kmín Luční 
Dutch Echte Karwij, Karwij, Karwijzaad, Kummel, Wilde Komijn 
Brazil Alcarávia (Portuguese) 
Spanish Alcarahueya, Alcarave, Alcaravia, Carvi, Comino de prado 
French Anis des Vosges, Carvi, Cumin des Prés, Cumin De Montagne, Kummel 
Swedish Kummin 
Gaelic Carbhaidh, Carvie, Cearbhas, Lus Dearg 
German Gemeiner Kümmel, Wiesenkümmel 
Italian Caro, Carvi, Cumino dei prati, Kümmel, cumino tedesco, German cumin 
Danish Almindelig Kommen, Karve, Kommen, Vild Kommen 
Turkish  Frenk kimyonu, Frankish cumin 
Hindi  Vilayati jeera, foreign cumin 
Galician Alcaravea, Alcaravía 
Romanian  Chimen 
Source: Taken/ modified from different sources (Brechbill, 2012; Skeat, 1892) 
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APPENDIX C: Randomization of candidates through the online randomization 
program 
Code No. of respondents Group type Code No. of respondents Group type 
1. Control 36. Control 
2. Control 37. Test 
3. Control 38. Test 
4. Control 39. Control 
5. Test 40. Test 
6. Test 41. Control 
7. Control 42. Control 
8. Control 43. Test 
9. Test 44. Test 
10. Test 45. Control 
11. Control 46. Test 
12. Test 47. Control 
13. Control 48. Test 
14. Test 49. Control 
15. Test 50. Test 
16. Control 51. Control 
17. Test 52. Control 
18. Test 53. Control 
19. Control 54. Control 
20. Test 55. Test 
21. Control 56. Control 
22. Test 57. Control 
23. Test 58. Test 
24. Test 59. Control 
25. Control 60. Test 
26. Control 61. Test 
27. Control 62. Test 
28. Control 63. Control 
29. Control 64. Test 
30. Control 65. Control 
31. Test 66. Control 
32. Test 67. Test 
33. Test 68. Test 
34. Test 69. Test 
35. Test 70. Control 
 
  
148 
APPENDIX D: Blood test methods 
Determination of total serum Cholesterol 
Principle: 
Enzymatic determination of total cholesterol was according to the following reactions 
(Allain et al., 1974): 
Cholesterol ester + H2O      
Cholesterol esterase         Cholesterol + Fatty acids 
Cholesterol + O2        
Cholesterol oxidase      Cholest-4-en-3-one + H2O2 
2 H2O2 + Phenol + 4-AAP    
Peroxidase  Quinoneimine + 4 H2O2 
4-AAP = Amino-4-antipyrine 
Reagents composition: 
Reagent: R 
Pipes buffer, pH 6.7  
  
50  
 
mmol/L 
Phenol  24 mmol/L 
Sodium cholate   5 mmol/L 
4-aminoantipyrine  0.5 mmol/L 
Cholesterol esterase ≥  180 U/L 
Cholesterol oxidase ≥  200 U/L 
Peroxidase  ≥  1000 U/L 
Reference values: 
The NCEP (American National Cholesterol Education Program) has established the 
following classification for serum total cholesterol levels according to the risk of 
developing coronary heart diseases (Goodman et al., 1988; Wilson et al., 1998): 
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Normal < 200 mg/dl 
Borderline high 200-239 mg/dl 
High ≥ 240 mg/dl 
 
Procedure: 
 Blank Standard Sample 
Reagent R 300 µL 300 µL 300 µL 
Distilled water 3 µL   
Standard  3 µL  
Sample   3 µL 
Mixed and the absorbance (A) was read at 500 nm after a 325 seconds incubation at 37 
°C. The samples were read against reagent blank. 
Calculation: 
(A sample / A standard) × n   n = standard concentration 
The performance data including analytical range, detection limit, sensitivity, precision 
and correlation were obtained using the COBAS MIRA analyzer (37 °C). 
Determination of serum Cholesterol LDL 
Principle: 
In first step, when a sample is mixed with reagent R1, non-LDL lipoproteins are 
solubilized by detergent 1 and released cholesterol is subject to enzymatic reactions to be 
eliminated: 
Cholesterol, HDL, VLDL, Chylomicron    Detergent1+CO+CHE     Colorless products 
In second step, when reagent R2 is added, LDL is solubilized by detergent 2, then LDL 
cholesterol is measured by enzymatic reactions:       
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LDL       
Detergent2 Solubilized LDL 
LDL cholesterol + O2       
CHE +CO  Cholest-4-en-3-one + H2O2 
H2O2 + 4-AA + DSBmT
     Peroxidase         Colored compound   
Reagents composition: 
Reagent1: R1 
MES buffer, pH 6.3 
   
Detergent 1 < 1.0 % 
Cholesterol esterase (CHE) <  1500 U/L 
Cholesterol oxidase (CO)  <  1500 U/L 
Peroxidase  <  1300 U/L 
4-Amino-Antipyrine (4-AA) < 0.1 % 
Ascorbate oxidase < 3000 U/L 
Reagent2: R2 
MES buffer, pH 6.3 
   
Detergent 2 < 1.0 % 
N,N-bis(4-sulphobutyl)-m-toluidine-disodium (DSBmT) < 1.0 mmol/L 
Reference values: 
The NCEP (American National Cholesterol Education Program) has established the 
following classification for serum LDL cholesterol levels according to the risk of 
developing coronary heart diseases (Adult Treatment Panel III, 2001): 
Optimal  < 100 mg/dl 
Near or above optimal 100-129 mg/dl 
Borderline high 130-159 mg/dl 
High 160-189 mg/dl 
Very high > 190 mg/dl 
Procedure: 
 Blank Standard Sample 
Reagent1 R1 240 µL 240 µL 240 µL 
Distilled water 2.4 µL - - 
Standard - 2.4 µL - 
Sample - - 2.4 µL 
Mixed and the absorbance (A1) was read at 578 nm after 4 minutes; 40 seconds 
incubation at 37 °C. Then, reagent 2 (R2) was added.  
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Reagent2 R2 80 µL 
Mixed and after 4 minutes incubation, the absorbance (A2) was measured. The samples 
were read against reagent blank. 
Calculation: 
(A2-A1) sample / (A2-A1) calibrator × n  n = calibrator concentration 
 
Determination of serum Cholesterol HDL-C 
Principle: 
Anti-human β-lipoprotein antibody (a mixture containing 5-chloro-2-methyl-2H-
isotiazo-3-one [EG No 247-500-7] and 2-methyl-2H-isothiazol-3-one [EG No 220-239-
6] (3:1) in R1 binds to lipoproteins (LDL, VLDL and chylomicrons) other than HDL. The 
antigen-antibody complexes formed block enzyme reactions when R2 is added. 
Cholesterol esterase (CHE) and cholesterol oxidase (CO) react only with HDL-C. 
Hydrogen peroxide produced by the enzyme reactions with HDL-C yields a blue color 
complex upon oxidative condensation of F-DAOS [N-ethyl-N-(2-hydroxy-3-
sulfopropyl)-3,5-dimethoxy-4-fluoroaniline, sodium salt] and 4-aminoantipyrine (4-AA) 
in the presence of peroxidase (POD). By measuring the absorbance of the blue color 
complex produced, the HDL-C concentration in the sample can be calculated when 
compared with the absorbance of the HDL-C calibrator. 
LDL, VLDL and chylomicrons       Anti-human β-lipoprotein antibody          antigen-antibody complex 
HDL-Cholesterol + H2O + O2 
      CHE & CO           ∆4-Cholesterol + Fatty acid + H2O2 
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Reagents composition: 
Reagent1: R1(pretreatment)   
Good’s Buffer, pH 7.0 30 mmol/L 
4-AA 0.9 mmol/L 
POD 2.4 IU/mL 
Ascorbate oxidase  2.7 IU/mL 
Anti-human β-lipoprotein antibody  
0.0015-0.06 
 
% 
Reagent2: R2 (Enzyme reagent)   
Good’s Buffer, pH 7.0 30 mmol/L 
CHE 4.0 IU/mL 
CO 20 IU/mL 
F-DAOS  0.8 mmol/L 
Reference values: 
The NCEP (American National Cholesterol Education Program) has established the 
following classification for serum LDL cholesterol levels according to the risk of 
developing coronary heart diseases (Adult Treatment Panel III, 2001): 
High HDL-cholesterol > 60 mg/dl 
Low HDL-cholesterol < 40  mg/dl 
 Procedure: 
 Blank Standard Sample 
Reagent1 R1 270 µL 270 µL 270 µL 
Distilled water 2.7 µL - - 
Standard - 2.7 µL - 
Sample - - 3 µL 
Mixed and the absorbance (A1) was read at 600 nm. After 5 minutes incubation at 37 °C 
the reagent 2 (R2) was added.  
Reagent2 R2 90 µL 
Mixed and after 5 minutes incubation, the absorbance (A2) was measured. The samples 
were read against reagent blank. 
Calculation: 
The final results are automatically calculated and printed in concentration. The results 
are given in mg/dl. 
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Determination of Triglycerides 
Principle: 
Enzymatic determination of triglyceride was according to the following reactions 
(Fossati & Prencipe, 1982): 
 Triglyceride + H2O        
LPL             Glycerol + Fatty acids 
 Glycerol + ATP             
Glycerol kinase        Glycerol-3-Phosphate + ADP 
 Glycerol-3-Phosphate + O2   
GPO            Dihydroxyacetone-P + H2O2 
 H2O2 + 4-AAP + p-Chlorophenol     
Peroxidase            Quinoneimine 
4-AAP = Amino-4-antipyrine 
LPL = Lipoprotein Lipase 
GPO = Glycerol-3-Phosphate oxidase  
The samples were serum and heparin or EDTA plasma from fasting patients. 
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Reagents composition: 
Reagent: R 
Pipes buffer, pH 7.0 
Mg2+  
  
50 
14.8  
 
mmol/L 
mmol/L 
p-Chlorophenol  
ATP     
 2.7 
3.15 
mmol/L 
mmol/L 
Potassium ferrocyanide   10 µmol/L 
4-aminoantipyrine 
Lipoprotein lipase 
 
   ≥    
0.31 
2 000 
mmol/L 
U/L 
Glycerol kinase    ≥  500 U/L 
Glycerol-3-Phosphate oxidase    ≥  4 000 U/L 
Peroxidase     ≥  500 U/L 
Reference values: 
The NCEP (American National Cholesterol Education Program) has established the 
following classification for serum triglyceride levels according to the risk of developing 
coronary heart diseases: 
Normal < 150 mg/dl 
Borderline high 150-200 mg/dl 
High 200-500 mg/dl 
Very high ≥ 500 mg/dl 
Procedure: 
 Blank Standard Sample 
Reagent R 300 µL 300 µL 300 µL 
Distilled water 3 µL   
Standard  3 µL  
Sample   3 µL 
Mixed and the absorbance (A) was read at 500 nm after a 425 seconds incubation at 37 
°C. The samples were read against reagent blank. 
Calculation: 
(A sample / A standard)×n  n = standard concentration 
The performance data including analytical range, detection limit, sensitivity, precision 
and correlation were obtained using the COBAS MIRA analyzer (37 °C). 
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Determination of serum urea 
Principle:  
Enzymatic determination of urea was done (Bretaudiere et al., 1976) according to the 
following reactions: 
Urea + 2 H2O     
Urease                2 NH4
+ + CO3
2- 
NH4
+ + α-Ketoglutarate + NADH       GIDH              L-Glu + NAD+ + H2O 
L-Glu = L-Glutamate 
GIDH = Glutamate dehydrogenase 
The Samples were serum or heparinized plasma.  
Reagents composition: 
Reagent 1: R1 
Tris buffer, pH 7.6 (37°C) 
  
125  
 
mmol/L 
ADP  1 mmol/L 
α-Ketoglutarate   9 mmol/L 
Urease ≥  8 100 U/L 
GIDH  ≥  1 350 U/L 
Reagent 2: R2    
NADH  1.5 mmol/L 
Standard: Std     
Urea   50 mg/dL 
    0.5 
8.32 
g/L 
mmol/L 
This standard is included in kits URSL-0407/0427/0507. 
Reference values were 10-50 mg/dL in serum, plasma sample. 
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Procedure: 
 Blank Standard Sample 
Reagent R1 200 µL 200 µL 200 µL 
Reagent R2 50 µL 50 µL 50 µL 
Distilled water 2.5 µL   
Standard  2.5 µL  
Sample   2.5 µL 
Mixed and the variation of absorbance (∆A) was read at 340 nm between 25 seconds and 
75 seconds incubation at 37 °C. The samples were read against reagent blank. 
Calculation: 
(∆A sample / ∆A standard)×n  n = standard concentration 
Determination of serum Creatinine  
Principle: 
The rate of formation of a coloured complex between Creatinine and alkaline picrate 
is measured. The effects of interfering substances were reduced using the kinetic 
procedure. The samples were serum, fluoride or heparinized plasma (Butler, 1975; 
Vasiliades, 1976). 
Reagents composition: 
Reagent 1: R1 
Picric acid  
Reagent 2: R2 
  
8.73  
 
mmol/L 
 
Sodium hydorxide  312.5 mmol/L 
Disodium phosphate 
Standard: Std  
 12.5 mmol/L 
 
Creatinine    2 mg/dL 
Reference values were 0.4-1.5 mg/dL (for women) in serum, plasma sample. 
157 
Procedure: 
 Blank Standard Sample 
Reagent R1 100 µL 200 µL 200 µL 
Reagent R2 100 µL 50 µL 50 µL 
Distilled water 2.5 µL   
Standard or Sample  20 µL 20 µL 
Mixed and the absorbance (A1) was measured at 500 nm after the sample or standard 
was added at 37 °C incubation. Exactly 2 minutes after reading, the second reading was 
taken. 
Calculation: 
[(A2-A1) sample / (A2-A1) standard] × n  n = standard concentration 
Determination of uric acid  
Principle:  
Enzymatic determination of uric acid was done (Fossati et al., 1980) according to the 
following reactions: 
Uric acid + 2 H2O + O2    
Uricase             Allantoin + CO2 + H2O2 
2 H2O2 + 4-AAP + EHSPT       
Peroxidase              Quinoneimine + 4H2O 
EHSPT = N-Ethyl-N-(2-Hydroxy-3-Sulfopropyl) m-Toluidine 
4-AAP = Amino-4-antipyrine  
The Samples were serum or heparinized plasma.  
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Reagents composition: 
Reagent: R 
Phosphate buffer, pH 7.0 
EHSPT 
  
100  
0.72 
 
mmol/L 
mmol/L 
Ferrocyanide   0.03 mmol/L 
Amino-4-antipyrine Uricase   
≥ 
0.37 
150 
mmol/L 
U/L 
Creatinine   ≥ 12 000 U/L 
Reference values were 3-6 mg/dL (for women) in serum, plasma sample. 
Procedure: 
 Blank Standard Sample 
Reagent R 200 µL 200 µL 200 µL 
Distilled water 5 µL   
Standard or Sample  5 µL 5 µL 
Mixed and the absorbance (A) was measured at 550 nm after 325 seconds incubation at 
37 °C. Exactly 2 minutes after reading, the second reading was taken. 
Calculation: 
(A sample / A standard) ×n  n = standard concentration 
Determination of serum Alanine aminotransferase (ALT/GPT) 
Principle:  
Kinetic determination of the Alanine aminotransferase (ALT) activity was done 
(Bergmeyer, 1985) according to the following reactions: 
L-Alanine + α-Ketoglutarate       ALT               Pyruvate + L-Glutamate  
Pyruvate + NADH + H+      LDH                   L-Lactate + NAD+  
LDH = Lactate dehydrogenase 
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The Samples were serum free from hemolysis or heparinized plasma.  
Reagents composition: 
Reagent 1: R1 
Tris buffer, pH 7.5 (30°C) 
  
125  
 
mmol/L 
L-Alanine  680 mmol/L 
LDH  ≥  2 000 U/L 
Reagent 2: R2    
NADH  1.1 mmol/L 
α-Ketoglutarate   97 mmol/L 
Reference values were 5-40 µ/L in serum, plasma sample. 
Procedure: 
 Blank Standard Sample 
Reagent R1 200 µL 200 µL 200 µL 
Reagent R2 50 µL 50 µL 50 µL 
Sample   25 µL 
Mixed and the change of absorbance per minute (∆A/min) was measured at 340 nm 
between 50 seconds and 150 seconds incubation at 37 °C. The samples were read against 
distilled water. 
Calculation: 
Calculation was done at 340 nm, for a 1 cm light path cuvette according to the 
following formula:  
Activity (U/L) = ∆A/min × 1746 
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Determination of serum Aspartate aminotransferase (AST/GOT) 
Principle:  
Kinetic determination of the Aspartate aminotransferase (AST) activity was done 
(Bergmeyer et al., 1986) according to the following reactions: 
L- Aspartate + α-Ketoglutarate       AST               Oxaloacetate + L-Glutamate  
 Oxaloacetate + NADH + H+        MDH                   L-Malate + NAD+  
MDH = Malate dehydrogenase 
Reagents composition: 
Reagent 1: R1 
Tris buffer, pH 7.8 (30°C) 
  
100  
 
mmol/L 
L-Aspartate  330 mmol/L 
LDH  
MDH 
≥ 
≥  
2 000 
1 000 
U/L 
U/L 
Reagent 2: R2    
NADH  1.1 mmol/L 
α-Ketoglutarate   78 mmol/L 
Reference values were 5-40 µ/L in serum, heparinized or EDTA plasma sample. 
Procedure: 
 Blank Standard Sample 
Reagent R1 200 µL 200 µL 200 µL 
Reagent R2 50 µL 50 µL 50 µL 
Sample   25 µL 
Mixed and the change of absorbance per minute (∆A/min) was measured at 340 nm 
between 50 seconds and 150 seconds incubation at 37 °C. The samples were read against 
distilled water. 
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Calculation: 
Calculation was done at 340 nm, for a 1 cm light path cuvette according to the 
following formula:  
Activity (U/L) = ∆A/min × 1746 
Determination of Alkaline phosphatase (ALP) 
Principle:  
In presence of Mg2+ and diethanolamine as phosphate acceptor, p-
nitrophenylphosphate is transformed by alkaline phosphatases into phosphate and p-
nitrophenol (yellow compound). Enzymatic-Kinetic determination of the alkaline 
phosphatase (ALP) activity was done according to the following reaction: 
 p-nitrophenylphosphate + H2O       
ALP               inorganic phosphate + p-nitrophenol   
Reagents composition: 
Reagent 1: R1 
Diethanolamine, pH 10.2  
  
1.4 
 
mol/L 
Magnesium chloride  0.625 mmol/L 
Reagent 2: R2    
p-nitrophenylphosphate  50 mmol/L 
Reference values were 64-306 U/L in serum (for female). 
Procedure: 
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 Blank Standard Sample 
Reagent R1 250 µL 250 µL 250 µL 
Reagent R2 60 µL 60 µL 60 µL 
Sample   5 µL 
Mixed and the change of absorbance per minute (∆A/min) was measured at 405 nm 
between 50 seconds and 125 seconds incubation at 37 °C. The samples were read against 
distilled water. 
Calculation: 
Calculation was done at 340 nm, for a 1 cm light path cuvette according to the 
following formula:  
Activity (U/L) = ∆A/ min × 3397 
Determination of Bilirubin 
Principle: 
Sulfanilic acid reacts with sodium nitrite to form diazotized sulfanilic acid. In the 
presence of accelerator (cetrimide), conjugated and unconjugated bilirubin reacts with 
diazotized Sulfanilic acid to form azobilirubin (bilirubin total 4+1). In the absence of 
accelerator, only conjugated bilirubin reacts (Bilirubin direct 4+1). The increase of 
absorbance at 550 nm is proportional to bilirubin concentration. The determination of the 
bilirubin was done according to the following reactions (Sherwin, 2003): 
Sulfanilic acid + NaNo2                                         Diazotized Sulfanilic acid 
Bilirubin + Diazotized Sulfanilic acid                          Azobilirubin 
The Samples were serum free of hemolysis or heparinized plasma.  
Reagents composition: 
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 Bilirubin  Bilirubin Bilirubin  
 Total 4+1 Direct 4+1 Total & direct 4+1  
 Reagent 1: R1  Reagent 2: R2  
Sulfanilic acid 29 26 - mmol/L 
Hydrochloric acid  67 67 - mmol/L 
Cetrimide 37 - - mmol/L 
Sodium nitrite  - - 5.8 mmol/L 
Reference values were 0.2-1.1 mg/dL for total bilirubin and < 0.25 mg/dL for direct 
bilirubin in serum, plasma sample. 
Procedure: 
 Calibration  Test  
Reagent R1 160 µL 160 µL 
Calibrator  20 µL - 
Sample - 20 µL 
Mixed and the absorbance (A1) was measured after 5 minutes incubation at 37 °C.  
Reagent R2 40 µL 40 µL 
Mixed and the absorbance (A2) was measured at 550 nm after 5 minutes incubation at 
37°C.  
Calculation: 
[(A2-A1) sample / (A2-A1) standard] × n  n = calibrator concentration 
Determination of serum glucose 
Principle: 
Enzymatic determination of glucose was done using the glucose oxidase (GOD) 
method (Burrin & Price, 1985; Trinder, 1969a, 1969b) according to the following 
reactions: 
Glucose + O2       
Glucose oxidase        Gluconic acid + H2O 
2 H2O2 + Phenol + 4-Aminoantipyrine   
Peroxidase            Quinoneimine + 4 H2O 
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The Samples were serum free of hemolysis, plasma collected on fluoride or heparin/ 
iodoacetate or any inhibitors of glycolysis. 
Reagents composition: 
Reagent: R 
Phosphate buffer, pH 7.4   
  
13.8 
 
mmol/L 
Phenol  10 mmol/L 
4-aminoantipyrine  0.3 mmol/L 
Glucose oxidase  ≥  10000 U/L 
Peroxidase  ≥  700 U/L 
Standard: Std   
D-Glucose 100 mg/dL 
 1 g/L 
 5.56 mmol/L 
ELITROL I 10×5 ml 
ELITROL II 10×5 ml 
Reference values were 70-110 mg/dL in serum, plasma sample. 
Procedure: 
 Blank Standard Sample 
Reagent R 300 µL 300 µL 300 µL 
Distilled water 3 µL   
Standard  3 µL  
Sample   3 µL 
Mixed and the variation of absorbance (∆A) was measured at 500 nm during 75 
seconds incubation at 37 °C. The samples were read against reagent blank. 
Calculation: 
(∆A sample / ∆A standard)×n    n = standard concentration 
Concentration value of Glucose standard 100 mg/dL is traceable to the standard 
reference material NIST 965a (of the national Institute of Standards and technology) 
(Barker et al., 2006). 
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Determination of hematological parameters (complete blood count-CBC) 
The samples were used for complete blood cell count (CBC) by automated hematology 
analyzer (Sysmex blood cell counter auto-analyzer model KX21; Japan). The analysis 
parameters include WBC (White Blood cell Count), RBC (Red Blood cell Count), HGB 
(hemoglobin), HCT (hematocrit), MCV (mean corpuscular volume), MCH (mean 
corpuscular hemoglobin), MCHC (mean corpuscular hemoglobin concentration), PLT 
(platelet), RDW-CV (RBC distribution width-coefficient of variation), PDW (platelet 
distribution width)*, and MPV (mean platelet volume).  
The KX-21 employs three detector blocks and two kinds of reagents for blood analysis; 
The HGB detector block measures the hemoglobin concentration using the non-cyanide 
hemoglobin method (volume or gram of hemoglobin in 1 dL of whole blood) (g/ dL). 
Non-cyanide hemoglobin analysis method rapidly converts blood hemoglobin as the 
Oxyhemoglobin method and contains no poisonous substance, making it suitable for 
automated method. Being capable of analysing methemoglobin, this method can 
accurately analyse control blood, etc. which contain methemoglobin. 
The WBC count was measured by the WBC detector block using the DC (direct 
current) detection method (WBC count in 1 mL of whole blood) (x103 µL). Blood 
samples were aspirated, measured to a predetermined volume, diluted at the specified 
ratio, and then fed into each transducer. The transducer chamber has a minute hole called 
the aperture. On both side of the aperture, there are the electrodes between which flows 
direct current. Blood cells suspended in the diluted sample pass through the aperture, 
causing direct current resistance to change between the electrodes. As direct current 
resistance was changed, the blood cell size was detected as electric pulses. Blood cell 
count was calculated by counting the pulses. 
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The RBC count and platelets (PLT) were taken by the RBC detector block, also using 
the DC detection method (RBC count in 1 mL of whole blood) (x106 µL); and Platelet 
count in 1 mL of whole blood (x103 µL). The Hematocrit value was measured using the 
cumulative pulse height detection method (Ratio (%) of whole RBC volume in whole 
blood). The mean RBC volume (fL) was measured in whole blood, which is calculated 
by HCT/RBC. The mean RBC hemoglobin volume (pg) per RBC was calculated by 
HGB/RBC. The mean RBC hemoglobin concentration (g/dL), was calculated by 
HGB/HCT. The RBC distribution width – CV (RDW-CV) (%) was calculated from the 
points defining 68.26% of the entire area spreading from the peak of the RBC particle 
distribution curve. The Platelet distribution width (fL) was measured at the height of 20% 
from the bottom with the peak of platelet particle distribution curve taken as 100%. The 
mean platelet volume (fL) was measured as the mean volume of platelet.  
For this experiment, the mode of analyzing collected blood sample was done in the 
whole blood status. Blood samples were heparinized by adding 1 drop (2 mg) EDTA to 
each 1 cc blood sample. The reagent used was WBC/HGB lyse-S III diff lytic reagent- 
PN 8546983 (STROMATOLYSER-WH).  
For the WBC/HGB analysis, the blood samples were aspirated from the sample probe 
into the sample rotor valve one after another. 6 mL of blood measured by the sample rotor 
valve was transferred to the WBC transducer chamber along with 1.994 mL of diluent. 
At the same time, 1.0 mL of WBC/HGB lyse was added to prepare 1:500 dilution sample. 
When the solution was made to react in this status for approximately 10 seconds, RBC 
was hemolyzed and platelets shrink, with WBC membrane held as they were. At the same 
time, hemoglobin was converted into red coloured methemoglobin. Of the 
diluted/hemolyzed sample in the WBC transducer chamber, approximately 1 mL was 
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transferred to the HGB flow cell. 500 mL of sample in the WBC transducer was aspirated 
through the aperture. The pulses of the blood cells when passing through the aperture 
were counted by the DC detection method. In the HGB flow cell, 555 nm wavelength 
beam irradiated from the light emitting diode (LED) was applied to the sample in the 
HGB flow cell. Concentration of this sample was measured as absorbance. This 
absorbance was compared with that of the diluent alone that was measured before addition 
of the sample, thereby calculating HGB (hemoglobin value). 
For analysis of RBC/PLT, blood was aspirated from the sample probe into the sample 
rotor valve. 4.0 mL of blood measured by the sample rotor valve is diluted into 1:500 
with 1.996 mL of diluent and brought to the mixing chamber as diluted sample (1st step 
dilution). Out of the 1:500 dilution samples, 40 mL is measured by the sample rotor valve, 
diluted into 1:25000 with 1.960 mL of diluent, and then transferred to the RBC/PLT 
transducer chamber (2nd step dilution). 250 mL of the sample in the RBC/PLT transducer 
chamber is aspirated through the aperture. At this time, RBC and PLT were counted by 
the DC detection method. At the same time, HCT (hematocrit value) was calculated by 
RBC pulse height detection method. 
Other standard solutions used include: Latron Controls - PN 7546914, Latron Primer 
- PN 7546915, Calibration S-CAL - PN 7546808, 5C Cell control normal - PN 7546923 
and 5C Cell Controls Tri Pack contains Normal, Abnormal I, and Abnormal II - PN 
7547001. The detection limits were determined according to the Lab Protocol NHANES 
2003–2004 (National Center for Health Statistics NHANES, 2004). 
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Reference values for females aged 19-65 years were as follows: 
WBC 4-10 ×103 µL 
RBC 3.6-6.1 ×106 µL 
HGB 11.5-18.8 g/dL 
HCT 34-54 % 
PLT 150-450 ×103 µL 
MCV 80-100 fL 
MCH 27-36 pg 
MCHC 32-36 g/dL 
RDW 11.6-14.6 % 
PDW 7-20 fL 
MPV 6-13 fL 
Calculation of RBC Constant: 
RBC constant (mean RBC volume, mean RBC hemoglobin, mean RBC haemoglobin 
concentration) were calculated from RBC, HGB, and HCT. 
1. Mean RBC Volume (MCV): Calculation was made from RBC and HCT by the 
formula below:  
MCV (fL) = HCT (%) / RBC (×106/μL) × 10 
2. Mean RBC Hemoglobin (MCH): Calculation is made from RBC and HGB by the 
formula below:  
MCH (pg) = HGB (g/dL) / RBC (× 106/μL) × 10 
3. Mean RBC Hemoglobin Concentration (MCHC): Calculation is made from HCT 
and HGB by the formula below: 
MCHC (g/dL) = HGB (g/dL) / HCT (%) ×100 
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Determination of specific gravity of urine 
Principle:  
The urine density test determines the concentration of ions in urine and shows a good 
correlation to the refractometrical method. The color of the test strip changes from deep 
blue in urine with low ionic concentration through green to yellow in urines with high 
ionic concentrations.  
Reference values for evaluation of the results: 
The test permits the determination of urine density between 1.000 and 1.030. Urines 
from adults with normal diets and normal fluid intake will have a density of 1.015-1.025. 
The chemical nature of the test strip may cause slightly different results from those 
obtained with other methods when elevated amounts of certain urine constituents are 
present; for example, the increase of urine density in dependence on glucose 
concentrations of > 1000 mg/dL (> 56 mmol/L) cannot be demonstrated by the strips. 
Elevated density readings maybe obtained in the presence of moderate quantities of 
protein. Highly buffered alkaline urines may cause low readings.  
Reactive ingredients: 
Bromothymol blue  
Copolymer  
12 µg 
295 µg 
Calculation: 
In any case, in order to establish a final diagnosis and prescribe an appropriate therapy, 
the results obtained with test strips should be verified with other medical results. The 
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effect of medicaments or their metabolic products on the test is not known in all cases. In 
case of doubt, it is recommended not to take the medicaments and then repeat the test.  
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APPENDIX E: Procedure of caraway water extract production in Baharan factory 
In general, steam distillation was conducted using a stainless still tank (tank A) which 
is the huge scale of clevenger apparatus. The caraway seeds were charged into the tank A 
from the top led using crane. Usually, the 2/3th of the tank A is filled with washed 
caraway seeds and water equally and 1/3th of the tank would be empty. The steam 
generated by the steam boiler (Rayiran and Garmiran, Iran) would be transferred into the 
tank A through steam lines and mixed with the caraway seeds. Further, the steam 
containing volatile compounds would be transferred into the connected condenser (Tank 
B) and the remaining caraway scum would be unloaded from the bottom of the tank. In 
tank B, the conveyed steam would be distilled into the water extract by cold water which 
is entrapped in the inner layer of the cooling tower placed on the top of the condenser. 
The remaining steam would be returned to the original tank by the steam trap and the 
condensed water extract would be transferred to the essence pitcher (Tank C- Schott 
Suprax Glass; Germany) through the water lines. During the distillation, the components 
would be vaporized and separated at different temperatures regardless of their solubility. 
However, the essential oil would be floated to the top of the essence pitcher and would 
be collected in the Petromax glass placed on the top of the still pitcher. The collected oil 
base product would be processed for export and the remaining water extract (herbal 
distillate) would be filtered, pumped into the storage tank and then filled into the PET 
bottles (1 or 4 liters). The final product would be labeled and dated to production and 
expire date and then stored in a dark store room before delivery to the market. The shelf 
life of the bottled water extract is around 1.5 year under suitable conditions (25 ᵒC and 
with low humidity and light). From each 1 kg of caraway seeds, 10 liters caraway water 
extract was produced. Consequently, the amount of caraway in terms of w/v was 0.1 
(10%) (3 gram caraway extract in 30 ml dose that was used) and, the distillation charge 
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defined as “the amount of plant material that can be processed in a single cycle” (Douglas 
et al., 2006) would be around 300-400 kg. Further, the detection, isolation and structural 
determination of bioactive compounds present in the extracted caraway essential water 
such as polyphenol compounds (such as tannins and saponins) were assessed through one 
of the modern chemical analysis (GC-Mass). 
 
APPENDIX E1: Diagram of the steam-distillation (Masango, 2005) 
 
 
APPENDIX E2: Flow chart of the steam-distillation of caraway (Douglas et al., 2006) 
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APPENDIX E3: Still tank 
 
APPENDIX E4: Condenser (cooling tank) 
 
APPENDIX E5: Oil separator tank (essence pitcher) 
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APPENDIX E6: Bottling and labelling of the product 
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 دانشگاه علوم پزشکی شهید بهشتی
 انستیتو تحقیقات و دانشکده علوم تغذیه و صنایع غذایی
 كد شناسایي....        برگه رضایت آگاهانه
 زیره بر کاهش وزن زنان دارای اضافه وزن: بررسی اثر مصرف عرق پروژه پژوهشی
رضایت خود را برای شرکت در پروژه تحقیقاتی فوق الذكر اعلام می  ...............اینجانب .............................
 دارم.
 ي تواندتمام اطلاعاتی که از اینجانب گرفته خواهد شد محرمانه باقی خواهد ماند. مشارکت داوطلبانه در این پژوهش م
من حق دارم در هر موقعي كه نیاز داشته باشم با محقق  .در تولید اطلاعات جدید برای پیشگیري یا درمان چاقی کمک کند
 درباره مشكلات احتمالي كه پیش مي آید تماس بگیرم.
 تاریخ : ...........................  
 امضاء : ...........................
 ه در مطالعه: آدرس فرد شرکت کنند
 تلفن ثابت (منزل/ محل کار): .......................
 تلفن همراه: ....................
  نظرات و پیشنهادات:
 671
 پرسشنامه اطلاعات عمومی
 اطلاعات عمومی .1
اهل . . . . . . . . . . . .شغل . . . . . . . .     رضایت شغلی . . . . . . . .  تحصیلات   . . . . . . . وضعیت ت سن
 شیرده     . . . . . . سن اولین زایمان. . . . . . نوع زایمان  . . . . حامله     . . . . . .     یائسه . . .   . . . تعداد زایمان
 تاریخچه پزشکی .
 تاریخچه پزشکی در حال حاضر:  -
 سابقه پزشکی در گذشته:  -
 :سابقه پزشکی خانواده -
دیابت، سرطان، فشار خون بالا، چربی خون، بیماری های قلبی و عروقی، اختلال  هر گونه مشکلات سلامتی مانند)
 ، کبد، کلیه، کیسه صفرا، مثانه...)تیروئید, غدد و متابولیک عملکرد
 اندازه گیری پارامترها .2
 مقادیر پارامترها
  )gk( وزن
   )mc( قد
  IMB
  )CAUM(دور بازو 
  دور کمر
  دور باسن 
   )RHW( باسن دور /دور کمر
  دور مچ دست
  دور ران
  فشار خون
  ضربان قلب
  )gk( توده استخوانی
  میزان سوخت و ساز پایه
   سرعت سوخت و ساز فعال
  درصد آب بدن٪
  توده چربی آزاد
   درصد توده چربی
  درصد عضله
 دارو مصرف .3
 (ماه گذشته  3 در حال حاضر و یا در  ) یا مکمل دارو مصرف
 استفاده از داروهای موثر بر عملکرد نورواندوکرین، متابولیسم یا اشتها؟ (توضیح) -
 مصرف هر گونه مکمل غذایی، چاقی، لاغری، ویتامین و مینرال ها (نام ببرید)       -
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  یبدن تینوع فعال .4
  ، نوع)شدت ، مدت(غیره          پیاده روی           ایروبیک  یوگا       
 رژیم غذایی  وا مصرف غذ تیوضع .5
  سیگار              غیره (نام ببرید)  مصرف الکل  -
  میان وعده   تعداد وعده ها ی اصلی  -
   عادت به خوردن صبحانه  -
غذاهای آماده    خام گیاه خوار  گیاه خوار    داشتن رژیم های غذایی خاص: -
 غیره        
گرم   سرد (آلرژی)       سابقه آلرژی و حساسیت به ماده غذائی خاص (توضیح):   -
 (کهیر)
یبوست     پرخاشگری و عصبانیت          حالت تهوع        ,عصبی  دچار مشکلات  -
   نفخ     درد شکم  
 هستید؟ یا تشنگی بیش از حد         پر اشتهائی            آیا دچار             کم اشتهائی  -
 علت)ذکر (باتمایل به مصرف یا مصرف داروهای گیاهی خاص؟   -
نوع ........ غذاهای سرخ کردنی .......  چای/قهوه...... نوشیدنی گازدار  .....میزان مصرف آب روزانه -
 ...روغن 
  هدف از كاهش وزن......   آیا تمایل به کاهش وزن دارید؟
 نتیجه گیری .6
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 اشتها آزمون
 : کد شناساییشماره       )SAV( مقیاس آنالوگ بصری برای امتیاز سیری و گرسنگی
 1 2 3 4 5 6 7 8 9 01 اشتها
  کاملا سیر               کاملا گرسنه   
 (از صبح تا شب)ساعت  1هر  یمتوال ریروزغ ٣ یبرا (براساس جدول بالا)  01تا1 لطفا شماره اشتهای خود را ا ز
 :یادداشت نمایید زیرجدول  در
  روز  روز  روز
 شماره اشتها ساعت هاشماره اشت ساعت شماره اشتها ساعت
      صبح7 
      صبح8
      صبح9
      صبح01
      صبح11
      بعد از ظهر 21
      بعد از ظهر 1
      بعد از ظهر 2
      بعد از ظهر 3
      بعد از ظهر4
      بعد از ظهر 5
      بعد از ظهر 6
      شب 7
      شب 8
      شب9
      شب01
      شب 11
      شب 21
      میانگین
 پیتزا آزمون
 دقیقه قبل از غذا) 22لطفا معجون را مطابق دستور مصرف کنید (
 عدد گوجه  1تخم مرغ آب پز +  1صبحانه: یک کف دست نان ضخیم+ 
ورده ی پیتزای خساعت بعد از صبحانه): مینی پیتزای مخصوص تا زمانیکه کاملا سیر شوید. سپس تعداد قاچ ها 4ناهار (
 .شده را یادداشت کنید. همچنین میزان اشتها و میزان میل به غذا را، هر یک ساعت شماره بزنید
 کنید.ذکر  دیشدمواجه  دوره در طول خاص عوارض جانبی هر گونه با اگر شما لطفا
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 دانشگاه علوم پزشکی شهید بهشتی
  ییدانشکده علوم تغذیه و صنایع غذاانستیتو تحقیقات و
  آیتمی 161پرسشنامه بسامد خوراک 
 ملاحضات
 متوسط بار مصرف
 مواد غذایی مقدار
 کد اقلام
 غذایی روز هفته ماه سال
 1 نان لواش   کف دست1             (تنوری، ماشینی)
 2 نان بربری  کف دست1          
 3 نان سنگک  کف دست1          
 4 نان تافتون  کف دست1          
 5  انواع نان های فانتزی   عدد کوچک1          ن باگت و ...نا 
 6 نان سبوس دار  کف دست1         )نان قهوه ای،جو...( 
 7 سایر نان ها   کف دست1         )سوخاری , قندی، روغنی، شیرمال،(
 8 برنج پخته  بشقاب غ خ 1          
 9 ماكاروني پخته  کفگیر    1              
 01 رشته (ورمشیل) پخته  لیوان 1           
 11 رشته  پخته  لیوان 1          
 21 آرد گندم یک استکان           
 31 جو پخته  ق،غ1          
 41 بلغور پخته  ق،غ1          
 51 عدس  ق،غ1          
 61 لوبیا (سفید،قرمز،چیتي)  ق،غ1          
 71 نخود  ق،غ1          
 81 باقلا پخته  ق،غ1          
 91 سویا  ق،غ1          
 02 ماش  ق،غ1          
 12 لپه  ق،غ1          
 22 گوشت گاو یا گوساله  تکه  خورشتي1          
 32 گوشت گوسفند  تکه  خورشتي1          
 42 گوشت چرخ کرده  ق،غ1          
 52 مرغ و جوجه با پوست  قطعه متوسط1          
 62 مرغ و جوجه بدون پوست  قطعه متوسط1          
 72 ماهي با ذکر نوع آن  قطعه متوسط1          ) به استثناي کنسرو تن  (
 82 تن ماهي(کنسرو) قوطی2/1          
 92 همبرگر  عدد1          
 03 سوسیس  عدد1          
 13 كالباس  برش1          
 23  ر و قلوهدل و جگ  تکه متوسط1          
 33 سیرابي و شیردان  قطعه1          
 081
 ملاحضات
 متوسط بار مصرف
 مواد غذایی مقدار
 کد اقلام
 غذایی روز هفته ماه سال
 43 زبان  عدد کامل1           
 53 مغز  عدد کامل1           
 63 کله  عدد کامل1           
 73 پاچه  عدد 1           
 83 تخم مرغ  عدد1          
 93 شیر بدون چربي/کم چرب  لیوان1         )>%5/2(
 04 شیر با چربی معمولی  یوانل1         )>%5/2(
 14 شیر پرچرب  لیوان1         )<%5/2(
 24 شیر کاکائو  شیشه تجاري1          
 34 شیر شکلاتي  شیشه تجاري1          
 44 ماست چکیده  ق،غ1          
 54 ماست کم چرب/ معمولي کاسه کوچک             
 64 ماست پرچرب کاسه کوچک            
 74 ماست خامه اي  ق،غ1          
 84 پنیر  قوطي کبریت1          ) به استثناي خامه اي و لیقوان  (
 94 پنیر خامه اي/لیقوان  قوطي کبریت1           
 05 دوغ  لیوان1          
 15 خامه و سر شیر  ق،غ1          
 25 بستني سنتي نصف لیوان          
 35  غیرسنتي بستني  نصف لیوان          
 45 كره  قوطي کبریت1           آنچه که به غذا افزوده میشود +  
 55 مارگارین  قوطي کبریت1          آنچه که به غذا افزوده میشود + 
 65 کشک  ق،غ1          
 75 کاهو خرد شده نصف لیوان          
 85 گوجه فرنگي  عدد متوسط1           
 95 خیار  سطعدد متو1           
 06 سبزي خوردن  پیش دستي1           
 16 سبزي (پخته) نصف لیوان         خورشتی/آش/کوکو 
 26 کدو حلوایي  6×6قطعه           
 36 کدو خورشتي  عدد متوسط1           
 46 بادمجان پخته  عدد متوسط1           
 56 کرفس پخته نصف لیوان          
 66 سیب زمینی  د متوسطعد1           
 76 سیب زمینی سرخ کرده  خلال متوسط 21          
 86 نخود سبز پخته نصف لیوان          
 96 لوبیا سبز پخته  ق،غ1          
 07 هویج خام  عدد متوسط1           
 17 هویج پخته  عدد متوسط1           
 27 سیر  حبه1          
 37 پیاز خام  عدد متوسط1           
 47 پیاز سرخ شده  ق،غ1          
 57 کلم و انواع آن  کاسه ماست خوری         )قرمز،قمری، گل کلم، بروکلی سفید،(
 67 فلفل دلمه اي  عدد متوسط1           
 181
 ملاحضات
 متوسط بار مصرف
 مواد غذایی مقدار
 کد اقلام
 غذایی روز هفته ماه سال
 77 اسفناج خام  برگ متوسط  22          
 87 اسفناج پخته نصف لیوان          
 97 شلغم  سطعدد متو1           
 08 قارچ پخته نصف لیوان          
 18 فلفل سبز  عدد متوسط1           
 28 ذرت و بلال  عدد متوسط1          
 38 رب گوجه فرنگی/سس قرمز  ق،غ1          
 48 ترشی (با ذکر محتویات)  ق،غ1          
 58 شور (با ذکر محتویات)  ق،غ1          
 68 خیار شور  توسطعدد م1           
 78 طالبی   طالبی متوسط4/1           
 88 خربزه  قاچ متوسط1           
 98 هندوانه  قاچ متوسط1           
 09 گلابي  عدد متوسط1           
 19 زردآلو  عدد متوسط1           
 29 گیلاس  عدد متوسط1           
 39 سیب  عدد متوسط1           
 49 هلو  عدد متوسط1           
 59 شلیل  عدد متوسط1           
 69 گوجه سبز  عدد متوسط1           
 79 انجیر تازه  عدد متوسط1           
 89 انجیر خشک  عدد متوسط1           
 99 انگور  خوشه کوچک1           
 001 کیوي  عدد متوسط1           
 101  تگریپ فرو  عدد متوسط1           
 201 پرتقال  عدد متوسط1           
 301 خرمالو  عدد متوسط1           
 401 نارنگي  عدد متوسط1           
 501 انار  عدد متوسط1           
 601 خرما  عدد متوسط1           
 701 آلو(زرد و قرمز)  عدد متوسط1           
 801 آلبالو  عدد متوسط21          
 901 توت فرنگي  عدد متوسط3           
 011 موز  عدد متوسط1           
 111 لیمو شیرین  عدد متوسط1           
 211 لیمو ترش  عدد متوسط1           
 311 آب گریپ فروت  لیوان1          
 411 آب پرتقال  لیوان1          
 511 آب سیب  لیوان1          
 611  یآب طالب  لیوان1          
 711 ذغال اخته  لیوان1          
 811 آناناس تازه  لیوان1          
 911 آناناس کنسرو  لیوان1          
 281
 ملاحضات
 متوسط بار مصرف
 مواد غذایی مقدار
 کد اقلام
 غذایی روز هفته ماه سال
 021 کشمش  ق،غ1          
 121 گرمک کاسه ماست خوري          
 221 توت تازه  عدد متوسط21          
 321 توت خشک  عدد متوسط22          
 421 برگه هلو  توسطعدد م21          
 521 برگه زردآلو  عدد متوسط21          
 621 کمپوت میوه جات -         )با ذکر نوع و مقدار( 
 721 زیتون سبز  عدد متوسط21          
 821 روغن نباتي جامد  ق،غ1          
 921 روغن مایع   ق،غ1         )…آفتاب گردان,ذرت ,سویا،(
 031  ن زیتونروغ  ق،غ1          
 131 پیه یک تکه متوسط          
 231 روغن حیواني  ق،غ1          
 331 سس مایونز  ق،غ1          
 431 بادام زمیني  عدد مغز22           
 531 بادام  عدد مغز21           
 631 گردو  عدد مغز کامل1           
 731 پسته  عدد21           
 831 فندق  عدد21           
 931 تخمه کاسه کوچک           (گردان،هندوانه کدو،آفتاب)
 041 بیسکویت(نوع و اندازه) -          
 141 کراکر  عدد1          
 241 کیک یزدي  عدد1          
 341 کیک خانگي(تولد و...)  برش متوسط1          
 441 سایر کیک ها و کلوچه  عدد1          
 541 شیریني خشک  عدد متوسط1           
 641 شیریني تر  عدد متوسط1           
 741 چاي  لیوان1          
 841 قند یا  شکر پنیر  حبه21           
 941 شکر  ق،م1          
 051 حلوا شکري  عدد4/1          
 151 عسل  ق،م1          
 251 مربا(با نوع)  ق،غ1         نوع:.........
 351 شکلات/کاکائو/تافی   عدد1         با ذکر نوع
 451 آبنبات  عدد1          
 551 نبات  تکه متوسط1           
 651 پفک  بسته1           
 751 چیپس  بسته1          ذکر تعداد حلقه  
 851 گز  عدد متوسط1         آردی/ لقمه ای
 951 سوهان  عدد1          
 061 نقل  ددع21          
 161 کرم کارامل  ق.غ1          
 261 حلوا خانگی  ق.غ1         نوع:.......
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 ملاحضات
 متوسط بار مصرف
 مواد غذایی مقدار
 کد اقلام
 غذایی روز هفته ماه سال
 361 پیراشکی   عدد1          
 461 قهوه / نسکافه  لیوان1          
 561 نوشابه گازدار  بطری1         رژیمی/معمولی
 661 آبمیوه صنعتی  بسته/لیوان1          
 761  /آبغورهآبلیمو  ق.م1          
 861 نمک  ق.م1     
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01  9  8   7  6   5  4   3   2  1           54 03   51    
01  9  8   7  6   5  4   3   2  1           54 03   51    
01  9  8   7  6   5  4   3   2  1           54 03   51    
ک ار/شغ ل: به صورت اغل ب در ح ال راه 
رفت ن، بل ن د ک ردن و ح م ل بار سبک
01  9  8   7  6   5  4   3   2  1           54 03   51    
ک ار/شغ ل:به صورت اغل ب در ح ال راه 
رفت ن، بل ن د ک ردن و ح م ل بار سنگی ن
01  9  8   7  6   5  4   3   2  1           54 03   51    
ک ار/شغ ل: به صورت ک ار دست ی سنگی ن
01  9  8   7  6   5  4   3   2  1           54 03   51    
6/2
ک ار/شغ ل: به صورت اغل ب نشسته
ک ار/شغ ل: به صورت  نی م ی از ساعات نشسته
ک ار/شغ ل: به صورت اغل ب ایستاد ه
در صورت شاغل بودن:
3/1
3
9/3
8/1
2/2
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AGRREEMWENT LETTER 
Research Topic: Evaluating the effect of caraway water extract intake on overweight 
and obese women 
I ……………………………..…..hereby, agree to attend in this research work. 
All the information taken will remain confidential. Participating in this research work 
could be helpful in providing new information for preventing and treatment of obesity. 
I have the right to contact with the researcher whenever I have problems regarding this 
research work. 
Date:…………. 
Signature:………. 
Address:………………………………………………………………………………
………. 
Phone number: ………….. 
Suggestions:……………………………………………………………………………
…….. 
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1- GENERAL INFORMATION QUESTIONNAIRE  
I. GENERAL INFORMATION 
Name______________   Age ___Gender _____Occupation _________Education  
Marital status ________ age of first delivery _____     number of delivery_____ 
Type of delivery_________ Pregnant ______Breast-
feeding______Menopause__________  
II. MEDICAL HISTORY 
-Present medical history: _____________________________________________ 
-Past medical history: ________________________________________________ 
-Family history: ____________________________________________________  
(Any health problems such as diabetes, cancer, high blood pressure, hyperlipidemia, 
cardiovascular diseases, hyper/hypo thyroid, and liver, kidney, gall bladder, bladder,…. 
dysfunction) 
III. BIOMEDICAL and ANTHROPOMETRIC MEASUREMENTS  
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Parameters Values 
Weight  
Height  
BMI  
MUAC  
Waist circumference  
Hip circumference  
WHR  
Wrist circumference  
BP (blood pressure)  
HR (heart rate)  
BM (bone mass)  
BMR (basic metabolic rate)  
AMR (active metabolic rate)  
Body water%  
FFM (fat free mass)  
FM (fat mass percentage)  
Muscle percentage   
 
IV. MEDICATIONS  
Indicate any medications, dietary or weight loss supplements you’re currently taking 
or have taken in the last three months: 
Other medications and dosages (if known): 
Name of medication Reason for taking and for how long have you been taking this 
  
  
  
V. PHYSICAL ACTIVITY (H / WK) 
 Yoga, aerobics, walking, etc. (intensity, duration, type)  
VI. FOOD INTAKE STATUS 
Smoking, alcohol consumption, etc. (specify) 
No of meals / day ______ 1  □   2 □ 3 □ ≥  
Breakfast skipper---------- 
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Any special dietary habits: Veg   □     non veg  □   mixed  □ 
Food allergy – yes/ no if yes specify _____________________________ 
Food fads – yes/ no if yes specify ____________________________ 
Nausea – yes /no, vomiting –yes/no, anorexia-yes/no, constipation  -  yes/no 
Are you interested to take or taking any specific herbal supplement? 
Are you interested in losing weight? Why? 
VII. CONCLUSION  
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APPETITE TESTS 
Visual analogue scale (VAS) for rating fullness and hunger           Identical code 
Appetite 10 9 8 7 6 5 4 3 2 1 
 Extremely hungry         Extremely full  
-Please note your appetite code from 1 to 10 (based on the above table) for 3 non
following table: consecutive days every 1 hour (from morning till night), in the 
 Day  Day  Day  
Appetite code Hour  Appetite code Hour  Appetite code Hour  
     7 AM 
     8 AM 
     9 AM 
     10 AM 
     11 AM 
     12 PM 
     1 PM 
     2 PM 
     3 PM 
     4 PM 
     5 PM 
     6 PM 
     7 PM 
     8 PM 
     9 PM 
     10 PM 
     11 PM 
     12 PM 
     Average 
Pizza Test: 
Please eat the provided preparation according to the instructions (20 minutes before 
meals)  
 
Breakfast: a palm-size thick bread + 1 boiled egg + 1 tomato  
Lunch (4 hours after breakfast): mini pizza until you are completely satisfied. Then write 
down the number of pizza slices eaten. Also, write down your appetite code every hour. 
Please mention if you encountered any specific side-effects during intervention period:  
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2- FOOD FREQUENCY QUESTIONNAIRE (168-item FFQ) 
Descriptions 
Average times consumed 
Amount/size Food item 
Code 
Year Month Week Day  
         1 Palm-sized Lavash bread  1 
         1 Palm-sized Barbari bread 2 
         1 Palm-sized Sangak bread 3 
         1 Palm-sized Taftoon bread 4 
         1 small Baguette bread 5 
Brown bread , barley 
bread,… 
        1 Palm-sized Whole meal bread 6 
Sugary, oily, milky, 
toasted,.. 
        1 Palm-sized Other breads  7 
         1 plate/dish Cooked rice 8 
          skimmer 1 Cooked spaghetti 9 
         1 cup Cooked noodle 10 
         1 cup Cooked reshteh 11 
         1 cup Wheat flour 12 
         1 tablespoon Cooked barley 13 
         1 tablespoon cooked grits 14 
         1 tablespoon Lentils 15 
         1 tablespoon  beans(white, red, pinto)  16 
         1 tablespoon Peas 17 
         1 tablespoon Cooked beans (baghela) 18 
         1 tablespoon Soya  19 
         1 tablespoon Mash 20 
         1 tablespoon Cotyledon 21 
          1 stewed piece  Beef 22 
         1 stewed piece Lamb  23 
         1 tablespoon Minced meat 24 
         1 medium piece chicken with the skin 25 
          1 medium piece chicken without skin 26 
Excluding canned tuna          1 medium piece Fish  27 
         1//2 can canned tuna fish 28 
         1  Burger 29 
         1 Sausage 30 
         1 slice  Kielbasa 31 
         1 medium piece  Heart, liver and kidney 32 
         1 piece Sirabi and shirdan 33 
         1 full Tongue  34 
         1 full Maghz  35 
         1 full Kale 36 
         1 full Paache  37 
         1 full egg  38 
(2/5%>)         1 glass Skimmed/low fat milk 39 
(2/5%>)         1 glass Milk with normal fat 40 
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Descriptions 
Average times consumed 
Amount/size Food item 
Code 
Year Month Week Day  
(2/5%<)         1 glass Whole milk 41 
         1 bottle Cocoa milk 42 
         1 bottle Chocolate milk 43 
         1 tablespoon Chekideh yogurt 44 
         1 small bowl    Low fat yogurt 45 
         1 bottle High fat yogurt 46 
         1 tablespoon Creamy yogurt 47 
         1 match-box Feta/white Cheese  48 
         1 match-box size Creamy cheese/Lighvan 49 
         1 glass Doogh/buttermilk 50 
         1 tablespoon Cream and sarshir 51 
         ½ glass Sonati ice cream 52 
         ½ glass Packed ice cream 53 
         1 match-box size Butter  54 
         1 match-box size Margarine  55 
         1 tablespoon Kashk  56 
         ½ cup Shredded lettuce  57 
          1  tomato 58 
         1 Cucumber  59 
         1 small plate Preemption herbs 60 
         ½ cup Cooked vegetables 61 
         Piece  6×6  pumpkin  62 
         1 medium zucchini 63 
         1 medium eggplant cooked 64 
         ½ cup Cooked celery 65 
         1 medium Potato  66 
         10 medium French fries 67 
         ½ cup Cooked green peas 68 
         1 tablespoon Cooked green beans 69 
          1 medium size Raw carrot 70 
          1 medium size Cooked carrot 71 
          1 clove garlic 72 
          1 medium size Raw onion 73 
         1 tablespoon Fried onion 74 
cauliflower, red, 
broccoli, white,… 
        A small bowl cabbage 75 
         1 medium sweet pepper 76 
         
 20 medium 
leaves 
raw spinach 77 
         ½ cup Cooked spinach 78 
         1 medium turnip 79 
         ½ cup cooked mushrooms 80 
         1 medium green pepper 81 
         1 medium size corn 82 
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Descriptions 
Average times consumed 
Amount/size Food item 
Code 
Year Month Week Day  
         1 tablespoon Ketchup/ tomato sauce 83 
         1 tablespoon pickle 84 
         1 tablespoon Sauerkraut  85 
         1 medium size Pickled cucumber 86 
         ¼ full   cantaloupe melon 87 
          1 medium slice melon 88 
         1 medium slice watermelon 89 
         1 medium size Pear  90 
         1 medium size Apricot 91 
         1 medium size cherry 92 
         1 medium size Apple  93 
         1 medium size Peach  94 
         1 medium size Nectarine  95 
         1 medium size Greengage 96 
         1 medium size fresh figs  97 
         1 medium size dried figs 98 
         1 small bunch Grapes  99 
         1 medium size Kiwi  100 
         1 medium size Grapefruit  101 
         1 medium size Orange  102 
         1 medium size Persimmons  103 
         1 medium size Tangerine  104 
         1 medium size Pomegranate  105 
         1 medium size Dates  106 
         1 medium size Plum  107 
         1 medium size Black cherry  108 
         1 medium size Strawberries  109 
         1 medium size Banana  110 
         1 medium size sweet lime 111 
         1 medium size Lemon  112 
         1 glass grapefruit juice  113 
         1 glass  orange juice 114 
         1 glass apple juice 115 
         1 glass Cantaloupe juice 116 
         1 glass Blueberries  117 
         1 glass  fresh pineapple 118 
         1 glass canned pineapple 119 
         1 tablespoon Raisins  120 
         1 small bowl Honeydew 121 
         10 medium size Fresh mulberry  122 
         20 medium size dried mulberry  123 
         10 medium size Dried peach 124 
         10 medium size Dried apricot 125 
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Descriptions 
Average times consumed 
Amount/size Food item 
Code 
Year Month Week Day  
Type and amount         -  Canned fruits 126 
         10 medium size Olives 127 
         1 tablespoon 
Hydrogenated vegetable 
oil 
128 
Rice bran,  soy, 
sunflower, 
Corn 
        1 tablespoon vegetable oil  129 
         1 tablespoon  olive oil 130 
         1 medium piece Tallow  131 
         1 tablespoon Ghee  132 
         1 tablespoon Mayonnaise  133 
          20 Peanut  134 
          10 Almonds  135 
          1 full Walnuts  136 
          10 Pistachios  137 
          10 Hazelnuts 138 
Pumpkin , sunflower , 
watermelon 
        Small bowl   Tokhme (Seeds) 139 
         1 medium size Biscuit 140 
         1 Cracker 141 
         1 Yazdi Cake 142 
         1 medium slice homemade cake 143 
         1 Cookies 144 
         1 medium size Dry sweets` 145 
         1 medium size Creamy sweets 146 
         Cup Tea 147 
         10 cubes sugar cubes  148 
         1 teaspoon Sugar  149 
         ¼ pieces  Sesame halva 150 
         1 teaspoon Honey  151 
         1 tablespoon Jam  152 
         1 Chocolate/Cocoa/toffee 153 
         1 Candy 154 
         1 medium piece Nabat 155 
         1 pack Snack  156 
         1 pack Chips  157 
         1 Gaz 158 
         1 Sohan 159 
         10  Noghl 160 
         1 tablespoon Creamy caramel  161 
         1 tablespoon Home-made halva 162 
         1 Donuts 163 
         1 glass Coffee/Nescafe  164 
         1 bottle Soda 165 
         1 glass/pack Juice  166 
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Descriptions 
Average times consumed 
Amount/size Food item 
Code 
Year Month Week Day  
         1 teaspoon Lemon juice 167 
         1 tablespoon Salt  168 
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3- PHYSICAL ACTIVITY LEVEL QUESTIONNAIRE 
Type of activity No. of 
days 
Total time 
Hours  : minutes 
└─┴─┘:└─┴─┘ 
MET 
Sleeping-resting, reclining   0.9 
Sitting, watching TV, reading   1 
Computer activities, sitting in the class, …   1.5 
Driving, daily house work & domestic chores   2 
Cleaning the house (dusting, sweeping,…), slow walking   3 
Moderate-intensity sports such as cycling, brisk walking   4 
Carrying/moving moderate loads, climb up the stairs   5 
Gardening, aerobics,….   6 
Vigorous-intensity sports such as running, fitness & games 
(volleyball, fast swimming, …)  
  > 6 
IF WORKING OR EMPLOYMENT 
Sitting frequently   1.3 
Half of time sitting    1.8 
Standing frequently   2.2 
Walking, carrying moderate loads frequently   2.6 
Walking, carrying heavy loads frequently   3 
Heavy working frequently, carrying or lifting heavy loads, 
digging or construction work 
  3.9 
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APPENDIX G: The first page of the publications and papers presented 
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APPENDIX H: APPROVAL OF MEDICAL ETHICS COMMITTEE  
 
